EP4669749A1 - OLIGONUCLEOTIDES FOR MODULATION OF SYNAPTOGYRIN-3 EXPRESSION - Google Patents

Abstract

The invention relates to regions within the synaptogyrin-3 RNA sequence that are targetable by oligonucleotide inhibitors such as antisense oligonucleotides. In particular, these synaptogyrin-3 inhibitors are provided for use as a medicament in general, and for treating or inhibiting progression of tauopathies or symptoms of tauopathies.

Description

PaVer/SyngrASO2/799 OLIGONUCLEOTIDES FOR MODULATING SYNAPTOGYRIN-3 EXPRESSION FIELD OF THE INVENTION The invention relates to regions within the synaptogyrin-3 RNA sequence that are targetable by oligonucleotide inhibitors such as antisense oligonucleotides. In particular, these synaptogyrin-3 inhibitors are provided for use as a medicament in general, and for treating or inhibiting progression of tauopathies or symptoms of tauopathies. BACKGROUND TO THE INVENTION Tau pathology is associated with more than twenty neurodegenerative diseases, including Alzheimer’s disease (Wang & Mandelkow 2016 Nat Rev Neurosci 17:5-21). Hyperphosphorylation or mutation of the microtubule-associated protein Tau is common to all of these diseases, collectively termed Tauopathies, and filamentous inclusions of hyperphosphorylated Tau are hallmark pathologies of Alzheimer’s disease and other Tauopathies (Ballatore et al 2007 Nature Reviews Neuroscience 8:663-672). Tau pathology is not merely a byproduct of other pathological pathways, but is a key mediator of neurotoxicity itself (Roberson et al 2007 Science 316:750-754; Hutton et al 1998 Nature 393:702-705; Caffrey & Wade- Martins 2007 Neurobiol Dis 27:1-10; Le Guennec et al 2016 Molecular Psychiatry 1-7). Under physiological conditions, Tau is expressed in neurons and is bound to axonal microtubules. However, under pathological conditions, mutations in Tau (in FTDP-17) or abnormal phosphorylation of Tau (including sporadic Alzheimer’s disease) decrease its microtubule binding affinity (Hong et al 1998 Science 282:1914-1917; Wang & Mandelkow 2016 Nat Rev Neurosci 17:5-21), leading to its dissociation from axonal microtubules and subsequent mislocalization to synapses (Spires-Jones & Hyman 2014 Neuron 82:756-771; Tai et al 2012 Am J Pathol 181:1426-1435; Tai et al 2014 Acta Neuropathol Commun 2:146). This mislocalisation of soluble Tau plays a key role in perturbing synaptic function in early disease stages, which may contribute to subsequent synapse loss and neurodegeneration. Previous work of the inventors of current application indicated that when Tau is present at pre-synaptic terminals it binds to and clusters synaptic vesicles. Synaptogyrin-3 (Syngr3) was identified as a physical interactor of Tau (WO2019/016123). Moreover, it was demonstrated in vivo that the partial loss of Syngr3 – both in mice and in fly expressing pathogenic P301S Tau (“PS19”), well-accepted models for tauopathy that recapitulates features seen in patients, including synaptic loss, neuroinflammation and cognitive decline – restores working memory and rescues synaptic degeneration. Interestingly, partial (and complete) loss of Syngr3 is benign in mice and fruit flies. Given the potential of Syngr3 as a clinical PaVer/SyngrASO2/799 target for tauopathies, it is advantageous to develop inhibitors that specifically downregulate Syngr3 transcript levels. SUMMARY OF THE INVENTION The inventors of current application have found that some subsequences within the Synaptogyrin-3 gene are significantly more accessible for oligonucleotides such as antisense oligonucleotide (ASO) molecules and therefore are preferred target regions for designing oligonucleotides suitable for or capable of reducing the expression and/or activity of Synaptogyrin-3. The borders of those identified target regions were determined by transcript-walking. In one aspect, the invention relates to oligonucleotides that specifically bind to Synaptogyrin-3 transcript and reduce the expression of Synaptogyrin-3 through antisense or RNAi technology. More particularly, an oligonucleotide of 10 to 50 nucleotides in length is provided, comprising a contiguous nucleotide sequence of at least 10 contiguous nucleotides in length, the contiguous nucleotide sequence being at least 90% complementary to an equal length portion of a target region within the Synaptogyrin-3 transcript as depicted in SEQ ID No. 1, wherein the target region is comprised between nucleobase positions 449 and 531, 549 and 653, 640 and 733, 720 and 875, 915 and 1108, 1197 and 1271, 1258 and 1344, 1332 and 1450, 1450 and 1527, 1515 and1600, 1580 and 1700, 1680 and 1837, 1824 and 1885, 1850 and 2100, 2100 and 2250, 2308 and 2428, 2416 and 2441, 2428 and 2625, 2649 and 2796, 2962 and 3086, 3153 and 3460, 3450 and 3530, 3508 and 3551, 3538 and 3636 or between nucleobase positions 3626 and 4599 of SEQ ID No.1 and wherein the endpoints are included. In one embodiment, the oligonucleotide can bind to the synaptogyrin-3 mRNA transcript as set forth in SEQ ID No. 1. In another embodiment, said binding of the oligonucleotide to said synaptogyrin-3 mRNA transcript can reduce the expression and/or activity of synaptogyrin-3. In one embodiment, the oligonucleotide is a single stranded nucleic acid molecule, more particularly an ASO molecule or the antisense portion of an RNAi molecule. In another embodiment, the oligonucleotide is at least 16 nucleotides in length. In a particular embodiment, the oligonucleotide of the application is at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 97%, at least about 99% complementary or fully complementary (100% complementary) to an equal length portion of a target region selected from SEQ ID No.10, 12, 20, 25, 29-31, 33, 50, 53, 58-59, 62, 69, 79, 84, 87, 91, 94, 110- 111, 135, 140-141, 170, 172, 179, 181, 184, 188, 193-194, 210, 216, 220-221, 224, 227, 229, 231, 235, 241, 246, 248, 250, 259, 268 or 269, more particularly said target region is selected from SEQ ID No.2-9, 11, 13-19, 21-24, 26-28, 32, 34-49, 51-52, 54-57, 60-61, 63-68, 70-78, 80-83, 85-86, 88-90, 92-93, 95-109, 112-134, 136-139, 142-169, 171, 173-178, 180, 182-183, 185-187, 189-192, 195-209, 211-215, 217-219, 222-223, 225-226, 228, 230, 232-234, 236-240, 242-245, 247, 249, 251-258 or 260-267. In a more PaVer/SyngrASO2/799 particular embodiment, the oligonucleotide comprises a contiguous nucleotide sequence of at least 10 contiguous nucleotides in length with at least 90% sequence identity to any of SEQ ID No.270-489. In another embodiment the contiguous nucleotide sequence from the oligonucleotide of the application is 100% complementary to one of the target regions herein disclosed. In another embodiment, the oligonucleotide of the application comprises one or more internucleoside linkage and/or one or more 2’ sugar modified nucleosides, more particularly the internucleoside linkage is a phosphorothioate internucleoside linkage and/or the 2’ sugar modified nucleoside is selected from the group consisting of 2ʹ-O-methyl-, 2ʹ-O-methoxyethyl-, 2’-O-alkyl-, 2’-alkoxy, 2’-amino-, 2ʹ-fluoro- and LNA nucleosides. In a particular embodiment, the oligonucleotide of the application comprises a gapmer of formula 5’-F-G-F’-3’, where region F and F’ independently comprise between 1 and 8 nucleosides, of which 1 to 5 independently are 2’ sugar modified nucleosides and define the 5’ and 3’ end of the F and F’ region, and G is a region between 5 and 18 nucleosides for recruiting RNaseH, more particularly the internucleoside linkages between one or more nucleosides of region F and/or F’ and/or between F and G and/or between F’ and G are phosphorothioate internucleoside linkages. Also provided is a pharmaceutical composition comprising the oligonucleotide of the application. Also provided is an antisense oligonucleotide or RNAi molecule capable of reducing the level of synaptogyrin-3 mRNA, synaptopgyrin-3 protein, synaptogyrin-3 activity, or a combination thereof in a cell by least 45% compared to a control situation in the absence of said antisense or RNAi molecule, wherein the antisense oligonucleotide or RNAi molecule nucleic acid sequence targets a subsequence of an mRNA encoding synaptogyrin-3 selected from the group consisting of SEQ ID No.10, 12, 20, 25, 29- 31, 33, 50, 53, 58-59, 62, 69, 79, 84, 87, 91, 94, 110-111, 135, 140-141, 170, 172, 179, 181, 184, 188, 193- 194, 210, 216, 220-221, 224, 227, 229, 231, 235, 241, 246, 248, 250, 259, 268 or 269. The oligonucleotides of the application, including the antisense oligonucleotides and RNAi molecules herein disclosed, are provided a therapeutic, more particularly to treat or reduce the symptoms of tauopathies. Therefore, pharmaceutical composition comprising the oligonucleotides of the application are provided as well as methods to treat tauopathies in a subject in need thereof, wherein the methods comprising the step of administering any of the antisense oligonucleotide and RNAi molecules herein provided. The oligonucleotide of the applications are also provided for use as a medicament, more particularly for use in treating or inhibiting progression of a tauopathic disorder or for use in treating or inhibiting a symptom of a tauopathic disorder. BRIEF DESCRIPTION OF THE FIGURES Figure 1 and 2 illustrate exemplary, non-limiting architectures of oligonucleotides of the application. In Figure 1 the oligonucleotide is an siRNA molecule a 21/19 bp structure, where the sense strand PaVer/SyngrASO2/799 is 19 nucleotides and the antisense strand is 21 nucleotides with 2 nucleotides overhanging on the 3’ end. The strands are 2’OMe (green)/2”F (blue) modified. The red bar indicates a phosphorothioate modification, and “N” is complementary to the target mRNA. Figure 2 A-B show other non-limiting, alternative architectures of the oligonucleotides of the present disclosure. Figure 3 shows the different target regions in the synaptogyrin-3 mRNA transcript that have been identified herein, their start (5’) and end (3’) position according to SEQ ID No.1, their sequence, as well as the sequences of the oligonucleotides herein disclosed. Figure 4 shows the extended target regions within the synaptogyrin-3 mRNA transcript. Figure 5 shows off-target analysis of three independent ASO molecules, said molecules consisting of sequence SEQ ID No.346, SEQ ID No.373 and SEQ ID No.384. The expression of Syngr3 and of several predicted off-target genes was quantified in human iPSC-derived neurons after 4 days of incubation with said ASO molecules. DETAILED DESCRIPTION OF THE INVENTION In one aspect, the current invention relates to oligonucleotides (“oligonucleotides of the present disclosure”) that specifically bind to Synaptogyrin-3 mRNA or pre-mRNA and reduce the expression of Synaptogyrin-3, e.g. through antisense or RNAi technology. In some aspect, the oligonucleotides of the present disclosure reduce Synaptogyrin-3 expression levels, Synaptopgyrin-3 activity (e.g., dopamine transporter activity), Synaptogyrin-3-mediated exocytosis, or a combination thereof. In some aspects, the oligonucleotide of the present disclosure is 10 to 50, 10 to 40, or of 10 to 30 nucleotides in length, and comprises a contiguous nucleotide sequence of at least 10 contiguous nucleotides in length which are at least 90% complementary to an equal portion of a target region within the Synaptogyrin-3 transcript as depicted in SEQ ID No.1. In some aspects, the target region within SEQ ID No.1 is located between nucleobase positions 449 and 531, 549 and 653, 640 and 733, 720 and 875, 915 and 1108, 1197 and 1271, 1258 and 1344, 1332 and 1450, 1450 and 1527, 1515 and1600, 1580 and 1700, 1680 and 1837, 1824 and 1885, 1850 and 2100, 2100 and 2250, 2308 and 2428, 2416 and 2441, 2428 and 2625, 2649 and 2796, 2962 and 3086, 3153 and 3460, 3450 and 3530, 3508 and 3551, 3538 and 3636, or between nucleobase positions 3626 and 4599 of SEQ ID No.1 and wherein the endpoints are included. In some aspects, the oligonucleotide of the present disclosure is 10 to 50, 10 to 40, or of 10 to 30 nucleotides in length, and comprises a contiguous nucleotide sequence of at least 10 contiguous nucleotides in length which are at least 90% complementary to an equal length portion of a target region within human Synaptogyrin-3, wherein the target region is selected from the list consisting of SEQ ID No. PaVer/SyngrASO2/799 10, 12, 20, 25, 29-31, 33, 50, 53, 58-59, 62, 69, 79, 84, 87, 91, 94, 110-111, 135, 140-141, 170, 172, 179, 181, 184, 188, 193-194, 210, 216, 220-221, 224, 227, 229, 231, 235, 241, 246, 248, 250, 259, 268 or 269. In some aspects, the oligonucleotide of the present disclosure is complementary (full or partially complementary) to a target region of Synaptogyrin-3 selected from the group consisting of SEQ ID No. 2-9, 11, 13-19, 21-24, 26-28, 32, 34-49, 51-52, 54-57, 60-61, 63-68, 70-78, 80-83, 85-86, 88-90, 92-93, 95-109, 112-134, 136-139, 142-169, 171, 173-178, 180, 182-183, 185-187, 189-192, 195-209, 211-215, 217-219, 222-223, 225-226, 228, 230, 232-234, 236-240, 242-245, 247, 249, 251-258, or 260-267. In some aspects, the oligonucleotide of the application comprises or consists of 14, 15, 16, 17, 18, 19, 20, 21, 22 or 23 nucleotides in length. In other aspects, the oligonucleotide of the application comprises or consists of 14, 15, 16 or more nucleotides in length and comprises or consists of the sequence selected from the list consisting of SEQ ID No.270-489 or overlaps with one of said SEQ ID No.270-489 for at least 12, 13, 14, 15 or 16 nucleotides. The present disclosure also provides methods of treatment comprising the administration of the oligonucleotides of the present disclosure, or a combination thereof, to a subject in need thereof. Also provides are pharmaceutical compositions, pharmaceutical formulations, and kits and articles of manufacture comprising the oligonucleotides of the present disclosure. Also provided are methods of manufacture of the oligonucleotides of the present disclosure. Definitions In order that the present description can be more readily understood, certain terms are first defined. Additional definitions are set forth throughout the detailed description. The present invention is described with respect to particular embodiments and with reference to certain drawings but the invention is not limited thereto but only by the claims. Any reference signs in the claims shall not be construed as limiting the scope. The drawings described are only schematic and are non-limiting. In the drawings, the size of some of the elements may be exaggerated and not drawn on scale for illustrative purposes. It is to be noted that the term “a” or “an” entity refers to one or more of that entity; for example, “a nucleotide sequence”, is understood to represent one or more nucleotide sequences. As such, the terms “a” (or “an”), “one or more” and “at least one” can be used interchangeably herein. Furthermore, “and/or” where used herein is to be taken as specific disclosure of each of the two specified features or components with or without the other. Thus, the term “and/or” as used in a phrase such as “A and/or B” herein is intended to include “A and B”, “A or B”, “A” (alone), and “B” (alone). Likewise, the term “and/or” as used in a phrase such as “A, B, and/or C” is intended to encompass each PaVer/SyngrASO2/799 of the following aspects: A, B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone). Where an indefinite or definite article is used when referring to a singular noun e.g. “a” or “an”, “the”, this includes a plural of that noun unless something else is specifically stated. Furthermore, the terms first, second, third and the like in the description and in the claims, are used for distinguishing between similar elements and not necessarily for describing a sequential or chronological order. It is to be understood that the terms so used are interchangeable under appropriate circumstances and that the embodiments of the invention described herein are capable of operation in other sequences than described or illustrated herein. It is understood that wherever aspects are described herein with the language “comprising”, otherwise analogous aspects described in terms of “consisting of” and/or “consisting essentially of” are also provided. Where the term “comprising” is used in the present description and claims, it does not exclude other elements or steps. Unless specifically defined herein, all terms used herein have the same meaning as they would to one skilled in the art of the present invention. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure is related. For example, the Concise Dictionary of Biomedicine and Molecular Biology, Juo, Pei-Show, 2nd ed., 2002, CRC Press; The Dictionary of Cell and Molecular Biology, 3rd ed., 1999, Academic Press; and the Oxford Dictionary of Biochemistry and Molecular Biology, Revised, 2000, Oxford University Press, provide one of skill with a general dictionary of many of the terms used in this disclosure. Practitioners are particularly directed to Sambrook et al., Molecular Cloning: A Laboratory Manual, 4th ed., Cold Spring Harbor Press, Plainsview, New York (2012); and Ausubel et al., current Protocols in Molecular Biology (Supplement 100), John Wiley & Sons, New York (2012), for definitions and terms of the art. The definitions provided herein should not be construed to have a scope less than understood by a person of ordinary skill in the art. Units, prefixes, and symbols are denoted in their Système International de Unites (SI) accepted form. Numeric ranges are inclusive of the numbers defining the range. Unless otherwise indicated, nucleotide sequences are written left to right in 5' to 3' orientation. Amino acid sequences are written left to right in amino to carboxy orientation. The headings provided herein are not limitations of the various aspects of the disclosure, which can be had by reference to the specification as a whole. Accordingly, the terms defined immediately below are more fully defined by reference to the specification in its entirety. The term “about” is used herein to mean approximately, roughly, around, or in the regions of. When the term “about” is used in conjunction with a numerical range, it modifies that range by extending the PaVer/SyngrASO2/799 boundaries above and below the numerical values set forth. In general, the term “about” can modify a numerical value above and below the stated value by a variance of, e.g., 10 percent, up or down (higher or lower). For example, if it is stated that an oligonucleotide of the present disclosure reduces expression the Syngr-3 transcript in a cell following administration of an oligonucleotide of the present disclosure by at least about 60%, it is implied that the Syngr-3 expression levels are reduced by a range of 50% to 70%. The terms “reverse complement”, “reverse complementary” and “reverse complementarity” as used herein are interchangeable with the terms “complement”, “complementary” and “complementarity”. The terms “identical” or percent “identity” in the context of two or more nucleic acids refer to two or more sequences that are the same or have a specified percentage of nucleotides or amino acid residues that are the same, when compared and aligned (introducing gaps, if necessary) for maximum correspondence, not considering any conservative amino acid substitutions as part of the sequence identity. The percent identity can be measured using sequence comparison software or algorithms or by visual inspection. Various algorithms and software are known in the art that can be used to obtain alignments of amino acid or nucleotide sequences. The term “percent sequence identity” or “percent identity” between two polynucleotide or polypeptide sequences refers to the number of identical matched positions shared by the sequences over a comparison window, taking into account additions or deletions (i.e. gaps) that must be introduced for optimal alignment of the two sequences. A matched position is any position where an identical nucleotide or amino acid is presented in both the target and reference sequence. Gaps presented in the target sequence are not counted since gaps are not nucleotides or amino acids. Likewise, gaps presented in the reference sequence are not counted since target sequence nucleotides or amino acids are counted, not nucleotides or amino acids from the reference sequence. One such non-limiting example of a sequence alignment algorithm is the algorithm described in Karlin et al., 1990, Proc. Natl. Acad. Sci., 87:2264-2268, as modified in Karlin et al., 1993, Proc. Natl. Acad. Sci., 90:5873-5877, and incorporated into the NBLAST and XBLAST programs (Altschul et al., 1991, Nucleic Acids Res., 25:3389-3402). In certain aspects, Gapped BLAST can be used as described in Altschul et al., 1997, Nucleic Acids Res. 25:3389-3402. BLAST-2, WU-BLAST-2 (Altschul et al., 1996, Methods in Enzymology, 266:460-480), ALIGN, ALIGN-2 (Genentech, South San Francisco, California) or Megalign (DNASTAR) are additional publicly available software programs that can be used to align sequences. In certain aspects, the percent identity between two nucleotide sequences is determined using the GAP program in the GCG software package (e.g., using a CMP matrix and a gap weight of 40, 50, PaVer/SyngrASO2/799 60, 70, or 90 and a length weight of 1, 2, 3, 4, 5, or 6). In certain alternative aspects, the GAP program in the GCG software package, which incorporates the algorithm of Needleman and Wunsch (J. Mol. Biol. (48):444-453 (1970)) can be used to determine the percent identity between two amino acid sequences (e.g., using either a BLOSUM 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5). Alternatively, in certain aspects, the percent identity between nucleotide or amino acid sequences is determined using the algorithm of Myers and Miller (CABIOS, 4:11-17 (1989)). For example, the percent identity can be determined using the ALIGN program (version 2.0) and using a PAM120 with residue table, a gap length penalty of 12 and a gap penalty of 4. One skilled in the art can determine appropriate parameters for maximal alignment by particular alignment software. In certain aspects, the default parameters of the alignment software are used. One skilled in the art will appreciate that the generation of a sequence alignment for the calculation of a percent sequence identity is not limited to binary sequence-sequence comparisons exclusively driven by primary sequence data. Sequence alignments can be derived from multiple sequence alignments. One suitable program to generate multiple sequence alignments is ClustalW2, available from www.clustal.org. Another suitable program is MUSCLE, available from www.drive5.com/muscle/. ClustalW2 and MUSCLE are alternatively available, e.g., from the EBI (European Bioinformatics Institute). In certain aspects, the percentage identity “X” of a first nucleotide sequence to a second nucleotide sequence is calculated as 100 x (Y/Z), where Y is the number of amino acid residues scored as identical matches in the alignment of the first and second sequences (as aligned by visual inspection or a particular sequence alignment program) and Z is the total number of residues in the second sequence. If the length of a first sequence is longer than the second sequence, the percent identity of the first sequence to the second sequence will be higher than the percent identity of the second sequence to the first sequence. Different regions within a single polynucleotide target sequence that align with a polynucleotide reference sequence can each have their own percent sequence identity. It is noted that the percent sequence identity value is rounded to the nearest tenth. For example, 80.11, 80.12, 80.13, and 80.14 are rounded down to 80.1, while 80.15, 80.16, 80.17, 80.18, and 80.19 are rounded up to 80.2. It also is noted that the length value will always be an integer. As used in the present disclosure, the terms “nucleic acid molecule of the invention” and “oligonucleotide of the present disclosure” and grammatical variants thereof are used interchangeably. The term “defined by SEQ ID No. X” as used herein refers to a biological sequence consisting of the sequence of nucleotides given in the SEQ ID No. X. SEQ ID No. X is interchangeable with SEQ ID NO: X. When the present application refers to “a group consisting of SEQ ID No.2-4”, this is identical to a group consisting of SEQ ID No.2, SEQ ID No.3 and SEQ ID No.4. PaVer/SyngrASO2/799 The target nucleic acid of the invention is a nucleic acid, e.g., an mRNA, a primary mRNA transcript or a pre-mRNA, encoding Synaptogyrin-3, more particularly human Synaptogyrin-3. “Synaptogyrin3”, “Synaptogyrin3”, “synaptogyrin-3”, “synaptogyrin-3”, “Syngr3”, “Syngr-3”, “SYNGR3” or “SYNGR-3” are interchangeably used and refer herein to Synaptogyrin-3 transcript if not otherwise specified. The “primary mRNA transcript” as used herein refers to the single-stranded ribonucleic acid (RNA) product synthesized by transcription of DNA that is subsequently processed (e.g. including 5' capping, 3'-polyadenylation, and alternative splicing) to yield various mature RNA products such as mRNAs, tRNAs, and rRNAs. The primary transcripts designated to be mRNAs are modified in preparation for translation. For example, a precursor mRNA or pre-mRNA is a type of primary transcript that becomes a messenger RNA (mRNA) after processing. The “pre-mRNA” is synthesized from a DNA template in the cell nucleus by transcription. Pre-mRNA comprises the bulk of heterogeneous nuclear RNA (hnRNA). Once pre-mRNA has been completely processed, it is termed “mature messenger RNA”, or simply “messenger RNA” or “mRNA”. The term hnRNA is often used as a synonym for pre-mRNA, although, in the strict sense, hnRNA may include nuclear RNA transcripts that do not end up as cytoplasmic mRNA. The human nucleic acid sequence of Synaptogyrin-3 (hSyngr-3) is set forth in SEQ ID No.1; however also within the scope of the invention are nucleic acid sequence variants of Synaptogyin-3 as may exist due to allelic variation, e.g., a mRNA encoding a Synaptogyrin-3 allelic variant. Such variations are defined herein as “allelic variants of SEQ ID No.1”. The term “allelic variants” refer to one of several alternate forms of a gene occupying a given locus on a chromosome of an organism (Genes II, Lewin, B., ed., John Wiley & Sons, New York (1985)). These allelic variants can vary at either the polynucleotide and/or polypeptide level and are included in the present disclosure. Alternatively, non-naturally occurring variants can be produced by mutagenesis techniques or by direct synthesis. In some aspects, the synaptogyrin-3 variant is a splice variant. In some aspects, the synaptogyrin-3 variant is a post- translationally modified variant. In some aspects, the synaptogyrin-3 variant is a mutant synaptogyrin-3, e.g., a mutant comprising at least one nucleotide point mutation, deletion, or insertion. In some aspects, the mutation is a silent mutation. In some aspects, the synaptogyrin-3 variant is a mutant protein comprising at least one amino acid substitution, deletion, or insertion. In some aspects, the synaptogyrin-3 variant is a loss of function variant. In some aspects, the synaptogyrin-3 variant is a gain of function variant. “Specific to synaptogyrin-3” as used herein is referring to the fact that the nucleic acid molecule or oligonucleotide of the invention is acting at the level of synaptogyrin-3 and not at the level of another PaVer/SyngrASO2/799 transcript. Specificity can be ascertained by e.g. determining the expression level of closely related RNA sequences. The term “statistically significantly” different is well known by the person skilled in the art. Statistical significance plays a pivotal role in statistical hypothesis testing. It is used to determine whether the null hypothesis should be rejected or retained. The null hypothesis is the default assumption that nothing happened or changed, hence that there is no difference for example in the synaptogyrin-3 transcript level in the presence of an antisense or RNAi molecule compared to the synaptogyrin-3 transcript level in the absence of said antisense or RNAi molecule. For the null hypothesis to be rejected, an observed result has to be statistically significant, i.e. the observed p-value is less than the pre-specified significance level α. The p-value of a result, p, is the probability of obtaining a result at least as extreme, given that the null hypothesis were true. In one embodiment, α is 0.05. In a more particular embodiment, α is 0.01. In an even more particular embodiment, α is 0.001. Nucleic acid molecules inhibiting the expression of Synaptogyrin-3 The present disclosure provides nucleic acid molecules, more particularly oligonucleotides, that comprise a sequence complementary (fully or partially) to a region of a mRNA or pre-mRNA encoding the human Synaptogyrin-3 protein, or a mRNA or pre-mRNA of an allelic variant or isoform thereof (e.g., any of the variants and isoform disclosed in the UniProtKB/Swiss-Prot O43761 entry). SEQ ID No. 1 represents the nucleic acid sequence of the human Synaptogyrin-3 gene (Ensembl GRCh38:16; 1989660:1994275). SEQ ID No.1: Gene Sequence human Syngr3, Ensembl GRCh38:16 (1989660:1994275) CCTACCCCTTTACTCCCTCACCCAAGTGCCCTTCCCAGAGGAGCGGACTCCTCCTGTCTGTCCTCCCGGCTCTAGCA AAGTCTGCGCCCAGCACCCGAGCCCCACCCTGCCCCCGGGGACCTGGCTGGTGGGTTCCTGAGGATGGTCTCCA TCTCGGGACCGGGGCAGGCAGGTGAGGGTGGGGGATGGGAGGTGGGCGCGGCGGAGGGAGAGGAGGGACC CGGCCCCGCGCGCATGGACCCAGTGGGGGGCGCGGGCGCGGCCCCGCCCCGTCCCGCGCGTCCCCGCCGCGGC CGGCGCGCGCTCCCGGGAGGCGGCAGCGGCTGCAGCGTTGGTAGCATCAGCATCAGCATCAGCGGCAGCGGCA GCGGCCTCGGGCGGGGCCGGCCGGACGGACAGGCGGACAGAAGGCGCCAGGGGCGCGCGTCCCGCCCGGGC CGGCCATGGAGGGCGCCTCCTTCGGCGCGGGCCGCGCAGGGGCCGCCCTGGACCCCGTGAGCTTTGCGCGGCG GCCCCAGACCCTGCTCCGGGTCGCGTCCTGGGTGAGTGGTCCCTGCCCGGGCCCCCGCTCCCGCCCCTGCCTCGC GACCTTCAGGCCCCTACCAGCCCCCTGCCCCCTACCCCCTGCCCCCTGCTTCTCGCCCCCCGACCTCACTCACTCTC ATCCTCGCCGGCCCCTCCCCCGCCGGCCTCAGGTTGGGGTGACGTCACCGGGCAGGGCGCGCCCACCTGCGGGC GGAGGAGGGGCCGGCGGCGCCGGAGAGGGACCTTGAGAGGTCACCGCCGGTCGCCTCTACCCCTACCTCCTCC PaVer/SyngrASO2/799 CCGGGTCTAATTTCAGTCCCTTTCCGCAGCCCTTACTCCGTTTTTCCTGTTCTCGTGACCTGGAAGCAGGGACGGG GTGGGGACGGAATTCTCCGAGGGGCAGGAGGGGGCTACGGGAACCGAGAAGCGCCTCCCCTTCCCCCGCACAC ACACCCTCGGGTCTCCTTGGCAGGGAGCCTGTCCCCTGGCCCCCAGTTCCAGCTGTGAGTTGAGGGAGGAGAGG CTCTGGGCTGGGAGGGCTTCCTGGCGGCGGTGTGGAAGGCAGGTTTGGGAGCAGCCTAGCCCACTGGGGCGTC CCTGGGAGGGCCCTGCTGCTCCTTCCCTCCGGCAGGGGAGGTGGCAGTTGGGTGCCGAGCTCTGGGTTTTGTCC AGGTGGCAACCTCTGGGCCAGCCGCACCTCGGCGCCTGTCTTGGAGGAGGGCGGTGCCCACGGTGGGGCAGGG GCTTTGGCCTCCCCTGCGGAGTGGCTCTGACCAGACCGGGAGGCAGGACGCTGCGTTTTGGTCCGAGCGCACGT CCCGACTTGTGGCCCACTCTTGGGGACAAGTGCATGTCCCGGCTTCCCCCTTGGCTCCACTCTCGGAGCTGGAGC GGGAAAGGAGCGAAGGGATGAGGTTGAGGCTGGAGGTCGTTTCTTGGAAACACAGGGCTGCCCCGTGCAGCG CTGGTTAAAATGACTGCGGTCCCCCTCATGCCTGTCTCCCGGAACTGGTGGGCAGGAGGCATTGAGGTTTGACG GAACCTCAGAGGTCAACGGTGTCATCTTTTCAGCCCAAACACTTACAGGTGATATTAATAATCAGTCACGTGGGG GCTGTCATCCCTCGGGTACCCACCACGTGCAGGAAGCTGGGTGGACATGTCTGTCCCAGCACTGCATGAGCTGT GCCCGTCACCCTATTTGCATGCTAGAAAACAGGCCAGACAGTTCCCAACCGCGCAGGAAGCAACAGCTCCGCTG CCTCCATACCCTCCCTCCCGCCCCGCTCTGCCTGCTGCACTCTCACCTCCCCTTCGCCGTTCCGGCTCCAGCCTGGG AATCGCGGGCCCAGGTGAAGGCTCCTGTTCCCACACTCTTGAGTGGGCTCTGAGGGGACTCCACGGGCCCACGC GGTGCAGAGTACCTGGCTTGAATCAACCCCGGCTTTTGTCAGCCATGTGATCCCGGACAAGTCACTTCACCTGTT GGGGTCCCAATGTCCCCCGCATTTATAAAGAGAATAAGAACAATGGCGATCCCACGGGGACTTTCTGAGGATTT GGTGAGGGGACGCATGTAAAGTGGCTGTTTAACACAATGTCTGGGCATAGTAGATGCTCACTAAACGGCCCGTG TTGTCAATAATTACTAAATACGCGAGGGTTCGGGAAAGAAAGAGGTGACACCGCCCCCCACCCAGATACGGGCC TGGGAACGCAGGGACAGGCCCAGGGGCGTGGGCGCTCGAGGCGGGCTCGCAGAGGTCGGGTCGCCGCAGGG CCCTGAGCGCCGCGCCGCACGCAGGTGTTCTCCATCGCCGTCTTCGGGCCCATCGTCAACGAGGGCTACGTGAA CACCGACAGCGGCCCCGAGCTGCGCTGCGTGTTCAACGGGAACGCGGGCGCCTGCCGCTTCGGCGTCGCGCTG GGCCTCGGAGCCTTCCTCGCCTGCGCCGCCTTCCTGCTGCTCGATGTGCGCTTCCAGCAAATCAGCAGCGTCCGC GACCGCCGGCGCGCGGTGTTGCTGGACCTGGGCTTCTCAGGTGGGCGGGGCCGGGGCGGTGAGCGCGGAGAG CCTTCCGGGTGGGCGGGGAGGGGGCGGGGCCTGGGCGGGGAACACCGCTGGAGTTTCCAGCTGGGCGTGGCC GTGACGAGGGGCGGGGACTGAGGCAGGGAGTGTCAATGGGCCTCCCGGGTGGGCGGGGAGGGGGCGGAGCC TGGACGGGGAGCGCCGCGGGACTTTCTAGGTAGGCGGGGCCCGGGTCTGGGCGGAGCCTGGGCGCGGAACGG GTCTGGCGCTCCCGGGTGGGCGGGGTCAGCGCAGGAGAGGGAGGCGGGACCTCGCGCCACGCGGCGAGCCCA GGCGAGGCGCCCCAAGCCTCGGGCCCACCGACCTTTCCTCCTCCGGGCGAGGCCGCCGTGGGCCACCGCGTGGA GCGTCGCCCTGACGCGCCGCACTGTTCGCAGGACTCTGGTCCTTCCTGTGGTTCGTGGGCTTCTGCTTCCTCACCA ATCAGTGGCAGCGCACGGCGCCAGGGCCGGCCACGACGCAGGCGGGGGACGCGGCGCGGGCCGCCATCGCCT TCAGCTTCTTCTCCATCCTCAGCTGGGTGAGTGCGGGGCCCGGGAGGGCGGGGCGAAGGGGCGGGCGCTCGGC TGATCCCGGCTGACCCCGCTGACCCCGCCCCGCGCAGGTGGCGCTCACCGTGAAGGCCCTGCAGCGGTTCCGCC TGGGCACCGACATGTCACTCTTCGCCACCGAACAGCTGAGCACCGGGGCGAGCCAGGCCTACCCCGGCTATCCG PaVer/SyngrASO2/799 GTGGGCAGCGGCGTGGAGGGCACCGAGACCTACCAGAGCCCGCCCTTCACCGAGACCCTGGACACCAGCCCCA AAGGGTACCAGGTGCCCGCCTACTAGCGGCTGGCAGGCACAGACCAGGGCTCCAAGGCCACCCCACCAACGCA GGCCCCAGGGTCTCCGGGACCTCCCTTGGGTCCTTCCAGCTCAGTGCCGCGGACAGAGTAGGTGGCCGCTTTGC GCCATCCGGGGCCAAGAGGGGGTGGACCCGCGTGTCTGGGCTGCCCCTGCCAAGTTCCCCCAGTCCCTCAGCAC CTGGCCCCAGGACTGAGGTCCTGAGAAGGGGATAGCACTGCCCAGGACGTGTGTCCCTAGCCTGGAATGGACT GGCCTGGGGAAGGCTTTCCCCTCTTGGGCCACACCTGCTCACTCTGGGGTTGGGGGTCCAGCTGCCCTCTACGAT CAGGTGCAGGGGCTGCCCAGGACAAAGCGGGGGCAGGGGAAAGACACCACCCTCGCCCCAAGACTGGGGATC CTGGCCACTGTTCCCATCCCATGTCCCTGTGGGTAGTGACTGTCTCGTTTCTGTCATGGTGGTGCGTCCCGTCCGG AGCCACTCTCCACTTTCTCTCACAGGCTGCTAGAACAGCCCAGCCCTGTCAGTGTTGTGATCATGGTCCAGTCTTC GGGTTTCACCTCCTAGTACTCCACAAGCTGCTCCTCTCTCTGTGGCCCCGGCCCCTGCCCAGGTGTGGGTGGTTCT GGCCAGGAAGGCACAAGGTAGCTGTGGGCCAAGACACCAGCCCTGTCCTAGCCCTTCAGTAAGACCTTGCCAGG AGAGGAGAAGGATGCCTGGGTGCCAGGCAAGACAAGCCCCTCAGCAGGAGAGAGGCCCAGAGGCTCCAGCTG GCCACCGTGCCCCACAAGATGGCCCCTGTGTGGTTCCCTTTACCTTGGCTTCCTGGCCCAGTCCCTGCCTCTCCAC CTGCACCCTGCTTCCTGGCCCAGTCCCAGGTTGGAGTCCCTCTGCATAGCTGACTACTCATGCATTGCTCAAAGCT GGCTTTTCACATTAAGTCAACACCAAACGTGGTTGCCACATTTCATCAGACAGACACCTCCCTCTGGAGATGCAGT TGAGTGACAACCTTGTTACATTGTAGCCTAGACCAATTCTGTGTGGATATTTAAGTGAACATGTTTACAATTTTTG TATATATCACTCTCTCCCTCTCCTGAAAGACCAGAGATTGTGTATTTTCAGTGTCCCATGTTCCGACTGCACCTTCT TTACAATAAAGACTGTAACTGAGCTGACTGTGA In some aspects, the nucleic acid molecule or the oligonucleotide of the present disclosure (e.g. ASO, siRNA, shRNA) comprises an oligonucleotide of between 10 and 50 nucleotides in length. In some aspects, the nucleic acid molecule or the oligonucleotide of the present disclosure comprises of or consists of 1 oligonucleotide (e.g., an ASO oligomer or a shRNA). In some aspects, the nucleic acid molecule or the oligonucleotide of the present disclosure comprises or consists of 2 oligonucleotides (e.g., a siRNA). In some aspects, the 2 oligonucleotides are a sense oligonucleotide and an antisense oligonucleotide. In some aspects, the sense oligonucleotide and the antisense oligonucleotide are connected by a loop. In some aspects, a nucleic acid molecule of the present disclosure comprises or consists of a sequence from about 8 to about 70 contiguous nucleotides in length disclosed herein, a sequence from about 10 to about 60 contiguous nucleotides in length disclosed herein, a sequence from about 12 to about 50 contiguous nucleotides in length disclosed herein, a sequence from about 8 to about 40 nucleotides in length, a sequence from about 10 to about 35 contiguous nucleotides in length disclosed herein, a sequence from about 12 to about 30 contiguous nucleotides in length disclosed herein, a sequence from PaVer/SyngrASO2/799 about 14 to about 28 contiguous nucleotides in length disclosed herein, a sequence from about 16 to about 25 nucleotides in length disclosed herein, a sequence from about 17 to about 24 nucleotides in length disclosed herein, or a sequence from about 18 to about 23 contiguous nucleotides in length disclosed herein. In some aspects, the nucleic acid molecule of the invention is 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, or 60 nucleotides in length. In one embodiment, “nucleotides in length” refers to “contiguous nucleotides in length”. “Nucleotides” as used herein refer to the building blocks of oligonucleotides and polynucleotides, and for the purposes of the present invention include both naturally occurring and non-naturally occurring nucleotides. In nature, nucleotides, such as DNA and RNA nucleotides comprise a ribose sugar moiety, a nucleobase moiety and one or more phosphate groups (which are absent in nucleosides). A nucleotide without a phosphate group is called a “nucleoside” and is thus a compound comprising a nucleobase moiety and a sugar moiety. As used herein, “nucleobase” means a group of atoms that can be linked to a sugar moiety to create a nucleoside that is capable of incorporation into an oligonucleotide, and wherein the group of atoms is capable of bonding with a complementary naturally occurring nucleobase of another oligonucleotide or nucleic acid. Naturally occurring nucleobases of RNA or DNA comprise the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U). The term “contiguous nucleotides” or “contiguous nucleotide sequence” refers to the region of the oligonucleotide which is complementary to the target nucleic acid. “Contiguous” as used herein means next or together in sequence, hence the contiguous nucleotides are linked nucleotides (i.e. no additional nucleosides are present between those that are linked). The target nucleic acid of the invention is Synaptogyrin-3. “Synaptogyrin3”, “synaptogyrin-3”, “Syngr3”, “Syngr-3”, “SYNGR3” or “SYNGR-3” are interchangeably used and refer herein to synaptogyrin-3 transcript if not otherwise specified. The human nucleic acid sequence of Synaptogyrin-3 is depicted in SEQ ID No. 1, however also within the scope of the invention are nucleic acid sequence variants of Synaptogyrin-3 as may exist due to allelic variation. Such variations are defined herein as “allelic variants of SEQ ID No.1”. The term “allelic variants” refer to one of several alternate forms of a gene occupying a given locus on a chromosome of an organism (Genes II, Lewin, B., ed., John Wiley & Sons, New York (1985)). These allelic variants can vary at either the polynucleotide and/or polypeptide level and are included in the present disclosure. Alternatively, non-naturally occurring variants can be produced by mutagenesis techniques or by direct synthesis. PaVer/SyngrASO2/799 The terms “oligomer” or “oligonucleotide” in the context of the present disclosure are used interchangeably and refer to a molecule formed by covalent linkage of two or more nucleotides. Herein, a single nucleotide (unit) can also be referred to as a monomer or unit. In some aspects, the present disclosure provides a derivative of an oligonucleotide of the present disclosure which is a conjugate, e.g., a GalNAc conjugate. The term “derivative” as used herein refers to a chemical compound related structurally to a compound disclosed herein (e.g., an oligonucleotide of the present disclosure), e.g., having the same carbon skeleton, but chemically modified to introduce, e.g., a side chain or group, in one or more positions, and wherein the derivative possesses a biological activity (e.g., the capacity to reduce Syngr3 expression) that is substantially similar to a biological activity of the entity or molecule it is a derivative. The term, “complementary” means that two sequences are complementary when the sequence of one can bind to the sequence of the other in an anti-parallel sense wherein the 3'-end of each sequence binds to the 5'-end of the other sequence and each A, T(U), G, and C of one sequence is then aligned with a T(U), A, C, and G, respectively, of the other sequence. Normally, the complementary sequence of the oligonucleotide has at least 90%, preferably 95%, most preferably 100% complementarity to a defined sequence. In determining the degree of “complementarity” between oligonucleotides of the disclosure (or regions thereof) and the target region, such as those disclosed herein, the degree of “complementarity” (also, “homology” or “identity”) is expressed as the percentage identity (or percentage homology) between the sequence of the oligonucleotide (or region thereof) and the sequence of the target region (or the reverse complement of the target region) that best aligns therewith. The percentage is calculated by counting the number of aligned bases that are identical between the two sequences, dividing by the total number of contiguous monomers (e.g. nucleotides) in the oligomer (e.g. oligonucleotide), and multiplying by 100. In such a comparison, if gaps exist, it is preferable that such gaps are merely mismatches rather than areas where the number of monomers within the gap differs between the oligomer of the disclosure and the target region. In some embodiments, the nucleic acid molecule described above or the contiguous nucleotide sequence thereof comprises or consists of less than 60 nucleotides, less than 59 nucleotides, less than 58 nucleotides, less than 57 nucleotides, less than 56 nucleotides, less than 55 nucleotides, less than 54 nucleotides, less than 53 nucleotides, less than 52 nucleotides, less than 51 nucleotides, less than 50 nucleotides, less than 49 nucleotides, less than 48 nucleotides, less than 47 nucleotides, less than 46 nucleotides, less than 45 nucleotides, less than 44 nucleotides, less than 43 nucleotides, less than 42 nucleotides, less than 41 nucleotides, less than 40 nucleotides, less than 39 nucleotides, less than 38 PaVer/SyngrASO2/799 nucleotides, less than 37 nucleotides, less than 36 nucleotides, less than 35 nucleotides, less than 34 nucleotides, less than 33 nucleotides, less than 32 nucleotides, less than 31 nucleotides, less than 30 nucleotides, less than 29 nucleotides, less than 28 nucleotides, less than 27 nucleotides, less than 26 nucleotides, less than 25 nucleotides, less than 24 nucleotides, less than 23 nucleotides, less than 22 nucleotides, less than 21 nucleotides, less than 20 nucleotides, less than 19 nucleotides, less than 18 nucleotides, less than 17 nucleotides, less than 16 nucleotides, less than 15 nucleotides, less than 14 nucleotides, less than 13 nucleotides, or less than 12 nucleotides. It is to be understood that any range given in current application includes the range endpoints. Accordingly, if a nucleic acid molecule is said to include from 10 to 30 nucleotides, both 10 and 30 nucleotides are included. In some embodiments, the contiguous nucleotide sequence comprises or consists of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29 or 30 contiguous nucleotides in length. In some aspects, the nucleic acid molecule of the invention is 14 nucleotides in length. In some aspects, the nucleic acid molecule of the invention is 15 nucleotides in length. In some aspects, the nucleic acid molecule of the invention is 16 nucleotides in length. In some aspects, the nucleic acid molecule of the invention is 17 nucleotides in length. In some aspects, the nucleic acid molecule of the invention is 18 nucleotides in length. In some aspects, the nucleic acid molecule of the invention is 19 nucleotides in length. In some aspects, the nucleic acid molecule of the invention is 20 nucleotides in length. In some aspects, the nucleic acid molecule of the invention is 21 nucleotides in length. In some aspects, the nucleic acid molecule of the invention is 22 nucleotides in length. In some aspects, the nucleic acid molecule of the invention is 24 nucleotides in length. The nucleic acid molecule(s) or oligonucleotide(s) of the application are typically for modulating the expression of Synaptogyrin-3 as target nucleic acid in a mammal. In some embodiments the nucleic acid molecule(s), such as siRNAs, shRNAs or antisense oligonucleotides, is typically for inhibiting the expression of a target nucleic acid. More particularly, the oligonucleotides of the application are provided as being capable of reducing the level of Synaptogyrin-3 (pre-)mRNA transcript (and thus indirectly SYNGR3 protein) in a cell, wherein the reduction is determined by comparison to a control situation, i.e. the level of Synaptogyrin-3 mRNA transcript in the same cell or same cell type grown in the same conditions but in the absence of the oligonucleotide of the application. The oligonucleotides described in the application are partially or fully complementary to an equal length portion of a target region within the Synaptogyrin-3 as depicted in SEQ ID No.1 or allelic variants thereof. PaVer/SyngrASO2/799 The specific target regions will be described in detail below. In another embodiment, the oligonucleotide of the invention comprises a contiguous nucleotide sequence which is complementary to one of said specific target regions, and may, in some embodiments further comprise one or more additional nucleotides, such as 1-30, such as 1-20, such as 1-10, such as 1, 2, 3, 4 or 5 further nucleotides in addition to the contiguous nucleotide sequence. In some embodiments the additional nucleotides are complementary to the contiguous nucleotide sequence and are capable of forming a stem loop (hairpin) structure by hybridizing to the contiguous nucleotide sequence. In some embodiments the additional nucleotides are 1 to 5 phosphodiester linked nucleotides. In some embodiments, all the nucleotides of the oligonucleotide form the contiguous nucleotide sequence. In one embodiment, the nucleic acid molecule(s) or the oligonucleotide(s) of the application is man- made and/or is chemically synthesized and/or is typically purified or isolated. In yet another embodiment, the oligonucleotide of the invention may be or comprise an antisense oligonucleotide (ASO) or may be another oligomeric nucleic acid molecule such as a CRISPR (g)RNA, a siRNA, shRNA, an aptamer or a ribozyme. In a particular embodiment the oligonucleotide of the invention is an antisense oligonucleotide (ASO), such as single stranded antisense oligonucleotide, such as a high affinity modified antisense oligonucleotide interacting with RNase H, such as a gapmer (for more details, see below). The term “antisense oligonucleotide” or “ASO” as used herein is defined as an oligonucleotide capable of modulating expression of a target gene by hybridizing to a target nucleic acid, in particular to a contiguous sequence on a target nucleic acid. The antisense oligonucleotides are not essentially double stranded and are therefore not siRNAs or shRNAs. Preferably, the antisense oligonucleotides of the present invention are single stranded. It is understood that single stranded oligonucleotides of the present invention can form hairpins or intermolecular duplex structures (duplex between two molecules of the same oligonucleotide), as long as the degree of intra or inter self- complementarity is less than 50% across of the full length of the oligonucleotide. In a further particular embodiment, the single stranded antisense oligonucleotide of the invention does not contain RNA nucleosides, since this will decrease nuclease resistance. More particularly, the antisense oligonucleotide of the invention comprises one or more modified nucleosides or nucleotides, such as 2’ sugar modified nucleosides. Furthermore, it is advantageous that the nucleosides which are not modified are DNA nucleosides. In another particular embodiment the oligonucleotide of the invention is a RNAi molecule or RNAi agent, more particularly a siRNA, di-siRNA, a shRNA or a miRNA. PaVer/SyngrASO2/799 The term “RNAi agent” or “RNA interference (RNAi) molecule” refers to any molecule inhibiting RNA expression or translation via the RNA reducing silencing complex (RISC) in a cell's cytoplasm, where the RNAi molecule interacts with the catalytic RISC component argonaute. A small interfering RNA (siRNA) is typically a double-stranded RNA complex comprising a passenger (sense) and a guide (antisense) oligonucleotide (strand), which when administered to a cell, results in the incorporation of the guide (antisense) strand into the RISC complex (siRISC) resulting in the RISC associated inhibition of translation or degradation of complementary RNA target nucleic acids in the cell. The sense strand is also referred to as the passenger strand, and the antisense strand as the guide strand. A small hairpin RNA (shRNA) is a single nucleic acid molecule which forms a stem loop (hairpin) structure that is able to degrade mRNA via RISC. RNAi nucleic acid molecules may be synthesized chemically (typical for siRNA complexes) or by in vitro transcription, or expressed from a vector. shRNA molecules are generally between 40 and 70 nucleotides in length, such as between 45 and 65 nucleotides in length, such as 50 and 60 nucleotides in length, and interacts with the endonuclease known as Dicer which is believed to processes dsRNA into 19-23 base pair short interfering RNAs with characteristic two base 3' overhangs which are then incorporated into an RNA-induced silencing complex (RISC). Typically, the guide (antisense) strand of an siRNA (or antisense region of a shRNA) is 17-25 nucleotide in length, such as 19-23 nucleotides in length and complementary to the target nucleic acid or target sequence. In an siRNA complex, the guide (antisense) strand and passenger (sense) strand form a double stranded duplex, which may comprise 3’ terminal overhangs of e.g.1- 3 nucleotides (resembles the product produced by Dicer), or may be blunt ended (no overhang at one or both ends of the duplex). It will be recognized that RNAi may be mediated by longer dsRNA substrates which are processed into siRNAs within the cell (a process which is thought to involve the dsRNA endonuclease DICER), such as miRNAs. In one embodiment, the oligonucleotide, e.g. the therapeutic antisense oligonucleotide, shRNA or siRNA, of the invention comprises one or more internucleoside linkages modified from the natural phosphodiester, such one or more modified internucleoside linkages that is for example more resistant to nuclease attack. The term “modified internucleoside linkage” is defined as generally understood by the skilled person as linkages other than phosphodiester (PO) linkages, that covalently couples two nucleosides together. Increased resistance of the oligonucleotide towards nucleases compared to a phosphodiester linkage is particular advantage for therapeutic oligonucleotides. Nuclease resistance may be determined by incubating the oligonucleotide in blood serum or by using a nuclease resistance assay (e.g. snake venom phosphodiesterase (SVPD)), both are well known in the art. Internucleoside linkages which are capable of enhancing the nuclease resistance of an oligonucleotide are referred to as PaVer/SyngrASO2/799 nuclease resistant internucleoside linkages. In some embodiments at least 50% of the internucleoside linkages in the oligonucleotide, or contiguous nucleotide sequence thereof, are modified, such as at least 60%, such as at least 70%, such as at least 80 or such as at least 90% of the internucleoside linkages in the oligonucleotide, or contiguous nucleotide sequence thereof, are nuclease resistant internucleoside linkages. In some embodiments all of the internucleoside linkages of the oligonucleotide, or contiguous nucleotide sequence thereof, are nuclease resistant internucleoside linkages. It will be recognized that, in some embodiments the nucleosides which link the oligonucleotide of the invention to a non- nucleotide functional group, such as a conjugate, may be phosphodiester. In a particular embodiment, the modified internucleoside linkage is phosphorothioate. Phosphorothioate internucleoside linkages are particularly useful due to nuclease resistance, beneficial pharmacokinetics and ease of manufacture. In some embodiments at least 50% of the internucleoside linkages in the oligonucleotide, or contiguous nucleotide sequence thereof, are phosphorothioate, such as at least 60%, such as at least 70%, such as at least 80% or such as at least 90% of the internucleoside linkages in the oligonucleotide, or contiguous nucleotide sequence thereof, are phosphorothioate. In some embodiments all of the internucleoside linkages of the oligonucleotide, or contiguous nucleotide sequence thereof, are phosphorothioate. The use of fully phosphorothioate modified oligonucleotides or contiguous nucleotide sequences is often used in antisense oligonucleotides, although in siRNAs partial phosphorothioate modifications may be preferred as fully phosphorothioate modifications have been reported to limit RNAi activity, particularly when used in the guide (antisense) strand. Phosphorothioate modifications may be incorporated into the 5’ and 3’ ends of an antisense strand of a siRNA without unduly limiting RNAi activity. Nuclease resistant linkages, such as phosphorothioate linkages, are particularly useful in oligonucleotide regions capable of recruiting nuclease when forming a duplex with the target nucleic acid, such as region G for gapmers. Phosphorothioate linkages may, however, also be useful in non-nuclease recruiting regions and/or affinity enhancing regions such as regions F and F’ for gapmers. Gapmer oligonucleotides may, in some embodiments comprise one or more phosphodiester linkages in region F or F’, or both region F and F’, which the internucleoside linkage in region G may be fully phosphorothioate. In particular embodiments, all the internucleoside linkages in the contiguous nucleotide sequence of the antisense oligonucleotide are phosphorothioate linkages. In other embodiments, antisense oligonucleotide may comprise other internucleoside linkages (other than phosphodiester and phosphorothioate), for example alkyl phosphonate / methyl phosphonate internucleosides. In some embodiments, the RNAi molecules of the disclosure comprise one or more phosphorothioate internucleoside linkages. In RNAi molecules internucleoside linkages may reduce the PaVer/SyngrASO2/799 nuclease cleavage in RICS and it is therefore advantageous that not all internucleoside linkages are modified. Phosphorothioate internucleoside linkages can advantageously be place in the 3’ and/or 5’ end of the RNAi molecule, in particular in part of the molecule that is not complementary to the target nucleic acid (e.g. the sense strand or passenger strand in an siRNA molecule). The region of the RNAi molecule that is complementary to the target nucleic acid (e.g. the antisense or guide strand in a siRNA molecule) may however also be modified in the first 2 to 3 internucleoside linkages in the 3’ and/or 5’ terminal. In other embodiments, the oligonucleotides of the disclosure may be chemically modified by incorporating high affinity nucleosides such as 2’ sugar modified nucleosides, such as 2’-4’ bicyclic ribose modified nucleosides, including LNA and cET or 2’ substituted modifications like of 2’-O-alkyl-RNA, 2’-O- methyl-RNA, 2’-alkoxy-RNA, 2’-O-methoxyethyl-RNA (MOE), 2’-amino-DNA, 2’-fluoro-DNA, arabino nucleic acid (ANA), 2’-fluoro-ANA. See for example WO 2002/044321 which discloses 2’-O-Methyl modified siRNAs, W02004083430 which discloses the use of LNA nucleosides in siRNA complexes, known as siLNAs, and W02007107162 which discloses the use of discontinuous passenger strands in siRNA such as siLNA complexes. In a particular embodiment, the oligonucleotide of the disclosure comprises a 2’ sugar modified nucleoside selected from the list consisting of 2ʹ-O-methyl (2ʹ-OMe), 2ʹ-O-methoxyethyl (2ʹ-MOE) and 2ʹ- Fluoro (2ʹ-F). In other embodiments, the oligonucleotides of the disclosure may comprise one or more of the above described chemically modified sugar nucleosides and may comprise one or more of the above described phosphorothioate internucleoside linkages. The skilled person is aware of how to design the oligonucleotides disclosed herein. siRNA and shRNA design programs are publicly and/or commercially available. Non-limiting examples are PFRED, an open source siRNA and ASO design tool from Pfizer (Sciabola et al 2020 PLoS One); the antisense LNA Gapmer Custom Builder Help from Qiagen; siDESIGN from ThermoScientific; siDirect (Naito et al); BLOCK-IT RNAi Designer from Invitrogen; siRNA Wizard from InvivoGen; shRNA design tool from Gene Link and shRNA design tool from transomic. Manufacturers of ASO and/or RNAi products also provide guidelines for designing ASO, siRNA and shRNA molecules. siRNA sequences between 19-29 nucleotides (nt) are generally the most effective. Sequences longer than 30 nt can result in nonspecific silencing. Ideal sites to target include AA dinucleotides and the 19 nt 3’ of them in the target mRNA sequence. Typically, siRNAs with 3’ dUdU or dTdT dinucleotide overhangs are more effective. Other dinucleotide overhangs could maintain activity but GG overhangs should Also to be avoided are siRNA designs with PaVer/SyngrASO2/799 a 4-6 poly(T) tract (acting as a termination signal for RNA pol III), and the G/C content is advised to be between 35-55%. shRNAs should comprise sense and antisense sequences (advised to each be 19-21 nt in length) separated by loop structure, and a 3’ AAAA overhang. Effective loop structures are suggested to be 3-9 nt in length. It is suggested to follow the sense-loop-antisense order in designing the shRNA cassette and to avoid 5’ overhangs in the shRNA construct. Finally, several companies commercially offer premade ASOs, siRNAs and shRNAs. In some aspects, any of the oligonucleotides of present disclosure are provided, wherein the oligonucleotide is an ASO or an RNAi molecule comprising at least one nucleotide variant (e.g., an LNA unit). In some aspects, the oligonucleotide of the present disclosure further comprises at least one non- nucleotide or non-polynucleotide moiety covalently (e.g., a GalNac moiety) attached to said oligonucleotide directly or via a linker positioned between the contiguous nucleotide sequence and the non-nucleotide or non-polynucleotide moiety. In some aspects, the present disclosure provides oligonucleotides of the present disclosure comprising 16 to 22 contiguous oligonucleotides in length comprising a contiguous sequence of 16 nucleotides in length which is 100% complementary to a human synaptogyrin-3 target sequence selected from the group consisting of SEQ ID No. 2-269, wherein oligonucleotide is an ASO or RNAi molecule such as a siRNA, shRNA or di-siRNA comprising at least one nucleotide variant (e.g., an LNA unit), and wherein the ASO or RNAi molecule targets the synaptogyrin-3 transcript as set forth in SEQ ID No.1. In some aspects, the oligonucleotide of the present disclosure comprises, consists, or consists essentially of an ASO or RNAi molecule binding to the human synaptogyrin-3 transcript as set forth in SEQ ID No.1, the ASO or RNAi molecule comprising a sequence selected from the group consisting of SEQ ID No.270- 489. In some aspects, the oligonucleotide of the present disclosure comprises an ASO or RNAi molecule comprising a sequence selected from the group consisting of SEQ ID No.270-489, except for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 nucleobase substitutions. In some aspects, the oligonucleotide of the present disclosure comprises an ASO or RNAi molecule comprising a sequence which is at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to a sequence selected from the group consisting of SEQ ID No.270-489. In some aspects, the oligonucleotide of the present disclosure comprises an ASO or RNAi molecule comprising a sequence which is about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, 99%, or about 100% identical to a sequence PaVer/SyngrASO2/799 selected from the group consisting of SEQ ID No.270-489. In some aspects, the oligonucleotide of the present disclosure comprises a sequence that overlaps with 9, 10, 11, 12, 13, 14, 15, or 16 nucleobase subsequence from a sequence selected from the group consisting of SEQ ID No.270-489. In some aspects, the oligonucleotide of the present disclosure comprises at least one non-cleavable internucleoside linkage, e.g., a phosphorothioate linkage. In some, aspects all the internucleoside linkages in an oligonucleotide of the present disclosure are non-cleavable, e.g., phosphorothioates linkages. In some aspects, the non-cleavable internucleoside linkages, e.g., a phosphorothioate linkages, are present only in the wing portions of a gapmer, e.g., the last 1, 2 or 3 linkages at the 5’ end or the oligonucleotide, and the last 1, 2 or 3 linkages at the 5’ end or the oligonucleotide. In some aspects, the oligonucleotide of the present disclosure comprises nucleotide analogues. In some aspects, the oligonucleotide of the present disclosure comprises affinity enhancing nucleotide analogues. In some aspects, the nucleotide analogues are sugar modified nucleotides, such as sugar modified nucleotides independently or dependently selected from the group consisting of 2'-O-alkyl-RNA units, 2'-OMe-RNA units, 2'-amino-DNA units, and 2'-fluoro-DNA units. In some aspects, the oligonucleotide of the present disclosure is an ASO or the antisense strand from an RNA duplex. In some aspects, the oligonucleotide of the present disclosure comprises one or more locked nucleic acids (LNA). In some aspects, the LNA oligonucleotide comprises a wing on each side (5' and 3') of 2 to 4 nucleotide analogues, preferably LNA analogues. In some aspects, the oligonucleotide of the present disclosure can optionally comprise a further 1 to 6 nucleotides (e.g., one, two, three, four, five or six nucleotides), which can form or comprise a biocleavable nucleotide region, such as a phosphate nucleotide linker. In some aspects, the biocleavable nucleotide region is formed of a short stretch of nucleotides (e.g. 1, 2, 3, 4, 5 or 6 nucleotides) which are physiologically labile. This can be achieved by using phosphodiester linkages with DNA/RNA nucleosides, or if physiological liability can be maintained, other nucleoside can be used. In some aspects, the LNA is oxy-LNA, thio-LNA, amino-5 LNA, 5'-methyl-LNA, ENA, cET, cMOE or a combination thereof. In some aspects, the LNA is an stereoisomer in the beta-D configuration or the alpha-L configuration. In some aspects, the oligonucleotide of the application comprises at least one cET unit. In some aspects, the oligonucleotide comprises 2, 3, 4, 5, 6 or 7 LNA units. In some aspects, every LNA unit in the oligonucleotide is a stereoisomer in the same configuration. In some aspects, every LNA unit in the oligonucleotide is a beta-D-oxy LNA unit or every LNA unit in the oligonucleotide is an alpha- L-oxy-LNA unit. In some aspects, the of the oligonucleotide comprises at least one PaVer/SyngrASO2/799 phosphorothioate, phosphorodithioate, or boranophosphate internucleoside linkage. In some aspects, one or more of the internucleoside linkages comprises a chiral center in the R conformation and/or in the S conformation. In some aspects, the oligonucleotide comprising an LNA can form a duplex with a human synaptogyrin-3 target sequence selected from the group consisting of SEQ ID No.2-269 of with increased thermal stability with respect to a corresponding duplex comprising the corresponding oligonucleotide without LNA. In some aspects, the oligonucleotide of the present disclosure is an ASO or an RNAi molecule conjugate comprising an ASO or RNAi molecule covalently attached to non-nucleotide or non-polynucleotide moiety, which can be attached to the 5’ end, 3’ end, or both. In some aspects, the non-nucleotide or non-polynucleotide moiety is a targeting moiety that is attached to the 5’-end or to the 3’-end of the ASO or RNAi molecule. In some aspects, the targeting moiety is linked to the ASO or RNAi molecule via a linker. In some aspects, the targeting moiety comprises a carbohydrate conjugate moiety comprising a carbohydrate selected from the group consisting of galactose, lactose, N-acetylgalactosamine (GalNAc), mannose, mannose-6-phosphate, and combinations thereof. In some aspects, the carbohydrate conjugate moiety is not a linear carbohydrate polymer. In some aspects, the carbohydrate conjugate moiety is a carbohydrate group comprising 1, 2, 3, or 4 carbohydrate moieties. In some aspects, the carbohydrate moieties are identical or non-identical. In some aspects, the carbohydrate conjugate moiety comprises at least one asialoglycoprotein receptor targeting conjugate moiety. In some aspects, the asialoglycoprotein receptor targeting conjugate moiety comprises a monovalent, divalent, trivalent, or tetravalent GalNAc cluster. In some aspects, each GalNAc in the GalNAc cluster is attached to a branch point group via a spacer. In some aspects, the branch point group comprises di-lysine. In some aspects, the spacer comprises a PEG spacer. In some aspects, the linker comprises a C6 to C12 amino alkyl group or a biocleavable phosphate nucleotide linker comprising between 1 to 6 nucleotides. In some aspects, the targeting moiety targets the oligonucleotide of the present disclosure to the central nervous system (CNS). In some aspects, the targeting moiety allow the oligonucleotide of the present disclosure to permeate through the blood-brain-barrier (BBB). In some aspects, the oligonucleotide of the application, more particularly the RNAi molecule of the application is a double stranded nucleic acid. In some aspects, the RNAi molecule is a siRNA. In some aspects, the RNAi molecule of the present disclosure is a di-siRNA. In some aspects, the RNAi molecule of the present disclosure is a shRNA. In some aspects, the antisense oligomer portion of an oligonucleotide of the present disclosure is an antisense oligonucleotide (ASO). In some aspects, the antisense oligomer portion of an oligonucleotide of the present disclosure is multimeric. In some aspects, PaVer/SyngrASO2/799 the antisense oligomer portion of an oligonucleotide of the present disclosure is a multimeric ASO, e.g., it can comprise several concatenated antisense oligomers of the present disclosure. In some aspects, the antisense oligomer portion of an oligonucleotide of the present disclosure comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more than 10 concatenated antisense oligomers. In some aspects, the concatenated oligomers are connected via cleavable linkers interposed between each ASO unit in the ASO multimer. In some aspects, the antisense oligomer portion of an oligonucleotide of the present disclosure can target a target region in the synaptogyrin-3 mRNA selected from the group consisting of SEQ ID No.2- 269. In some aspects, the antisense oligomer portion of an oligonucleotide of the present disclosure comprises a complementarity region that is complementary to at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16 nucleotides of a target region in the synaptogyrin-3 mRNA selected from the group consisting of SEQ ID No.2-269. The oligonucleotides of the present disclosure are capable of modulating the expression of the synaptogyrin-3 gene by specifically targeting a targeting region in a synaptogyrin-3 RNA, e.g., a mRNA or pre-mRNA. In some aspects, the oligonucleotide of the present disclosure is capable of down-regulating expression of the synaptogyrin-3 gene by binding to such target region. Thus, in some aspects, the oligonucleotide of the present disclosure can affect (reduce or inhibit) the expression of synaptogyrin-3, e.g., in a mammalian subject such a human, by binding to a specific target region in a synaptogyrin-3 RNA, e.g., an mRNA or pre-mRNA. In some aspects, the oligonucleotide of the present disclosure can affect the expression of synaptogyrin-3 in a human cell, by binding to a specific target region in a synaptogyrin-3 RNA, e.g., an mRNA. In some aspects, the RNA is an mRNA, such as pre-mRNA. In some aspects, the RNA is a mature mRNA. The oligonucleotide according to the present disclosure is preferably capable of hybridizing to the target nucleic acid. In some aspects, the target sequence can extend 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides beyond the 5’ end of a synaptogyrin-3 target region comprising or consisting of a sequence set forth in SEQ ID No.2- 269. In some aspects, the target sequence can extend 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides beyond the 3’ end of a synaptorgyrin-3 target region comprising or consisting of a sequence set forth in SEQ ID No. SEQ ID No. 2-269. In some aspects, the target sequence can extend 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides beyond the 5’ end and/or 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides beyond the 3’ end of a synaptogyrin-3 target region comprising or of a sequence set forth in SEQ ID No. 2-269. In PaVer/SyngrASO2/799 some aspects, the extended target region overlaps with 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16 nucleotides of a synaptogyrin-3 target region comprising or consisting of a sequences set forth in SEQ ID No.2-269. In some aspects, the nucleotides extending beyond the 5’ end and/or the 3’ end of a sequence set forth in SEQ ID No.2-269 is complementary (partially or fully complementary) to a corresponding sequence in the nucleotide sequence of SEQ ID No.1. The present disclosure also provides antisense oligonucleotides that are complementary, e.g., fully complementary, to these target sequences. In some aspects, the present disclosure provides a target sequence comprising a 21-mer sequence selected from SEQ ID No.10, 12, 20, 25, 29-31, 33, 50, 53, 58-59, 62, 69, 79, 84, 87, 91, 94, 110-111, 135, 140-141, 170, 172, 179, 181, 184, 188, 193-194, 210, 216, 220-221, 224, 227, 229, 231, 235, 241, 246, 248, 250, 259, 268 or 269, or a 12, 13, 14, 15, 16, 17, 18, 19, or 20-mer subsequence thereof. Furthermore, the present disclosure provides a target sequence comprising (i) a sequence selected from the group consisting of SEQ ID No.10, 12, 20, 25, 29-31, 33, 50, 53, 58-59, 62, 69, 79, 84, 87, 91, 94, 110- 111, 135, 140-141, 170, 172, 179, 181, 184, 188, 193-194, 210, 216, 220-221, 224, 227, 229, 231, 235, 241, 246, 248, 250, 259, 268 or 269, and 12-mer, 13-mer, 14-mer, 15-mer, 16-mer, 17-mer, 18-mer, 19- mer, or 20-mer subsequences thereof, plus (ii) 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 additional 5’ nucleotides and/or 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 additional 3’ nucleotides. In some aspects, the additional 5’ and/or 3’ nucleotides are complementary (partially or fully complementary) to a corresponding sequence in the mRNA transcript of SEQ ID No. 1. The present disclosure also provides antisense oligonucleotides that are complementary, e.g., fully complementary, to these target sequences. In some aspects, the present disclosure provides a target sequence comprising a 16-mer sequence selected from SEQ ID No.2-9, 11, 13-19, 21-24, 26-28, 32, 34-49, 51-52, 54-57, 60-61, 63-68, 70-78, 80- 83, 85-86, 88-90, 92-93, 95-109, 112-134, 136-139, 142-169, 171, 173-178, 180, 182-183, 185-187, 189- 192, 195-209, 211-215, 217-219, 222-223, 225-226, 228, 230, 232-234, 236-240, 242-245, 247, 249, 251- 258 or 260-267, or a 12, 13, 14, 15-mer subsequence thereof. Furthermore, the present disclosure provides a target sequence comprising (i) a sequence selected from the group consisting of SEQ ID No. 2-9, 11, 13-19, 21-24, 26-28, 32, 34-49, 51-52, 54-57, 60-61, 63-68, 70-78, 80-83, 85-86, 88-90, 92-93, 95-109, 112-134, 136-139, 142-169, 171, 173-178, 180, 182-183, 185-187, 189-192, 195-209, 211-215, 217-219, 222-223, 225-226, 228, 230, 232-234, 236-240, 242-245, 247, 249, 251-258 or 260-267, and 12- mer, 13-mer, 14-mer, 15-mer, 16-mer, 17-mer, 18-mer, 19-mer, or 20-mer subsequences thereof, plus (ii) 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 additional 5’ nucleotides and/or 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 additional 3’ nucleotides. In some aspects, the additional 5’ and/or 3’ nucleotides are complementary (partially or fully complementary) to a corresponding in the mRNA transcript of SEQ ID No.1. The present PaVer/SyngrASO2/799 disclosure also provides antisense oligonucleotides that are complementary, e.g., fully complementary, to these target sequences. In some aspects, the target region comprises or consists of a corresponding target sequence region derived from the sequence of a mutant or allelic variant of a human synaptogyrin-3 gene encoding the mRNA transcript of SEQ ID No. 1. In other aspects, the target region can be a subsequence present in another synaptogyrin-3 mRNA transcript variant encoding human synaptogyrin-3. In some aspects, the target region comprises or consists of a corresponding target sequence region derived from the sequence of a paralog or ortholog of the human synaptogyrin-3 gene encoding the pre-mRNA of SEQ ID No.1. In some aspects, the target region is within an exon. In some aspects, the target region comprises the junction between and intron and an exon. In some aspects, the oligonucleotides of the present disclosure bind to the target nucleic acid (e.g., a subsequence of an mRNA or pre-mRNA transcript wherein the subsequence is selected from the group consisting of SEQ ID No.2-269 and the effect on synaptogyrin-3 expression and/or activity level is at least about 10% to about 20% reduction in synaptogyrin-3 expression and/or activity level compared to the normal or control synaptogyrin-3 expression level (e.g., the synaptogyrin-3 expression level of a cell, animal or human treated with saline) and/or normal or control synaptogyrin-3 activity level (e.g. the expression level of a cell, animal or human treated with saline). In some aspects, the reduction in synaptogyrin-3 expression and/or activity is at least about 10%, about least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% compared to the normal or control expression and/or activity level. In some aspects, the reduction in synaptogyrin-3 expression and/or activity is about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% compared to the normal or control synaptogyrin-3 expression and/or activity level. In some aspects, the synaptogyrin-3 expression level and/or protein level and/or activity level after the administration of an oligonucleotide of the present disclosure is less than about 2%, less than about 5%, less than about 10%, less than about 15%, less than about 20%, less than about 25%, less than about 30%, less than about 35%, less than about 40%, less than about 45%, less than about 50%, less than PaVer/SyngrASO2/799 about 55%, less than about 60%, less than about 65%, less than about 70%, less than about 75%, or less than about 80% of the synaptogyrin-3 expression level and/or protein level and/or activity level prior to the administration of an oligonucleotide of the present disclosure. In some aspects, the synaptogyrin-3 expression level and/or protein level and/or activity level after the administration of an oligonucleotide of the present disclosure is about 2% to about 5%, about 5% to about 10%, about 10% to about 15%, about 15% to about 20%, about 20%, to about 25%, about 25% to about 30%, about 30% to about 35%, about 35% to about 40%, about 40% to about 45%, about 45% to about 50%, about 50% to about 55%, about 55% to about 60%, about 60% to about 65%, about 65% to about 70%, about 70% to about 75%, or about 75% to about 80% of the synaptogyrin-3 expression level and/or protein level and/or activity level prior to the administration of an oligonucleotide of the present disclosure. The present disclosure therefore provides an in vitro or in vivo method of down-regulating or inhibiting the expression of synaptogyrin-3 protein and/or mRNA transcript in a cell which is expressing synaptogyrin-3 protein and/or mRNA, said method comprising administering an oligonucleotide of the present disclosure, e.g., as a pharmaceutical composition of the present disclosure to said cell to down- regulate or inhibit the expression of synaptogyrin-3 protein and/or mRNA in said cell. Suitably the cell is a mammalian cell such as a human cell. It is to be understood that in some aspects the oligonucleotides of the present disclosure can be multimers comprising, e.g., 2, 3, 4, 5, 6, or more concatenated oligonucleotides disclosed herein, which can optionally be connected by spacers or linkers comprising nucleotide or non-nucleotide units interposed between each oligonucleotide in the multimer. Accordingly, in some aspects, the oligonucleotides of the present disclosure can comprise or consist of a contiguous nucleotide sequence of a total of at least about 20, at least about 25, at least about 30, at least about 35, at least about 40, at least about 45, at least about 50, at least about 55, at least about 60, at least about 65, at least about 70, at least about 75, at least about 80, at least about 85, at least about 90, at least about 95, at least about 100, at least about 110, at least about 120, at least about 130, at least about 140, at least about 150, at least about 160, at least about 170, at least about 180, at least about 190, or at least about 200 contiguous nucleotides in length. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in ID No. 270, or a 12 to 16 contiguous nucleotides PaVer/SyngrASO2/799 subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.271, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.272, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No. 273, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.274, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.275, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No. 276, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.277, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.278, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No. 279, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.280, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.281, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No. 282, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.283, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.284, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded PaVer/SyngrASO2/799 oligomer comprising an antisense sequence set forth in SEQ ID No. 285, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.286, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.287, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No. 288, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.289, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.290, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No. 291, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.292, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.293, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No. 294, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.295, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.296, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No. 297, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.298, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.299, or a 12 to 16 nucleotides subsequence thereof, e.g., a PaVer/SyngrASO2/799 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No. 300, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.301, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer.In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.302, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer.In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No. 303, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer.In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.304, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer.In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.305, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer.In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No. 306, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer.In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.307, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer.In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.308, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer.In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No. 309, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer.In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.310, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer.In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.311, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer.In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No. 312, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer.In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.313, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer.In some aspects, the oligonucleotide of the present disclosure a single stranded oligomer comprising an antisense PaVer/SyngrASO2/799 sequence set forth in SEQ ID No.314, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer.In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No. 315, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer.In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.316, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer.In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.317, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer.In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No. 318, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer.In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.319, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer.In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.320, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer.In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No. 321, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer.In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.322, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer.In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.323, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer.In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No. 324, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.325, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer.In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.326, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer.In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No. 327, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer.In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.328, or a 12 to 16 contiguous nucleotides thereof, e.g., a 16-mer.In some aspects, the PaVer/SyngrASO2/799 oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.329, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No. 330, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.331, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.332, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No. 333, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.334, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.335, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No. 336, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.337, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.338, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No. 339, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.340, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.341, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No. 342, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer an antisense sequence set forth in SEQ ID PaVer/SyngrASO2/799 No.343, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.344, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No. 345, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.346, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer.In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.347, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer.In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No. 348, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer.In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.349, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer.In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.350, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No. 351, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.352, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.353, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No. 354, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.355, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.356, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No. 357, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present PaVer/SyngrASO2/799 disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.358, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.359, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No. 360, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.361, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.362, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No. 363, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.364, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.365, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No. 366, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.367, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer.In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.368, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer.In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No. 369, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer.In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.370, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer.In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.371, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No. 372, or a 12 to 16 contiguous PaVer/SyngrASO2/799 nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.373, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.374, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No. 375, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.376, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.377, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No. 378, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.379, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.380, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No. 381, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.382, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.383, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No. 384, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.385, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.386, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded PaVer/SyngrASO2/799 oligomer comprising an antisense sequence set forth in SEQ ID No. 387, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.388, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer.In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.389, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer.In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No. 390, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer.In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.391, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer.In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.392, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No. 393, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.394, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.395, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No. 396, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.397, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.398, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No. 399, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.400, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.401, or a 12 to 16 nucleotides subsequence thereof, e.g., a PaVer/SyngrASO2/799 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No. 402, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.403, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.404, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No. 405, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.406, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.407, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No. 408, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.409, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer.In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.410, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer.In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No. 411, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer.In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.412, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer.In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.413, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No. 414, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.415, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure a single stranded oligomer comprising an antisense PaVer/SyngrASO2/799 sequence set forth in SEQ ID No.416, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No. 417, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.418, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.419, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No. 420, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.421, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.422, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No. 423, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.424, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.425, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No. 426, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.427, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.428, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No. 429, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.430, or a 12 to 16 contiguous nucleotides thereof, e.g., a 16-mer.In some aspects, the PaVer/SyngrASO2/799 oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.431, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer.In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No. 432, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer.In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.433, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer.In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.434, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No. 435, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.436, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.437, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No. 438, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.439, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.440, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No. 441, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.442, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.443, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No. 444, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer an antisense sequence set forth in SEQ ID PaVer/SyngrASO2/799 No.445, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.446, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No. 447, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.448, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.449, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No. 450, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.451, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer.In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.452, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer.In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No. 453, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer.In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.454, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer.In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.455, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No. 456, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.457, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.458, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No. 459, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present PaVer/SyngrASO2/799 disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.460, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.461, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No. 462, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.463, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.464, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No. 465, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.466, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.467, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No. 468, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.469, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.470, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No. 471, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.472, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer.In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.473, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer.In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No. 474, or a 12 to 16 contiguous PaVer/SyngrASO2/799 nucleotides subsequence thereof, e.g., a 16-mer.In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.475, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer.In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.476, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No. 477, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.478, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.479, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No. 480, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.481, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.482, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No. 483, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.484, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.485, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No. 486, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.487, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded oligomer comprising an antisense sequence set forth in SEQ ID No.488, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects, the oligonucleotide of the present disclosure comprises a single stranded PaVer/SyngrASO2/799 oligomer comprising an antisense sequence set forth in SEQ ID No. 489, or a 12 to 16 contiguous nucleotides subsequence thereof, e.g., a 16-mer. In some aspects of the antisense sequence disclosed above, all odd positions in the antisense sequence comprise a 2'O-Methyl modification and all even positions in the antisense sequence comprise a 2'fluoro modification. In some aspects of the antisense sequences disclosed above the first two 5' and the last two 3' internucleoside linkages are phosphorothioate. In some aspects, the nucleic acid of the present disclosure is a duplex (e.g., a siRNA or an shRNA) comprising the antisense sequence disclosed above and a sense strand which is partially of fully complementary to said antisense sequence. In some aspects of said nucleic acid duplex sequences, the 3' end of the sense strand and the 5' end of the antisense strand are connected by a loop. In some aspects of said nucleic acid duplex sequences, all odd positions in the antisense strand sequence comprise a 2'- O-Methyl modification and all even positions in the antisense sequence comprise a 2'-Fluoro modification. In some aspects of said nucleic acid duplex sequences, all even positions in the sense sequence comprise a 2'-O-Methyl modification, and all off positions in the sense strand sequence comprise a 2'-Fluoro modification, except the first 5' end nucleotide (position 1) which comprises a 2'- O-Methyl modification. In some aspects of said nucleic acid duplex sequences, the first two 5' and the last two 3' internucleoside linkages of the sense strand are phosphorothioate. In some aspects of said nucleic acid duplex sequences, the first two 5' and the last two 3' internucleoside linkages of the antisense strand are phosphorothioate. The target regions within Synaptogyrin-3 of the application It was surprisingly found that some regions within the Synaptogyrin-3 pre-mRNA transcript are significantly more accessible for oligonucleotides such as ASO molecules and therefore are preferred regions for designing oligonucleotides suitable for or capable of reducing the expression and/or activity of Synaptogyrin-3. By transcript-walking the borders of the identified regions were determined (Table 1). The level of Syngr-3 mRNA was determined in SH-SY5Y cells using 30 nM and 3 nM doses of ASOs comprising a 16-mer oligonucleotide sequence. A dose response curve (DRC) was determined for ASOs that could significantly reduce the Syngr-3 mRNA transcript level (Table 2). PaVer/SyngrASO2/799 Table 1. Overview of ASO molecules developed and tested by the inventors of current application listed based on their binding position on the synaptogyrin-3 transcript as set forth in SEQ ID No.1 from 5’ to 3’. X-reactivity SH-SY5Y primary transcript (main Dual dose isoform) 5' position of 3' position of n s target site target site a o u e s su % inhib. at % inhib. at according to according to m n u y e H C h o R M 3 nM 30 nM SEQ ID No.1 SEQ ID No.1 322 337 1 0 0 0 14 22 323 338 1 0 0 0 21 21 324 339 1 0 0 0 24 24 325 340 1 0 0 0 5 29 326 341 1 0 0 0 16 29 327 342 1 0 0 0 15 31 328 343 1 0 0 0 7 25 329 344 1 0 0 0 20 25 330 345 1 0 0 0 18 32 394 409 1 1 1 0 22 39 396 411 1 1 1 0 16 30 398 413 1 1 1 0 17 41 447 462 1 1 1 0 23 43 448 463 1 1 1 0 31 44 492 507 1 0 0 1 28 52 493 508 1 0 0 1 38 58 494 509 1 0 0 1 35 46 495 510 1 0 0 1 35 48 496 511 1 0 0 1 32 47 500 515 1 0 0 1 23 52 501 516 1 0 0 1 21 57 502 517 1 0 0 1 27 52 517 532 1 1 1 0 0 26 533 548 1 0 0 0 3 25 548 563 1 1 1 0 5 15 587 602 1 1 1 0 38 45 639 654 1 0 0 0 15 40 684 699 1 1 1 0 35 45 694 709 1 1 1 1 47 51 695 710 1 1 1 1 29 45 696 711 1 1 1 1 28 56 697 712 1 1 1 0 19 47 698 713 1 1 1 0 26 45 700 715 1 1 1 0 34 52 719 734 1 1 1 1 19 42 770 785 1 1 1 0 16 47 771 786 1 1 1 0 20 48 773 788 1 1 1 0 20 51 775 790 1 1 1 0 9 46 861 876 1 1 1 0 32 44 863 878 1 1 1 0 38 37 914 929 1 1 1 0 15 41 PaVer/SyngrASO2/799 X-reactivity SH-SY5Y primary transcript (main Dual dose isoform) 5' position of 3' position of n s target site target site a o u es m n se u % inhib. at % inhib. at according to according to u y H C h o R M 3 nM 30 nM SEQ ID No.1 SEQ ID No.1 956 971 1 0 0 0 25 55 966 981 1 0 0 0 40 48 1052 1067 1 0 0 0 36 54 1094 1109 1 1 1 0 14 25 1133 1148 1 0 0 0 -1 25 1148 1163 1 0 0 0 1 22 1196 1211 1 0 0 0 -18 11 1208 1223 1 0 0 0 33 51 1257 1272 1 1 1 0 13 41 1270 1285 1 1 1 0 32 56 1276 1291 1 1 1 0 46 53 1282 1297 1 1 1 0 21 49 1295 1310 1 1 1 0 23 51 1296 1311 1 1 1 0 10 49 1297 1312 1 1 1 0 14 46 1299 1314 1 1 1 0 9 48 1300 1315 1 1 1 0 7 50 1301 1316 1 1 1 0 35 59 1302 1317 1 1 1 0 51 56 1303 1318 1 1 1 0 49 49 1304 1319 1 1 1 0 31 53 1305 1320 1 1 1 0 22 57 1306 1321 1 1 1 0 18 54 1307 1322 1 1 1 0 17 50 1309 1324 1 1 1 0 17 56 1330 1345 1 1 1 0 44 43 1331 1346 1 1 1 0 41 39 1356 1371 1 1 1 0 28 51 1357 1372 1 1 1 0 22 50 1399 1414 1 1 1 0 20 50 1400 1415 1 1 1 0 15 49 1401 1416 1 1 1 0 25 47 1412 1427 1 1 1 0 25 47 1502 1517 1 1 1 0 45 47 1506 1521 1 1 1 0 29 48 1513 1528 1 1 1 0 30 38 1514 1529 1 1 1 0 28 39 1556 1571 1 1 1 0 41 45 1559 1574 1 1 1 0 25 48 1560 1575 1 1 1 0 26 45 1561 1576 1 1 1 0 39 45 1562 1577 1 1 1 0 34 53 1563 1578 1 1 1 0 28 55 1603 1618 1 1 1 0 42 58 1604 1619 1 1 1 0 52 61 1605 1620 1 1 1 0 49 60 1606 1621 1 1 1 0 34 55 1607 1622 1 1 1 0 38 55 PaVer/SyngrASO2/799 X-reactivity SH-SY5Y primary transcript (main Dual dose isoform) 5' position of 3' position of n s target site target site a o u es m n % inhib. at % inhib. y se u at according to according to u H C h o R M 3 nM 30 nM SEQ ID No.1 SEQ ID No.1 1608 1623 1 1 1 0 12 56 1609 1624 1 1 1 0 30 55 1610 1625 1 1 1 0 38 54 1636 1651 1 0 0 0 43 55 1701 1716 1 1 1 0 42 55 1735 1750 1 0 0 0 50 59 1737 1752 1 0 0 0 45 58 1757 1772 1 0 0 0 2 47 1823 1838 1 0 0 0 -1 37 1841 1856 1 1 1 0 37 52 1845 1860 1 1 1 0 17 53 1875 1890 1 1 1 0 20 51 1895 1910 1 0 0 0 40 53 1913 1928 1 1 1 0 40 60 1951 1966 1 0 0 0 18 59 1972 1987 1 0 0 0 54 54 2013 2028 1 0 0 0 60 64 2031 2046 1 1 1 0 40 62 2032 2047 1 1 1 0 49 62 2033 2048 1 1 1 0 47 62 2034 2049 1 1 1 0 42 56 2036 2051 1 1 1 0 44 54 2037 2052 1 1 1 0 45 49 2038 2053 1 1 1 0 47 55 2039 2054 1 1 1 0 41 53 2040 2055 1 1 1 0 50 54 2041 2056 1 1 1 0 48 61 2042 2057 1 1 1 0 49 56 2043 2058 1 1 1 0 37 48 2045 2060 1 1 1 0 33 53 2047 2062 1 1 1 0 33 57 2124 2139 1 1 1 0 43 59 2125 2140 1 1 1 0 18 60 2126 2141 1 1 1 0 13 55 2129 2144 1 1 1 0 31 64 2130 2145 1 1 1 0 10 53 2131 2146 1 1 1 0 20 58 2132 2147 1 1 1 0 22 58 2133 2148 1 1 1 0 14 56 2134 2149 1 1 1 0 26 49 2135 2150 1 1 1 0 44 53 2136 2151 1 1 1 0 46 47 2138 2153 1 1 1 0 45 51 2139 2154 1 1 1 0 30 56 2140 2155 1 1 1 0 38 56 2141 2156 1 1 1 0 44 57 2153 2168 1 1 1 0 39 65 2154 2169 1 1 1 0 40 65 PaVer/SyngrASO2/799 X-reactivity SH-SY5Y primary transcript (main Dual dose isoform) 5' position of 3' position of n s target site target site a o u es m n % inhib. at % inhib. y se u at according to according to u H C h o R M 3 nM 30 nM SEQ ID No.1 SEQ ID No.1 2155 2170 1 1 1 0 49 63 2156 2171 1 1 1 0 39 61 2157 2172 1 1 1 0 27 56 2158 2173 1 1 1 0 32 62 2159 2174 1 1 1 0 42 63 2160 2175 1 1 1 0 21 63 2206 2221 1 1 1 0 21 57 2208 2223 1 1 1 0 23 52 2212 2227 1 1 1 0 51 45 2213 2228 1 1 1 0 50 39 2265 2280 1 1 1 0 12 30 2266 2281 1 1 1 0 17 32 2267 2282 1 1 1 0 25 37 2306 2321 1 1 1 0 34 25 2307 2322 1 1 1 0 30 34 2315 2330 1 1 1 0 37 56 2316 2331 1 1 1 0 36 53 2323 2338 1 1 1 0 43 58 2330 2345 1 1 1 0 28 49 2333 2348 1 1 1 0 23 54 2334 2349 1 1 1 0 34 50 2336 2351 1 1 1 0 44 52 2337 2352 1 1 1 0 38 57 2340 2355 1 1 1 0 -1 48 2342 2357 1 1 1 0 8 55 2346 2361 1 1 1 1 11 51 2350 2365 1 1 1 1 25 48 2355 2370 1 1 1 0 37 53 2356 2371 1 1 1 0 34 54 2357 2372 1 1 1 0 26 61 2358 2373 1 1 1 0 15 57 2359 2374 1 1 1 0 25 47 2360 2375 1 1 1 0 19 53 2382 2397 1 1 1 0 2 54 2383 2398 1 1 1 0 21 54 2385 2400 1 1 1 0 21 52 2386 2401 1 1 1 0 31 48 2388 2403 1 1 1 0 24 47 2389 2404 1 1 1 0 32 49 2390 2405 1 1 1 0 25 48 2394 2409 1 0 0 0 2 50 2395 2410 1 0 0 0 27 55 2397 2412 1 0 0 0 20 52 2414 2429 1 1 1 1 8 28 2415 2430 1 1 1 1 12 28 2421 2436 1 1 1 0 45 67 2427 2442 1 1 1 0 29 37 2475 2490 1 1 1 0 11 53 PaVer/SyngrASO2/799 X-reactivity SH-SY5Y primary transcript (main Dual dose isoform) 5' position of 3' position of n s target site target site a o u es m n se u % inhib. at % inhib. at according to according to u y H C h o R M 3 nM 30 nM SEQ ID No.1 SEQ ID No.1 2476 2491 1 1 1 0 33 61 2477 2492 1 1 1 0 53 48 2478 2493 1 1 1 0 51 43 2498 2513 1 1 1 0 31 48 2499 2514 1 1 1 0 12 50 2611 2626 1 1 1 0 0 20 2612 2627 1 1 1 0 14 31 2613 2628 1 1 1 0 -4 16 2614 2629 1 1 1 0 -7 8 2615 2630 1 1 1 0 1 11 2616 2631 1 1 1 0 0 12 2648 2663 1 1 1 0 19 27 2732 2747 1 1 1 0 43 47 2782 2797 1 0 0 0 19 25 2810 2825 1 0 0 0 11 25 2831 2846 1 0 0 0 10 37 2874 2889 1 1 0 0 1 21 2919 2934 1 0 0 0 -9 20 2920 2935 1 0 0 0 -10 14 2926 2941 1 0 0 0 -8 1 2953 2968 1 0 0 0 3 30 2954 2969 1 0 0 0 -3 25 2956 2971 1 0 0 0 -3 26 2957 2972 1 0 0 0 13 23 2958 2973 1 0 0 0 4 23 2959 2974 1 0 0 0 3 33 2960 2975 1 0 0 0 9 33 2961 2976 1 0 0 0 13 35 2980 2995 1 1 1 0 46 50 2983 2998 1 1 1 0 31 46 3011 3026 1 1 1 0 37 50 3013 3028 1 1 1 0 18 47 3017 3032 1 1 1 0 32 56 3034 3049 1 1 1 0 38 47 3042 3057 1 1 1 0 15 47 3043 3058 1 1 1 0 23 46 3046 3061 1 1 1 0 16 48 3072 3087 1 1 1 0 8 37 3147 3162 1 1 1 0 0 17 3150 3165 1 1 1 0 12 23 3152 3167 1 1 1 0 7 25 3188 3203 1 1 1 0 7 45 3192 3207 1 1 1 1 18 45 3194 3209 1 1 1 1 40 50 3195 3210 1 1 1 1 41 49 3196 3211 1 1 1 1 43 56 3214 3229 1 1 1 1 33 50 3219 3234 1 1 1 0 28 52 PaVer/SyngrASO2/799 X-reactivity SH-SY5Y primary transcript (main Dual dose isoform) 5' position of 3' position of n s target site target site a o u es m n % inhib. at % inhib. y se u at according to according to u H C h o R M 3 nM 30 nM SEQ ID No.1 SEQ ID No.1 3231 3246 1 1 1 0 53 58 3232 3247 1 1 1 0 47 51 3233 3248 1 1 1 0 47 39 3236 3251 1 1 1 0 49 40 3237 3252 1 1 1 0 49 54 3238 3253 1 1 1 0 34 56 3239 3254 1 1 1 0 45 58 3240 3255 1 1 1 0 41 55 3276 3291 1 1 1 0 25 46 3293 3308 1 1 1 0 29 50 3294 3309 1 1 1 0 31 50 3295 3310 1 1 1 0 36 49 3322 3337 1 1 1 0 48 43 3395 3410 1 1 1 0 27 49 3396 3411 1 1 1 0 44 55 3397 3412 1 1 1 0 30 53 3495 3510 1 0 0 0 51 50 3498 3513 1 0 0 0 53 55 3507 3522 1 0 0 0 11 31 3525 3540 1 1 1 0 43 49 3529 3544 1 1 1 0 25 47 3537 3552 1 1 1 0 9 28 3549 3564 1 0 0 0 23 50 3622 3637 1 0 0 0 30 38 3627 3642 1 1 1 0 -2 40 3645 3660 1 0 0 0 48 53 3735 3750 1 0 0 0 48 64 3741 3756 1 0 0 0 34 50 3760 3775 1 0 0 0 47 55 3850 3865 1 0 0 0 47 54 3852 3867 1 0 0 0 40 57 3862 3877 1 0 0 0 50 51 3864 3879 1 1 1 0 37 60 3878 3893 1 0 0 0 39 53 3920 3935 1 0 0 0 40 56 3948 3963 1 0 0 0 53 51 3957 3972 1 0 0 0 49 56 3982 3997 1 0 0 0 46 52 4096 4111 1 1 1 0 42 49 4197 4212 1 0 0 0 49 36 4294 4309 1 1 1 0 31 46 4312 4327 1 1 1 0 48 55 4314 4329 1 1 1 0 51 49 4315 4330 1 1 1 0 45 52 4350 4365 1 1 1 0 42 54 4351 4366 1 1 1 0 51 44 4361 4376 1 0 0 0 28 50 4368 4383 1 0 0 0 32 45 PaVer/SyngrASO2/799 X-reactivity SH-SY5Y primary transcript (main Dual dose isoform) 5' position of 3' position of n s target site target site a o u es m n s % inhib. cording to according to e u at % inhib. at ac u y H C h o R M 3 nM 30 nM SEQ ID No.1 SEQ ID No.1 4416 4431 1 1 1 0 44 53 4423 4438 1 1 1 0 32 51 4440 4455 1 1 1 0 41 62 4442 4457 1 1 1 0 51 61 4443 4458 1 1 1 0 52 63 4545 4560 1 1 0 0 19 54 4546 4561 1 1 0 0 30 55 4547 4562 1 1 0 0 46 52 4585 4600 1 1 1 0 10 31 The threshold for a region suitable for oligonucleotide design was set at the level of the tested ASO in at least one of the experiments (at a 3 nM or 30 nM dose) would be able to reduce the human Syngr-3 transcript with at least 45% with respect to a reference system (e.g., baseline levels in an individual or population of individuals, or below a pre-determined threshold value). Nevertheless, therapeutic effects may be obtained at levels of inhibition of the expression of the human Syngr-3 below 45% as the DRC results consequently showed a stronger reduction of the Syngr-3 transcript level (Table 1-2). The ASO molecules selected from the primary screen were retested in two different cell lines (i.e. SH-SY5Y and iPSC-derived neurons) (Table 2). Table 2. Confirmation of the IC50 and maximum inhibition of selected ASO molecules from Table 1 in SH-SY5Y cells and iPSC-derived neurons. SH-SY5Y iPSC-derived neurons DRC Dual dose 5' position of 3' position of target site target site IC50 max. max. inhib. max. inhib. at according to according to [nM] inhib. [%] at 1 µM [%] 5 µM [%] SEQ ID No.1 SEQ ID No.1 494 509 - - 38 55 495 510 - - 4 35 496 511 - - 50 61 497 512 - - 41 51 498 513 - - 40 54 500 515 - - 49 45 501 516 - - 0 27 694 709 2.7 50 69 69 1301 1316 4.4 66 91 67 1302 1317 1.0 65 87 0 1303 1318 0.9 50 89 83 1556 1571 2.6 52 92 64 PaVer/SyngrASO2/799 SH-SY5Y iPSC-derived neurons DRC Dual dose 5' position of 3' position of target site target site IC50 max. max. inhib. max. inhib. at according to according to [nM] inhib. [%] at 1 µM [%] 5 µM [%] SEQ ID No.1 SEQ ID No.1 1561 1576 4.3 59 88 74 1603 1618 5.3 65 84 82 1604 1619 2.6 63 71 84 1605 1620 2.1 61 55 80 1607 1622 5.1 59 44 73 1610 1625 5.4 60 36 62 1841 1856 4.0 61 82 93 2013 2028 0.8 71 69 80 2031 2046 3.4 65 82 93 2032 2047 3.1 63 88 90 2033 2048 2.0 68 70 87 2034 2049 5.5 54 77 89 2124 2139 7.4 49 75 90 2138 2153 2.0 48 61 79 2141 2156 1.5 67 74 85 2153 2168 1.7 76 48 69 2154 2169 1.0 70 12 34 2155 2170 2.8 73 59 81 2156 2171 4.7 71 55 80 2159 2174 9.4 59 71 85 2212 2227 18.2 35 80 88 2421 2436 3.7 67 34 38 2614 2629 #N/A 11 10 25 2732 2747 3.8 52 42 54 2733 2748 10.2 57 6 38 2980 2995 2.1 64 37 40 3011 3026 5.0 53 49 66 3231 3246 0.6 58 0 25 3295 3310 5.4 61 0 0 3498 3513 0.9 59 75 82 3505 3520 #N/A 38 40 55 3850 3865 8.6 44 74 86 3852 3867 4.5 59 81 93 3862 3877 4.5 52 78 90 3864 3879 7.0 61 44 64 3948 3963 1.8 59 76 88 3957 3972 2.7 57 73 81 4312 4327 0.7 61 66 71 4414 4429 8.2 48 27 16 4416 4431 2.4 62 57 72 4440 4455 2.9 71 66 75 4442 4457 1.3 69 67 87 4443 4458 0.6 68 80 89 As used herein, the term “reducing”, e.g., reducing the expression of hSYNGR3 mRNA transcript and/or hSYNGR3 protein level and/or hSYNGR3 activity refers to the ability of an oligonucleotide of the present disclosure (e.g., an ASO or siRNA) to statistically reduce (or decrease, inhibit or lower) the PaVer/SyngrASO2/799 expression of the hSYNGR3 gene transcript and/or hSYNGR3 protein level and/or activity in a cell, a tissue, or a subject. In some aspects, the term “reducing” refer to complete inhibition (100% inhibition or non-detectable level) of hSyngr3 gene transcript and/or hSyngr3 protein level and/or activity. In other aspects, the term “reducing” refers, e.g., to at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, to at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least 90%, at least 95% or at least 99% reduction or inhibition of hSyngr3 mRNA transcript and/or hSYNGR3 protein expression and/or activity in a cell, a tissue, or a subject. The terms “individual”, “subject”, “host”, and “patient”, are used interchangeably herein and refer to any mammalian subject for whom diagnosis, treatment, or therapy is desired, particularly humans. The compositions and methods described herein are applicable to both human therapy and veterinary applications. In some aspects, the subject is a mammal, and in other aspects the subject is a human. As used herein, a “mammalian subject” includes all mammals, including without limitation, humans, domestic animals (e.g., dogs, cats and the like), farm animals (e.g., cows, sheep, pigs, horses and the like) and laboratory animals (e.g., monkey, rats, mice, rabbits, guinea pigs and the like). The application thus provides target regions within the human Syngr-3 gene or the Syngr3 (pre-)mRNA transcript for designing oligonucleotides (e.g. ASO, siRNA, shRNA) that reduce the expression of hSyngr3 by at least 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least 90%, at least 95% or at least 99% compared to a control situation, e.g. where no oligonucleotide (e.g. ASO, siRNA, shRNA) was administered or where a scrambled control molecule was added as negative control. Said target regions and the corresponding sequences are shown in Figure 3 and 4. In one embodiment, a synaptogyrin-3 mRNA transcript target sequence selected from SEQ ID No.10, 12, 20, 25, 29-31, 33, 50, 53, 58-59, 62, 69, 79, 84, 87, 91, 94, 110-111, 135, 140-141, 170, 172, 179, 181, 184, 188, 193-194, 210, 216, 220-221, 224, 227, 229, 231, 235, 241, 246, 248, 250, 259, 268 or 269 are provided for designing an antisense oligonucleotide or RNAi molecule capable of reducing the level of Synaptogyrin-3 transcript, the level of expressed synaptogyrin-3, the level of synaptogyrin-3 activity, or a combination thereof in a cell with at least 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about PaVer/SyngrASO2/799 85%, at least 90%, at least 95% or at least 99% compared to a control situation, e.g., where no oligonucleotide (e.g., ASO, siRNA or shRNA) was administered or where a scrambled control molecule was used as a negative control. In a particular embodiment, said synaptogyrin-3 mRNA transcript target sequence comprises or consists of a sequence selected from the group consisting of SEQ ID No.2-9, 11, 13-19, 21-24, 26-28, 32, 34-49, 51-52, 54-57, 60-61, 63-68, 70-78, 80-83, 85-86, 88-90, 92-93, 95-109, 112-134, 136-139, 142-169, 171, 173-178, 180, 182-183, 185-187, 189-192, 195-209, 211-215, 217-219, 222-223, 225-226, 228, 230, 232-234, 236-240, 242-245, 247, 249, 251-258 or 260-267. In another embodiment, the oligonucleotide of the application (described in detail above) comprises a contiguous nucleotide sequence of at least 10 contiguous nucleotides in length which are partially or fully complementary to a target region of Synaptogyrin-3 as set forth in SEQ ID No.1 or allelic variants thereof. In a particular embodiment, the contiguous nucleotide sequence of at least 10 contiguous nucleotides in length is at least 80%, at least 81%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% complementary to the target region in the Syngr-3 mRNA transcript. In a particular embodiment, the contiguous nucleotide sequence of at least 10 contiguous nucleotides in length is about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, about 100% complementary to the target region in the Syngr-3 mRNA transcript. In another particular embodiment, the contiguous nucleotide sequence of at least 10 contiguous nucleotides in length is complementary to an equal length portion of a target region in the Synaptogyin-3 mRNA transcript as set forth in SEQ ID No.1 or a variant thereof, e.g. an allelic variant thereof. The target regions of the present disclosure are defined below as subsequences of SEQ ID No.1, wherein the subsequences are delineated by a 5’-end position and a 3’-end position. For example, a target region between nucleobases 2-10 of SEQ ID No.1 consists of nucleobases 2, 3, 4, 5, 6, 7, 8, 9 and 10 of SEQ ID No.1 or CTACCCCTT. It is thus to be understood that any range given in current application includes the range endpoints. Accordingly, if a target region is between nucleotides 2 and 10 of SEQ ID No.1, both nucleotides 2 and 10 of SEQ ID No.1 are included. As used throughout the present disclosure, the terms “target regions of SEQ ID No.1” or “target region in the synaptogyrin-3 mRNA transcript” or “target region” in general, as well as grammatical variants thereof refer to regions or subsequences in a synaptogyrin-3 mRNA transcript that are targeted by the oligonucleotides of the present disclosure. In some aspects, the synaptogyrin-3 mRNA transcript PaVer/SyngrASO2/799 containing the target region is the synaptogyrin-3 mRNA transcript set forth in SEQ ID No.1. However, in other aspects, the synaptogyrin-3 mRNA transcript containing the target region can be a synaptogyrin- 3 mRNA transcript variant, e.g., an allelic variant, of the synaptogyrin-3 mRNA transcript set forth in SEQ ID No.1, an isoform thereof, or an ortholog thereof. In one particular embodiment, the target region is a subsequence located between nucleobase positions 449 and 531 of the Syngr-3 mRNA transcript set forth in SEQ ID No. 1, or is comprised within the nucleotide subsequence defined by nucleobase 449 and 531 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1. Particularly, the target region is between nucleobase positions 450 and 531, 451 and 531, 452 and 531, 453 and 531, 454 and 531, 455 and 531, 456 and 531, 457 and 531, 458 and 531, 459 and 531, 460 and 531, 461 and 531, 462 and 531, 463 and 531, 464 and 531, 465 and 531, 466 and 531, 467 and 531, 468 and 531, 469 and 531, 470 and 531, 471 and 531, 472 and 531, 473 and 531, 474 and 531, 475 and 531, 476 and 531, 477 and 531, 478 and 531, 479 and 531, 480 and 531, 481 and 531, 482 and 531, 483 and 531, 484 and 531, 485 and 531, 486 and 531, 487 and 531, 449 and 522, 449 and 523, 449 and 524, 449 and 525, 449 and 526, 449 and 527, 449 and 528, 449 and 529 or 449 and 530 of the Syngr- 3 mRNA transcript set forth in SEQ ID No. 1. More particularly the target region is located between nucleobase positions 487 and 522 of the Syngr-3 mRNA transcript set forth in SEQ ID No. 1, more particularly between nucleobase positions 488 and 521, 489 and 520, 490 and 519, 491 and 518, even more particularly between nucleobase positions 492 and 517 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1. In a more particular embodiment, the target region is defined by SEQ ID No. 10. In an even more particular embodiment, the target region is defined by (or comprises of consists of) SEQ ID No.2, 4, 5, 6, 7, 8 and/or 9. In a most particular embodiment, the oligonucleotide (e.g., ASO, siRNA, shRNA) comprises or consists of SEQ ID No.270, 271, 272, 273, 274, 275, 276 and/or 277. In another particular embodiment, the target region is a subsequence located between nucleobase positions 549 and 653 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1, or is comprised within the nucleotide subsequence defined by nucleobase 549 and 653 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1. Particularly, the target region is a subsequence located between nucleobase positions 550 and 653, 551 and 653, 552 and 653, 553 and 653, 554 and 653, 555 and 653, 556 and 653, 557 and 653, 558 and 653, 559 and 653, 560 and 653, 561 and 653, 562 and 653, 563 and 653, 564 and 653, 565 and 653, 566 and 653, 567 and 653, 568 and 653, 569 and 653, 570 and 653, 571 and 653, 572 and 653, 573 and 653, 574 and 653, 575 and 653, 576 and 653, 577 and 653, 578 and 653, 579 and 653, 580 and 653, 581 and 653, 582 and 653, 549 and 607, 549 and 608, 549 and 609, 549 and 610, 549 and 611, 549 PaVer/SyngrASO2/799 and 612, 549 and 613, 549 and 614, 549 and 615, 549 and 616, 549 and 617, 549 and 618, 549 and 619, 549 and 620, 549 and 621, 549 and 622, 549 and 623, 549 and 624, 549 and 625, 549 and 626, 549 and 627, 549 and 628, 549 and 629, 549 and 630, 549 and 631, 549 and 632, 549 and 633, 549 and 634, 549 and 635, 549 and 636, 549 and 637, 549 and 638, 549 and 639, 549 and 640, 549 and 641, 549 and 642, 549 and 643, 549 and 644, 549 and 645, 549 and 646, 549 and 647, 549 and 648, 549 and 649, 549 and 650, 549 and 651 or 549 and 652 of the Syngr-3 mRNA transcript set forth in SEQ ID No. 1. More particularly, the target region is located between nucleobase positions 582 and 607 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1, more particularly between nucleobase positions 583 and 606, 584 and 605, 585 and 604, 586 and 603, even more particularly between nucleobase positions 587 and 602 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1. In a more particular embodiment, the target region is defined by SEQ ID No. 12. In an even more particular embodiment, the target region is defined by (or comprises of consists of) SEQ ID No.11. In a most particular embodiment, the oligonucleotide (e.g., ASO, siRNA, shRNA) comprises or consists of SEQ ID No.278. In another particular embodiment, the target region is located between nucleobase positions 640 and 733 or is comprised within the nucleotide subsequence defined by nucleobase 640 and 733 of the Syngr- 3 mRNA transcript set forth in SEQ ID No.1. Particularly, the target region is located between nucleobase positions 641 and 733, 642 and 733, 643 and 733, 644 and 733, 645 and 733, 646 and 733, 647 and 733, 648 and 733, 649 and 733, 650 and 733, 651 and 733, 652 and 733, 653 and 733, 654 and 733, 655 and 733, 656 and 733, 657 and 733, 658 and 733, 659 and 733, 660 and 733, 661 and 733, 662 and 733, 663 and 733, 664 and 733, 665 and 733, 666 and 733, 667 and 733, 668 and 733, 669 and 733, 670 and 733, 671 and 733, 672 and 733, 673 and 733, 674 and 733, 675 and 733, 676 and 733, 677 and 733, 678 and 733, 679 and 733, 640 and 720, 640 and 721, 640 and 722, 640 and 723, 640 and 724, 640 and 725, 640 and 726, 640 and 727, 640 and 728, 640 and 729, 640 and 730, 640 and 731 or 640 and 732 of the Syngr- 3 mRNA transcript set forth in SEQ ID No. 1. More particularly between nucleobase positions 679 and 720 of SEQ ID No.1, more particularly between nucleobase positions 680 and 719, 681 and 718, 682 and 717, 683 and 716, even more particularly between nucleobase positions 684 and 715 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1. In a more particular embodiment, the target region is defined by SEQ ID No. 20. In an even more particular embodiment, the target region is defined by (or comprises of consists of) SEQ ID No.13, 14, 15, 16, 17, 18 and/or 19. In a most particular embodiment, the oligonucleotide (e.g., ASO, siRNA, shRNA) comprises or consists of SEQ ID No.279, 280, 281, 282, 283, 284 and/or 285. PaVer/SyngrASO2/799 In another particular embodiment, the target region is located between nucleobase positions 720 and 875 or is comprised within the nucleotide subsequence defined by nucleobase 720 and 875 of the Syngr- 3 mRNA transcript set forth in SEQ ID No.1. Particularly, the target region is located between nucleobase positions 721 and 875, 722 and 875, 723 and 875, 724 and 875, 725 and 875, 726 and 875, 727 and 875, 728 and 875, 729 and 875, 730 and 875, 731 and 875, 732 and 875, 733 and 875, 734 and 875, 735 and 875, 736 and 875, 737 and 875, 738 and 875, 739 and 875, 740 and 875, 741 and 875, 742 and 875, 743 and 875, 744 and 875, 745 and 875, 746 and 875, 747 and 875, 748 and 875, 749 and 875, 750 and 875, 751 and 875, 752 and 875, 753 and 875, 754 and 875, 755 and 875, 756 and 875, 757 and 875, 758 and 875, 759 and 875, 760 and 875, 761 and 875, 762 and 875, 763 and 875, 764 and 875, 765 and 875, 720 and 795, 720 and 796, 720 and 797, 720 and 798, 720 and 799, 720 and 800, 720 and 801, 720 and 802, 720 and 803, 720 and 804, 720 and 805, 720 and 806, 720 and 807, 720 and 808, 720 and 809, 720 and 810, 720 and 811, 720 and 812, 720 and 813, 720 and 814, 720 and 815, 720 and 816, 720 and 817, 720 and 818, 720 and 819, 720 and 820, 720 and 821, 720 and 822, 720 and 823, 720 and 824, 720 and 825, 720 and 826, 720 and 827, 720 and 828, 720 and 829, 720 and 830, 720 and 831, 720 and 832, 720 and 833, 720 and 834, 720 and 835, 720 and 836, 720 and 837, 720 and 838, 720 and 839, 720 and 840, 720 and 841, 720 and 842, 720 and 843, 720 and 844, 720 and 845, 720 and 846, 720 and 847, 720 and 848, 720 and 849, 720 and 850, 720 and 851, 720 and 852, 720 and 853, 720 and 854, 720 and 855, 720 and 856, 720 and 857, 720 and 858, 720 and 859, 720 and 860, 720 and 861, 720 and 862, 720 and 863, 720 and 864, 720 and 865, 720 and 866, 720 and 867, 720 and 868, 720 and 869, 720 and 870, 720 and 871, 720 and 872, 720 and 873 or 720 and 874 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1. More particularly between nucleobase positions 765 and 795 of SEQ ID No. 1, more particularly between nucleobase positions 766 and 794, 767 and 793, 768 and 792, 769 and 791, even more particularly between nucleobase positions 770 and 790 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1. In a more particular embodiment, the target region is defined by SEQ ID No. 25. In an even more particular embodiment, the target region is defined by (or comprises of consists of) SEQ ID No.21, 22, 23 and/or 24. In a most particular embodiment, the oligonucleotide (e.g., ASO, siRNA, shRNA) comprises or consists of SEQ ID No.286, 287, 288 and/or 289. In another particular embodiment, the target region is located between nucleobase positions 915 and 1108 or is comprised within the nucleotide subsequence defined by nucleobase positions 915 and 1108 of the Syngr-3 mRNA transcript set forth in SEQ ID No. 1. Particularly, the target region is located between nucleobase positions 916 and 1108, 917 and 1108, 918 and 1108, 919 and 1108, 920 and 1108, 921 and 1108, 922 and 1108, 923 and 1108, 924 and 1108, 925 and 1108, 926 and 1108, 927 and 1108, 928 and 1108, 929 and 1108, 930 and 1108, 931 and 1108, 932 and 1108, 933 and 1108, 934 and 1108, PaVer/SyngrASO2/799 935 and 1108, 936 and 1108, 937 and 1108, 938 and 1108, 939 and 1108, 940 and 1108, 941 and 1108, 942 and 1108, 943 and 1108, 944 and 1108, 945 and 1108, 946 and 1108, 947 and 1108, 948 and 1108, 949 and 1108, 950 and 1108, 951 and 1108, 915 and 1072, 915 and 1073, 915 and 1074, 915 and 1075, 915 and 1076, 915 and 1077, 915 and 1078, 915 and 7079, 915 and 1080, 915 and 1081, 915 and 1082, 915 and 1083, 915 and 1084, 915 and 1085, 915 and 1086, 915 and 1087, 915 and 1088, 915 and 1089, 915 and 1090, 915 and 1091, 915 and 1092, 915 and 1093, 915 and 1094, 915 and 1095, 915 and 1096, 915 and 1097, 915 and 1098, 915 and 1099, 915 and 1100, 915 and 1101, 915 and 1102, 915 and 1103, 915 and 1104, 915 and 1105, 915 and 1106 or 915 and 1107 of the Syngr-3 mRNA transcript set forth in SEQ ID No. 1. More particularly between nucleobase positions 951 and 1072 of SEQ ID No. 1, more particularly between nucleobase positions 952 and 1071, 953 and 1070, 954 and 1069, 955 and 1068, even more particularly between nucleobase positions 956 and 1067 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1. In a more particular embodiment, the target region is defined by SEQ ID No. 29. In an even more particular embodiment, the target region is defined by (or comprises of consists of) SEQ ID No.26, 27 and/or 28. In a most particular embodiment, the oligonucleotide (e.g., ASO, siRNA, shRNA) comprises or consists of SEQ ID No.290, 291 and/or 292. In another particular embodiment, the target region is located between nucleobase positions 915 and 1000 or is comprised within the nucleotide subsequence defined by nucleobase positions 915 and 1000 of the Syngr-3 mRNA transcript set forth in SEQ ID No. 1. Particularly, the target region is located between nucleobase positions 916 and 986, 917 and 1000, 918 and 1000, 919 and 1000, 920 and 1000, 921 and 1000, 922 and 1000, 923 and 1000, 924 and 1000, 925 and 1000, 926 and 1000, 927 and 1000, 928 and 1000, 929 and 1000, 930 and 1000, 931 and 1000, 932 and 1000, 933 and 1000, 934 and 1000, 935 and 1000, 936 and 1000, 937 and 1000, 938 and 1000, 939 and 1000, 940 and 1000, 941 and 1000, 942 and 1000, 943 and 1000, 944 and 1000, 945 and 1000, 946 and 1000, 947 and 1000, 948 and 1000, 949 and 1000, 950 and 1000, 951 and 1000, 915 and 986, 915 and 987, 915 and 988, 915 and 989, 915 and 990, 915 and 991, 915 and 992, 915 and 993, 915 and 994, 915 and 995, 915 and 996, 915 and 997, 915 and 998 or 915 and 999 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1. More particularly the target regions is located between nucleobase positions 951 and 986 of SEQ ID No. 1, more particularly between nucleobase positions 952 and 985, 953 and 984, 954 and 983, 955 and 982, even more particularly between nucleobase positions 956 and 981 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1. In a more particular embodiment, the target region is defined by SEQ ID No.30. PaVer/SyngrASO2/799 In another particular embodiment, the target region is located between nucleobase positions 1000 and 1108 or is comprised within the nucleotide subsequence defined by nucleobase positions 1000 and 1108 of SEQ ID No.1. Particularly, the target region is located between nucleobase positions 1001 and 1108, 1002 and 1108, 1003 and 1108, 1004 and 1108, 1005 and 1108, 1006 and 1108, 1007 and 1108, 1008 and 1108, 1009 and 1108, 1010 and 1108, 1011 and 1108, 1012 and 1108, 1013 and 1108, 1014 and 1108, 1015 and 1108, 1016 and 1108, 1017 and 1108, 1018 and 1108, 1019 and 1108, 1020 and 1108, 1021 and 1108, 1021 and 1108, 1022 and 1108, 1023 and 1108, 1024 and 1108, 1025 and 1108, 1026 and 1108, 1027 and 1108, 1028 and 1108, 1029 and 1108, 1030 and 1108, 1031 and 1108, 1032 and 1108, 1033 and 1108, 1034 and 1108, 1035 and 1108, 1036 and 1108, 1037 and 1108, 1038 and 1108, 1039 and 1108, 1040 and 1108, 1041 and 1108, 1042 and 1108, 1043 and 1108, 1044 and 1108, 1045 and 1108, 1046 and 1108, 1047 and 1108, 1000 and 1072, 1000 and 1073, 1000 and 1074, 1000 and 1075, 1000 and 1076, 1000 and 1077, 1000 and 1078, 1000 and 1079, 1000 and 1080, 1000 and 1080, 1000 and 1082, 1000 and 1083, 1000 and 1084, 1000 and 1085, 1000 and 1086, 1000 and 1087, 1000 and 1088, 1000 and 1089, 1000 and 1090, 1000 and 1091, 1000 and 1092, 1000 and 1093, 1000 and 1094, 1000 and 1095, 1000 and 1096, 1000 and 1097, 1000 and 1098, 1000 and 1099, 1000 and 1100, 1000 and 1101, 1000 and 1102, 1000 and 1103, 1000 and 1104, 1000 and 1105, 1000 and 1106 or 1000 and 1107 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1. More particularly the target region is located between nucleobase positions 1047 and 1072 of SEQ ID No. 1, more particularly between nucleobase positions 1048 and 1071, 1049 and 1070, 1050 and 1069, 1051 and 1068, even more particularly between nucleobase positions 1052 and 1067 of SEQ ID No.1. In a more particular embodiment, the target region is defined by SEQ ID No.31. In another particular embodiment, the target region is located between nucleobase positions 1197 and 1271 or is comprised within the nucleotide subsequence defined by nucleobase positions 1197 and 1271 of SEQ ID No.1. Particularly, the target region is located between nucleobase positions 1198 and 1271, 1199 and 1271, 1200 and 1271, 1201 and 1271, 1202 and 1271, 1203 and 1271, 1197 and 1228, 1197 and 1229, 1197 and 1230, 1197 and 1231, 1197 and 1232, 1197 and 1233, 1197 and 1234, 1197 and 1235, 1197 and 1236, 1197 and 1237, 1197 and 1238, 1197 and 1239, 1197 and 1240, 1197 and 1241, 1197 and 1242, 1197 and 1243, 1197 and 1244, 1197 and 1245, 1197 and 1246, 1197 and 1247, 1197 and 1248, 1197 and 1249, 1197 and 1250, 1197 and 1251, 1197 and 1252, 1197 and 1253, 1197 and 1254, 1197 and 1255, 1197 and 1256, 1197 and 1257, 1197 and 1258, 1197 and 1259, 1197 and 1260, 1197 and 1261, 1197 and 1262, 1197 and 1263, 1197 and 1264, 1197 and 1265, 1197 and 1266, 1197 and 1267, 1197 and 1268, 1197 and 1269 or 1197 and 1270 of the Syngr-3 mRNA transcript set forth in SEQ ID No. 1. More particularly the target is located between nucleobase positions 1203 and PaVer/SyngrASO2/799 1228 of SEQ ID No.1, more particularly between nucleobase positions 1204 and 1227, 1205 and 1226, 1206 and 1225, 1207 and 1224, even more particularly between nucleobase positions 1208 and 1223 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1. In a more particular embodiment, the target region is defined by SEQ ID No. 33. In an even more particular embodiment, the target region is defined by (or comprises of consists of) SEQ ID No.32. In a most particular embodiment, the oligonucleotide (e.g., ASO, siRNA, shRNA) comprises or consists of SEQ ID No.293. In another particular embodiment, the target region is located between nucleobase positions 1258 and 1344 or is comprised within the nucleotide subsequence defined by nucleobase positions 1258 and 1344 of the Syngr-3 mRNA transcript set forth in SEQ ID No. 1. Particularly, the target region is located between nucleobase positions 1259 and 1344, 1260 and 1344, 1261 and 1344, 1262 and 1344, 1263 and 1344, 1264 and 1344, 1265 and 1344, 1258 and 1329, 1258 and 1330, 1258 and 1331, 1258 and 1332, 1258 and 1333, 1258 and 1334, 1258 and 1335, 1258 and 1336, 1258 and 1337, 1258 and 1338, 1258 and 1339, 1258 and 1340, 1258 and 1341, 1258 and 1342 or 1258 and 1343 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1. More particularly the target region is located between nucleobase positions 1265 and 1329 of SEQ ID No. 1, more particularly between nucleobase positions 1266 and 1328, 1267 and 1327, 1268 and 1326, 1269 and 1325, even more particularly between nucleobase positions 1270 and 1324 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1. In a more particular embodiment, the target region is located defined by SEQ ID No.50. In an even more particular embodiment, the target region is defined by (or comprises of consists of) SEQ ID No.34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48 and/or 49. In a most particular embodiment, the oligonucleotide (e.g., ASO, siRNA, shRNA) comprises or consists of SEQ ID No.294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308 and/or 309. In another particular embodiment, the target region is located between nucleobase positions 1332 and 1450 or is comprised within the nucleotide subsequence defined by nucleobase positions 1332 and 1450 of the Syngr-3 mRNA transcript set forth in SEQ ID No. 1. Particularly, the target region is located between nucleobase positions 1333 and 1450, 1334 and 1450, 1335 and 1450, 1336 and 1450, 1337 and 1450, 1338 and 1450, 1339 and 1450, 1340 and 1450, 1341 and 1450, 1342 and 1450, 1343 and 1450, 1344 and 1450, 1345 and 1450, 1346 and 1450, 1347 and 1450, 1348 and 1450, 1349 and 1450, 1350 and 1450, 1351 and 1450, 1332 and 1432, 1332 and 1433, 1332 and 1434, 1332 and 1435, 1332 and 1436, 1332 and 1437, 1332 and 1438, 1332 and 1439, 1332 and 1440, 1332 and 1441, 1332 and 1442, 1332 and 1443, 1332 and 1444, 1332 and 1446, 1332 and 1447, 1332 and 1448 or 1332 and 1449 of the PaVer/SyngrASO2/799 Syngr-3 mRNA transcript set forth in SEQ ID No.1. More particularly the target region is located between nucleobase positions 1351 and 1432 of SEQ ID No. 1, more particularly between nucleobase positions 1352 and 1431, 1353 and 1430, 1354 and 1429, 1355 and 1428, even more particularly between nucleobase positions 1356 and 1427 of SEQ ID No.1. In a more particular embodiment, the target region is defined by SEQ ID No.59. In another particular embodiment, the target region is located between nucleobase positions 1332 and 1400 or is comprised within the nucleotide subsequence defined by nucleobase positions 1332 and 1400 of the Syngr-3 mRNA transcript set forth in SEQ ID No. 1. Particularly, the target region is located between nucleobase positions 1333 and 1400, 1334 and 1400, 1335 and 1400, 1336 and 1400, 1337 and 1400, 1338 and 1400, 1339 and 1400, 1340 and 1400, 1341 and 1400, 1342 and 1400, 1343 and 1400, 1344 and 1400, 1345 and 1400, 1346 and 1400, 1347 and 1400, 1348 and 1400, 1349 and 1400, 1350 and 1400, 1351 and 1400, 1332 and 1378, 1332 and 1379, 1332 and 1380, 1332 and 1381, 1332 and 1382, 1332 and 1383, 1332 and 1384, 1332 and 1385, 1332 and 1386, 1332 and 1387, 1332 and 1388, 1332 and 1389, 1332 and 1390, 1332 and 1391, 1332 and 1392, 1332 and 1393, 1332 and 1394, 1332 and 1395, 1332 and 1396, 1332 and 1397, 1332 and 1398 or 1332 and 1399 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1. More particularly the target region is located between nucleobase positions 1351 and 1377 of SEQ ID No. 1, more particularly between nucleobase positions 1352 and 1376, 1353 and 1375, 1354 and 1374, 1355 and 1373, even more particularly between nucleobase positions 1356 and 1372 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1. In a more particular embodiment, the target region is defined by SEQ ID No. 53. In an even more particular embodiment, the target region is defined by (or comprises of consists of) SEQ ID No.51 and/or 52. In a most particular embodiment, the oligonucleotide (e.g., ASO, siRNA, shRNA) comprises or consists of SEQ ID No.310 and/or 311. In another particular embodiment, the target region is located between nucleobase positions 1380 and 1450 or is comprised within the nucleotide subsequence defined by nucleobase positions 1380 and 1450 of the Syngr-3 mRNA transcript set forth in SEQ ID No. 1. Particularly, the target region is located between nucleobase 1381 and 1450, 1382 and 1450, 1383 and 1450, 1384 and 1450, 1385 and 1450, 1386 and 1450, 1387 and 1450, 1388 and 1450, 1389 and 1450, 1390 and 1450, 1391 and 1450, 1392 and 1450, 1393 and 1450, 1394 and 1450, 1380 and 1433, 1380 and 1434, 1380 and 1435, 1380 and 1436, 1380 and 1437, 1380 and 1438, 1380 and 1439, 1380 and 1440, 1380 and 1441, 1380 and 1442, 1380 and 1443, 1380 and 1444, 1380 and 1445, 1380 and 1446, 1380 and 1447, 1380 and 1448 or 1380 and 1449 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1. More particularly the target region is PaVer/SyngrASO2/799 located between nucleobase 1394 and 1432 of SEQ ID No. 1, more particularly between nucleobase positions 1395 and 1431, 1396 and 1430, 1397 and 1429, 1398 and 1428, even more particularly between nucleobase positions 1399 and 1427 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1. In a more particular embodiment, the target region is defined by SEQ ID No. 58. In an even more particular embodiment, the target region is defined by (or comprises of consists of) SEQ ID No.54, 55, 56 and/or 57. In a most particular embodiment, the oligonucleotide (e.g., ASO, siRNA, shRNA) comprises or consists of SEQ ID No.312, 313, 314 and/or 315. In another particular embodiment, the target region is located between nucleobase positions 1450 and 1527 or is comprised within the nucleotide subsequence defined by nucleobase 1450 and 1527 of the Syngr-3 mRNA transcript set forth in SEQ ID No. 1. Particularly, the target region is located between nucleobase positions 1451 and 1527, 1452 and 1527, 1453 and 1527, 1454 and 1527, 1455 and 1527, 1456 and 1527, 1457 and 1527, 1458 and 1527, 1459 and 1527, 1460 and 1527, 1461 and 1527, 1462 and 1527, 1463 and 1527, 1464 and 1527, 1465 and 1527, 1466 and 1527, 1467 and 1527, 1468 and 1527, 1469 and 1527, 1470 and 1527, 1471 and 1527, 1472 and 1527, 1473 and 1527, 1474 and 1527, 1475 and 1527, 1476 and 1527, 1477 and 1527, 1478 and 1527, 1479 and 1527, 1480 and 1527, 1481 and 1527, 1482 and 1527, 1483 and 1527, 1484 and 1527, 1485 and 1527, 1486 and 1527, 1487 and 1527, 1488 and 1527, 1489 and 1527, 1490 and 1527, 1491 and 1527, 1492 and 1527, 1493 and 1527, 1494 and 1527, 1495 and 1527, 1496 and 1527, 1497 and 1527 or 1450 and 1526 of SEQ ID No.1. More particularly the target regions is located between nucleobase positions 1497 and 1526 of SEQ ID No.1, more particularly between nucleobase positions 1498 and 1525, 1499 and 1524, 1500 and 1523, 1501 and 1522, even more particularly between nucleobase positions 1502 and 1521 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1. In a more particular embodiment, the target region is defined by SEQ ID No. 62. In an even more particular embodiment, the target region is defined by (or comprises of consists of) SEQ ID No.60 and/or 61. In a most particular embodiment, the oligonucleotide (e.g., ASO, siRNA, shRNA) comprises or consists of SEQ ID No.316 and/or 317. In another particular embodiment, the target region is located between nucleobase positions 1515 and 1600 or is comprised within the nucleotide subsequence defined by nucleobase positions 1515 and 1600 of the Syngr-3 mRNA transcript set forth in SEQ ID No. 1. Particularly, the target region is located between nucleobase positions 1516 and 1600, 1517 and 1600, 1518 and 1600, 1519 and 1600, 1520 and 1600, 1521 and 1600, 1522 and 1600, 1523 and 1600, 1524 and 1600, 1525 and 1600, 1526 and 1600, 1527 and 1600, 1528 and 1600, 1529 and 1600, 1530 and 1600, 1531 and 1600, 1532 and 1600, 1533 PaVer/SyngrASO2/799 and 1600, 1534 and 1600, 1535 and 1600, 1536 and 1600, 1537 and 1600, 1538 and 1600, 1539 and 1600, 1540 and 1600, 1541 and 1600, 1542 and 1600, 1543 and 1600, 1544 and 1600, 1545 and 1600, 1546 and 1600, 1547 and 1600, 1548 and 1600, 1549 and 1600, 1550 and 1600, 1551 and 1600, 1515 and 1583, 1515 and 1584, 1515 and 1585, 1515 and 1586, 1515 and 1587, 1515 and 1588, 1515 and 1589, 1515 and 1590, 1515 and 1591, 1515 and 1592, 1515 and 1593, 1515 and 1594, 1515 and 1595, 1515 and 1596, 1515 and 1597, 1515 and 1598 or 1515 and 1599 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1. More particularly between nucleobase positions 1551 and 1583 of SEQ ID No.1, more particularly between nucleobase positions 1552 and 1582, 1553 and 1581, 1554 and 1580, 1555 and 1579, even more particularly between nucleobase positions 1556 and 1578 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1. In a more particular embodiment, the target region is defined by SEQ ID No. 69. In an even more particular embodiment, the target region is defined by (or comprises of consists of) SEQ ID No.63, 64, 65, 66, 67 and/or 68. In a most particular embodiment, the oligonucleotide (e.g., ASO, siRNA, shRNA) comprises or consists of SEQ ID No.318, 319, 320, 321, 322 and/or 323. In another particular embodiment, the target region is located between nucleobase positions 1580 and 1700 or is comprised within the nucleotide subsequence defined by nucleobase 1580 and 1700 of the Syngr-3 mRNA transcript set forth in SEQ ID No. 1. Particularly, the target region is located between nucleobase positions 1581 and 1700, 1582 and 1700, 1583 and 1700, 1584 and 1700, 1585 and 1700, 1586 and 1700, 1589 and 1700, 1590 and 1700, 1591 and 1700, 1592 and 1700, 1593 and 1700, 1594 and 1700, 1595 and 1700, 1596 and 1700, 1597 and 1700, 1598 and 1700, 1580 and 1656, 1580 and 1657, 1580 and 1658, 1580 and 1659, 1580 and 1660, 1580 and 1661, 1580 and 1662, 1580 and 1663, 1580 and 1664, 1580 and 1665, 1580 and 1666, 1580 and 1667, 1580 and 1668, 1580 and 6169, 1580 and 6170, 1580 and 1671, 1580 and 1672, 1580 and 1673, 1580 and 1674, 1580 and 1675, 1580 and 1676, 1580 and 1677, 1580 and 1678, 1580 and 1679, 1580 and 1680, 1580 and 1681, 1580 and 1682, 1580 and 1683, 1580 and 1684, 1580 and 1685, 1580 and 1686, 1580 and 1687, 1580 and 1688, 1580 and 1689, 1580 and 1690, 1580 and 1691, 1580 and 1692, 1580 and 1693, 1580 and 1694, 1580 and 1695, 1580 and 1696, 1580 and 1697, 1580 and 1698 or 1580 and 1699 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1. More particularly between nucleobase positions 1598 and 1656 of SEQ ID No. 1, more particularly between nucleobase positions 1599 and 1655, 1600 and 1654, 1601 and 1653, 1602 and 1652, even more particularly between nucleobase positions 1603 and 1651 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1. In a more particular embodiment, the target region is defined by SEQ ID No. 79. In an even more particular embodiment, the target region is defined by (or comprises of consists of) SEQ ID No.70, 71, PaVer/SyngrASO2/799 72, 73, 74, 75, 76, 77 and/or 78. In a most particular embodiment, the oligonucleotide (e.g., ASO, siRNA, shRNA) comprises or consists of SEQ ID No.324, 325, 326, 327, 328, 329, 330, 331 and/or 332. In another particular embodiment, the target region is located between by nucleobase positions 1680 and 1837 or is comprised within the nucleotide subsequence defined by nucleobase positions 1680 and 1837 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1. Particularly, the target region is located between nucleobase positions 1681 and 1837, 1682 and 1837, 1683 and 1837, 1684 and 1837, 1685 and 1837, 1686 and 1837, 1689 and 1837, 1690 and 1837, 1691 and 1837, 1692 and 1837, 1693 and 1837, 1694 and 1837, 1695 and 1837, 1696 and 1837, 1680 and 1777, 1680 and 1778, 1680 and 1779, 1680 and 1780, 1680 and 1781, 1680 and 1782, 1680 and 1783, 1680 and 1784, 1680 and 1785, 1680 and 1786, 1680 and 1787, 1680 and 1788, 1680 and 1789, 1680 and 1790, 1680 and 1791, 1680 and 1792, 1680 and 1793, 1680 and 1794, 1680 and 1795, 1680 and 1796, 1680 and 1797, 1680 and 1798, 1680 and 1799, 1680 and 1800, 1680 and 1801, 1680 and 1802, 1680 and 1803, 1680 and 1804, 1680 and 1805, 1680 and 1806, 1680 and 1807, 1680 and 1808, 1680 and 1809, 1680 and 1810, 1680 and 1811, 1680 and 1812, 1680 and 1813, 1680 and 1814, 1680 and 1815, 1680 and 1816, 1680 and 1817, 1680 and 1818, 1680 and 1819, 1680 and 1820, 1680 and 1821, 1680 and 1822, 1680 and 1823, 1680 and 1824, 1680 and 1825, 1680 and 1826, 1680 and 1827, 1680 and 1828, 1680 and 1829, 1680 and 1830, 1680 and 1831, 1680 and 1832, 1680 and 1833, 1680 and 1834, 1680 and 1835 or 1680 and 1836 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1. More particularly the target region is located between nucleobase positions 1696 and 1777 of SEQ ID No. 1, more particularly between nucleobase positions 1697 and 1776, 1698 and 1775, 1699 and 1774, 1700 and 1773, even more particularly between nucleobase positions 1701 and 1772 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1. In a more particular embodiment, the target region is defined by SEQ ID No. 84. In an even more particular embodiment, the target region is defined by (or comprises of consists of) SEQ ID No.80, 81, 82 and/or 83. In a most particular embodiment, the oligonucleotide (e.g., ASO, siRNA, shRNA) comprises or consists of SEQ ID No.333, 334, 335 and/or 336. In another particular embodiment, the target region is located between nucleobase positions 1824 and 1885 or is comprised within the nucleotide subsequence defined by nucleobase positions 1824 and 1885 of the Syngr-3 mRNA transcript set forth in SEQ ID No. 1. Particularly, the target region is located between nucleobase positions 1825 and 1885, 1826 and 1885, 1827 and 1885, 1828 and 1885, 1829 and 1885, 1830 and 1885, 1831 and 1885, 1832 and 1885, 1833 and 1885, 1834 and 1885, 1835 and 1885, 1836 and 1885, 1824 and 1865, 1824 and 1866, 1824 and 1867, 1824 and 1868, 1824 and 1869, 1824 and 1870, 1824 and 1871, 1824 and 1872, 1824 and 1873, 1824 and 1874, 1824 and 1875, 1824 and PaVer/SyngrASO2/799 1876, 1824 and 1877, 1824 and 1878, 1824 and 1879, 1824 and 1880, 1824 and 1881, 1824 and 1882, 1824 and 1883 or 1824 and 1884 of the Syngr-3 mRNA transcript set forth in SEQ ID No. 1. More particularly the target region is located between nucleobase positions 1836 and 1865 of SEQ ID No.1, more particularly between nucleobase positions 1837 and 1864, 1838 and 1863, 1839 and 1862, 1840 and 1861, even more particularly between nucleobase positions 1841 and 1860 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1. In a more particular embodiment, the target region is defined by SEQ ID No. 87. In an even more particular embodiment, the target region is defined by (or comprises of consists of) SEQ ID No.85 and/or 86. In a most particular embodiment, the oligonucleotide (e.g., ASO, siRNA, shRNA) comprises or consists of SEQ ID No.337 and/or 338. In another particular embodiment, the target region is located between nucleobase positions 1850 and 2100 or is comprised within the nucleotide subsequence defined by nucleobase positions 1850 and 2100 of the Syngr-3 mRNA transcript set forth in SEQ ID No. 1. Particularly, the target region is located between nucleobase positions 1851 and 2100, 1852 and 2100, 1853 and 2100, 1854 and 2100, 1855 and 2100, 1856 and 2100, 1857 and 2100, 1858 and 2100, 1859 and 2100, 1860 and 2100, 1861 and 2100, 1862 and 2100, 1863 and 2100, 1864 and 2100, 1865 and 2100, 1866 and 2100, 1867 and 2100, 1868 and 2100, 1869 and 2100, 1870 and 2100, 1850 and 2067, 1850 and 2068, 1850 and 2069, 1850 and 2070, 1850 and 2071, 1850 and 2072, 1850 and 2073, 1850 and 2074, 1850 and 2075, 1850 and 2076, 1850 and 2077, 1850 and 2078, 1850 and 2079, 1850 and 2080, 1850 and 2081, 1850 and 2082, 1850 and 2083, 1850 and 2084, 1850 and 2085, 1850 and 2086, 1850 and 2087, 1850 and 2088, 1850 and 2089, 1850 and 2090, 1850 and 2091, 1850 and 2092, 1850 and 2093, 1850 and 2094, 1850 and 2095, 1850 and 2096, 1850 and 2097, 1850 and 2098 or 1850 and 2099 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1. More particularly the target region is located between nucleobase positions 1870 and 2067 of SEQ ID No. 1, more particularly between nucleobase positions 1871 and 2066, 1872 and 2065, 1873 and 2064, 1874 and 2063, even more particularly between nucleobase positions 1875 and 2062 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1. In a more particular embodiment, the target region is defined by SEQ ID No.111. In another particular embodiment, the target region is located between nucleobase positions 1850 and 1950 or is comprised within the nucleotide subsequence defined by nucleobase positions 1850 and 1950 of the Syngr-3 mRNA transcript set forth in SEQ ID No. 1. Particularly, the target region is located between nucleobase positions 1851 and 1950, 1852 and 1950, 1853 and 1950, 1854 and 1950, 1855 and 1950, 1856 and 1950, 1857 and 1950, 1858 and 1950, 1859 and 1950, 1860 and 1950, 1861 and 1950, PaVer/SyngrASO2/799 1862 and 1950, 1863 and 1950, 1864 and 1950, 1865 and 1950, 1866 and 1950, 1867 and 1950, 1868 and 1950, 1869 and 1950, 1870 and 1950, 1850 and 1933, 1850 and 1934, 1850 and 1935, 1850 and 1936, 1850 and 1937, 1850 and 1938, 1850 and 1939, 1850 and 1940, 1850 and 1941, 1850 and 1942, 1850 and 1943, 1850 and 1944, 1850 and 1945, 1850 and 1946, 1850 and 1947, 1850 and 1948 or 1850 and 1949 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1. More particularly the target region is located between nucleobase positions 1870 and 1933 of SEQ ID No. 1, more particularly between nucleobase positions 1871 and 1932, 1872 and 1931, 1873 and 1930, or 1874 and 1929, even more particularly between nucleobase positions 1875 and 1928 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1. In a more particular embodiment, the target region is defined by SEQ ID No. 91. In an even more particular embodiment, the target region is defined by (or comprises of consists of) SEQ ID No.88, 89 and/or 90. In a most particular embodiment, the oligonucleotide (e.g., ASO, siRNA, shRNA) comprises or consists of SEQ ID No.339, 340 and/or 341. In another particular embodiment, the target region is located between nucleobase positions 1930 and 2000 or is comprised within the nucleotide subsequence defined by nucleobase positions 1930 and 2000 of the Syngr-3 mRNA transcript set forth in SEQ ID No. 1. Particularly, the target region is located between nucleobase positions 1931 and 2000, 1932 and 2000, 1933 and 2000, 1934 and 2000, 1935 and 2000, 1936 and 2000, 1937 and 2000, 1938 and 2000, 1939 and 2000, 1940 and 2000, 1941 and 2000, 1942 and 2000, 1943 and 2000, 1944 and 2000, 1945 and 2000, 1946 and 2000, 1930 and 1992, 1930 and 1993, 1930 and 1994, 1930 and 1995, 1930 and 1996, 1930 and 1997, 1930 and 1998 or 1930 and 1999 of SEQ ID No.1. More particularly the target region is located between nucleobase positions 1946 and 1992 of SEQ ID No. 1, more particularly between nucleobase positions 1947 and 1991, 1948 and 1990, 1949 and 1989, or 1950 and 1988, even more particularly between nucleobase positions 1951 and 1987 of SEQ ID No.1. In a more particular embodiment, the target region is defined by SEQ ID No. 94. In an even more particular embodiment, the target region is defined by (or comprises of consists of) SEQ ID No.92 and/or 93. In a most particular embodiment, the oligonucleotide (e.g., ASO, siRNA, shRNA) comprises or consists of SEQ ID No.342 and/or 343. In another particular embodiment, the target region is located between nucleobase positions 1995 and 2100 or is comprised within the nucleotide subsequence defined by nucleobase positions 1995 and 2100 of the Syngr-3 mRNA transcript set forth in SEQ ID No. 1. Particularly, the target region is located between nucleobase positions 1996 and 2100, 1997 and 2100, 1998 and 2100, 1999 and 2100, 2000 and PaVer/SyngrASO2/799 2100, 2001 and 2100, 2002 and 2100, 2003 and 2100, 2004 and 2100, 2005 and 2100, 2006 and 2100, 2007 and 2100, 2008 and 2100, 1995 and 2067, 1995 and 2068, 1995 and 2069, 1995 and 2070, 1995 and 2071, 1995 and 2072, 1995 and 2073, 1995 and 2074, 1995 and 2075, 1995 and 2076, 1995 and 2077, 1995 and 2078, 1995 and 2079, 1995 and 2080, 1995 and 2081, 1995 and 2082, 1995 and 2083, 1995 and 2084, 1995 and 2085, 1995 and 2086, 1995 and 2087, 1995 and 2088, 1995 and 2089, 1995 and 2090, 1995 and 2091, 1995 and 2092, 1995 and 2093, 1995 and 2094, 1995 and 2095, 1995 and 2096, 1995 and 2097, 1995 and 2098 or 1995 and 2099 of SEQ ID No. 1. More particularly the target region is located between nucleobase positions 2008 and 2067 of SEQ ID No. 1, more particularly between nucleobase positions 2009 and 2066, 2010 and 2065, 2011 and 2064, or 2012 and 2063, even more particularly between nucleobase positions 2013 and 2062 of SEQ ID No.1. In a more particular embodiment, the target region is defined by SEQ ID No. 110. In an even more particular embodiment, the target region is defined by (or comprises of consists of) SEQ ID No.95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108 and/or 109. In a most particular embodiment, the oligonucleotide (e.g., ASO, siRNA, shRNA) comprises or consists of SEQ ID No.344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357 and/or 358. In another particular embodiment, the target region is a subsequence located between nucleobase positions 2100 and 2250 or is comprised within the nucleotide subsequence defined by nucleobase 2100 and 2250 of the Syngr-3 mRNA transcript set forth in SEQ ID No. 1. Particularly, the target region is between nucleobase 2101 and 2250, 2102 and 2250, 2103 and 2250, 2104 and 2250, 2105 and 2250, 2106 and 2250, 2107 and 2250, 2108 and 2250, 2109 and 2250, 2110 and 2250, 2111 and 2250, 2112 and 2250, 2113 and 2250, 2114 and 2250, 2115 and 2250, 2116 and 2250, 2117 and 2250, 2118 and 2250, 2119 and 2250, 2100 and 2233, 2100 and 2234, 2100 and 2235, 2100 and 2236, 2100 and 2237, 2100 and 2238, 2100 and 2239, 2100 and 2240, 2100 and 2241, 2100 and 2242, 2100 and 2243, 2100 and 2244, 2100 and 2245, 2100 and 2246, 2100 and 2247, 2100 and 2248 or 2100 and 2249 of SEQ ID No.1. More particularly the target region is located between nucleobase positions 2119 and 2233 of SEQ ID No.1, more particularly between nucleobase positions 2120 and 2232, 2121 and 2231, 2122 and 2230, or 2123 and 2229, even more particularly between nucleobase 2124 and 2228 of SEQ ID No.1. In a more particular embodiment, the target region is defined by SEQ ID No.141. In another particular embodiment, the target region is a subsequence located between nucleobase positions 2100 and 2190 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1, or is comprised within the nucleotide subsequence defined by nucleobase 2100 and 2190 of the Syngr-3 mRNA transcript set forth in SEQ ID No. 1. Particularly, the target is a subsequence located between nucleobase PaVer/SyngrASO2/799 positions 2101 and 2190, 2102 and 2190, 2103 and 2190, 2104 and 2190, 2105 and 2190, 2106 and 2190, 2107 and 2190, 2108 and 2190, 2109 and 2190, 2110 and 2190, 2111 and 2190, 2112 and 2190, 2113 and 2190, 2114 and 2190, 2115 and 2190, 2116 and 2190, 2117 and 2190, 2118 and 2190, 2119 and 2190, 2100 and 2180, 2100 and 2181, 2100 and 2182, 2100 and 2183, 2100 and 2184, 2100 and 2185, 2100 and 2186, 2100 and 2187, 2100 and 2188 or 2100 and 2189 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1. More particularly, the target region is located between nucleobase positions 2119 and 2180 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1, more particularly between nucleobase positions 2120 and 2179, 2121 and 2178, 2122 and 2177, or 2123 and 2176, even more particularly between nucleobase positions 2124 and 2175 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1. In a more particular embodiment, the target region is defined by SEQ ID No. 135. In an even more particular embodiment, the target region is defined by (or comprises of consists of) SEQ ID No.112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133 and/or 134. In a most particular embodiment, the oligonucleotide (e.g., ASO, siRNA, shRNA) comprises or consists of SEQ ID No. 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380 and/or 381. In another particular embodiment, the target region is a subsequence located between nucleobase positions 2180 and 2250 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1, or is comprised within the nucleotide subsequence defined by nucleobase 2180 and 2250 of the Syngr-3 mRNA transcript set forth in SEQ ID No. 1. Particularly, the target region is a subsequence located between nucleobase positions 2181 and 2250, 2182 and 2250, 2183 and 2250, 2184 and 2250, 2185 and 2250, 2186 and 2250, 2187 and 2250, 2188 and 2250, 2189 and 2250, 2190 and 2250, 2191 and 2250, 2192 and 2250, 2193 and 2250, 2194 and 2250, 2195 and 2250, 2196 and 2250, 2197 and 2250, 2198 and 2250, 2199 and 2250, 2200 and 2250, 2201 and 2250, 2180 and 2233, 2180 and 2234, 2180 and 2235, 2180 and 2236, 2180 and 2237, 2180 and 2238, 2180 and 2239, 2180 and 2240, 2180 and 2241, 2180 and 2242, 2180 and 2243, 2180 and 2244, 2180 and 2245, 2180 and 2246, 2180 and 2247, 2180 and 2248 or 2180 and 2249 of the Syngr-3 mRNA transcript set forth in SEQ ID No. 1. More particularly, the target region is located between nucleobase positions 2201 and 2233 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1, more particularly between nucleobase positions 2202 and 2232, 2203 and 2231, 2204 and 2230, or 2205 and 2229, even more particularly between nucleobase positions 2206 and 2228 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1. In a more particular embodiment, the target region is defined by SEQ ID No. 140. In an even more particular embodiment, the target region is defined by (or comprises of consists of) SEQ ID No.136, 137, PaVer/SyngrASO2/799 138 and/or 139. In a most particular embodiment, the oligonucleotide (e.g., ASO, siRNA, shRNA) comprises or consists of SEQ ID No.382, 383, 384 and/or 385. In another particular embodiment, the target region is a subsequence located between nucleobase positions 2308 and 2428 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1, or is comprised within the nucleotide subsequence defined by nucleobase 2308 and 2428 of the Syngr-3 mRNA transcript set forth in SEQ ID No. 1. Particularly, the target region is a subsequence located between nucleobase positions 2309 and 2428, 2310 and 2428, 2308 and 2417, 2308 and 2418, 2308 and 2419, 2308 and 2420, 2308 and 2421, 2308 and 2422, 2308 and 2423, 2308 and 2424, 2308 and 2425, 2308 and 2426 or 2308 and 2027 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1. More particularly, the target region is located between nucleobase positions 2310 and 2417 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1, more particularly between nucleobase positions 2311 and 2416, 2312 and 2415, 2313 and 2414, or 2314 and 2413, even more particularly between nucleobase positions 2315 and 2412 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1. In a more particular embodiment, the target region is defined by SEQ ID No. 170. In an even more particular embodiment, the target region is defined by (or comprises of consists of) SEQ ID No.142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168 and/or 169. In a most particular embodiment, the oligonucleotide (e.g., ASO, siRNA, shRNA) comprises or consists of SEQ ID No.386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412 and/or 413. In another particular embodiment, the target region is a subsequence located between nucleobase positions 2416 and 2441 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1, or is comprised within the nucleotide subsequence defined by nucleobase 2416 and 2441 of the Syngr-3 mRNA transcript set forth in SEQ ID No. 1. Particularly, the target region is a subsequence located between nucleobase positions 2417 and 2441, 2418 and 2441, 2419 and 2441, 2420 and 2441, 2421 and 2441, 2416 and 2436, 2416 and 2437, 2416 and 2438, 2416 and 2439 or 2416 and 2440 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1. More particularly, the target region is located between nucleobase positions 2421 and 2436 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1. In a more particular embodiment, the target region is defined by SEQ ID No. 172. In an even more particular embodiment, the target region is defined by (or comprises of consists of) SEQ ID No.171. In a most particular embodiment, the oligonucleotide (e.g., ASO, siRNA, shRNA) comprises or consists of SEQ ID No.414. PaVer/SyngrASO2/799 In another particular embodiment, the target region is a subsequence located between nucleobase positions 2428 and 2625 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1, or is comprised within the nucleotide subsequence defined by nucleobase 2428 and 2625 of the Syngr-3 mRNA transcript set forth in SEQ ID No. 1. Particularly, the target region is a subsequence located between nucleobase positions 2429 and 2625, 2430 and 2625, 2431 and 2625, 2432 and 2625, 2433 and 2625, 2434 and 2625, 2435 and 2625, 2436 and 2625, 2437 and 2625, 2438 and 2625, 2439 and 2625, 2440 and 2625, 2441 and 2625, 2442 and 2625, 2443 and 2625, 2444 and 2625, 2445 and 2625, 2446 and 2625, 2447 and 2625, 2448 and 2625, 2449 and 2625, 2450 and 2625, 2451 and 2625, 2452 and 2625, 2453 and 2625, 2454 and 2625, 2455 and 2625, 2456 and 2625, 2457 and 2625, 2458 and 2625, 2459 and 2625, 2460 and 2625, 2461 and 2625, 2462 and 2625, 2463 and 2625, 2664 and 2625, 2665 and 2625, 2666 and 2625, 2667 and 2625, 2668 and 2625, 2669 and 2625, 2470 and 2625, 2428 and 2519, 2428 and 2520, 2428 and 2521, 2428 and 2522, 2428 and 2523, 2428 and 2524, 2428 and 2525, 2428 and 2526, 2428 and 2527, 2428 and 2528, 2428 and 2529, 2428 and 2530, 2428 and 2531, 2428 and 2532, 2428 and 2533, 2428 and 2534, 2428 and 2535, 2428 and 2536, 2428 and 2537, 2428 and 2538, 2428 and 2539, 2428 and 2540, 2428 and 2541, 2428 and 2542, 2428 and 2543, 2428 and 2544, 2428 and 2545, 2428 and 2546, 2428 and 2547, 2428 and 2548, 2428 and 2549, 2428 and 2550, 2428 and 2551, 2428 and 2552, 2428 and 2553, 2428 and 2554, 2428 and 2555, 2428 and 2556, 2428 and 2557, 2428 and 2558, 2428 and 2559, 2428 and 2560, 2428 and 2561, 2428 and 2562, 2428 and 2563, 2428 and 2564, 2428 and 2565, 2428 and 2566, 2428 and 2567, 2428 and 2568, 2428 and 2569, 2428 and 2570, 2428 and 2571, 2428 and 2572, 2428 and 2573, 2428 and 2574, 2428 and 2575, 2428 and 2576, 2428 and 2577, 2428 and 2578, 2428 and 2579, 2428 and 2580, 2428 and 2581, 2428 and 2582, 2428 and 2583, 2428 and 2584, 2428 and 2585, 2428 and 2586, 2428 and 2587, 2428 and 2588, 2428 and 2589, 2428 and 2590, 2428 and 2591, 2428 and 2592, 2428 and 2593, 2428 and 2594, 2428 and 2595, 2428 and 2596, 2428 and 2597, 2428 and 2598, 2428 and 2599, 2428 and 2600, 2428 and 2601, 2428 and 2602, 2428 and 2603, 2428 and 2604, 2428 and 2605, 2428 and 2606, 2428 and 2607, 2428 and 2608, 2428 and 2609, 2428 and 2610, 2428 and 2611, 2428 and 2612, 2428 and 2613, 2428 and 2614, 2428 and 2615, 2428 and 2616, 2428 and 2617, 2428 and 2618, 2428 and 2619, 2428 and 2620, 2428 and 2621, 2428 and 2622, 2428 and 2623 or 2428 and 2624 of the Syngr-3 mRNA transcript set forth in SEQ ID No. 1. More particularly, the target region is located between nucleobase positions 2470 and 2519 of the Syngr- 3 mRNA transcript set forth in SEQ ID No.1, more particularly between nucleobase positions 2471 and 2518, 2472 and 2517, 2473 and 2516, or 2474 and 2515, even more particularly, the target region is located between nucleobase positions 2475 and 2514 of SEQ ID No.1. In a more particular embodiment, the target region is defined by SEQ ID No. 179. In an even more particular embodiment, the target region is defined (or comprises of consists of) SEQ ID No.173, 174, PaVer/SyngrASO2/799 175, 176, 177 and/or 178. In a most particular embodiment, the oligonucleotide (e.g., ASO, siRNA, shRNA) comprises or consists of SEQ ID No.415, 416, 417, 418, 419 and/or 420. In another particular embodiment, the target region is a subsequence located between nucleobase positions 2649 and 2796 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1, or is comprised within the nucleotide subsequence defined by nucleobase 2649 and 2796 of the Syngr-3 mRNA transcript set forth in SEQ ID No. 1. Particularly, the target region is a subsequence located between nucleobase positions 2650 and 2796, 2651 and 2796, 2652 and 2796, 2653 and 2796, 2654 and 2796, 2655 and 2796, 2656 and 2796, 2657 and 2796, 2658 and 2796, 2659 and 2796, 2670 and 2796, 2671 and 2796, 2672 and 2796, 2673 and 2796, 2674 and 2796, 2675 and 2796, 2676 and 2796, 2677 and 2796, 2678 and 2796, 2679 and 2796, 2680 and 2796, 2681 and 2796, 2682 and 2796, 2683 and 2796, 2684 and 2796, 2685 and 2796, 2686 and 2796, 2687 and 2796, 2688 and 2796, 2689 and 2796, 2690 and 2796, 2691 and 2796, 2692 and 2796, 2693 and 2796, 2694 and 2796, 2695 and 2796, 2696 and 2796, 2697 and 2796, 2698 and 2796, 2699 and 2796, 2700 and 2796, 2701 and 2796, 2702 and 2796, 2703 and 2796, 2704 and 2796, 2705 and 2796, 2706 and 2796, 2707 and 2796, 2708 and 2796, 2709 and 2796, 2710 and 2796, 2711 and 2796, 2712 and 2796, 2713 and 2796, 2714 and 2796, 2715 and 2796, 2716 and 2796, 2717 and 2796, 2718 and 2796, 2719 and 2796, 2720 and 2796, 2721 and 2796, 2722 and 2796, 2723 and 2796, 2724 and 2796, 2725 and 2796, 2726 and 2796, 2727 and 2796, 2649 and 2752, 2649 and 2753, 2649 and 2754, 2649 and 2755, 2649 and 2756, 2649 and 2757, 2649 and 2758, 2649 and 2759, 2649 and 2760, 2649 and 2761, 2649 and 2762, 2649 and 2763, 2649 and 2764, 2649 and 2765, 2649 and 2766, 2649 and 2767, 2649 and 2768, 2649 and 2769, 2649 and 2770, 2649 and 2771, 2649 and 2772, 2649 and 2773, 2649 and 2774, 2649 and 2775, 2649 and 2776, 2649 and 2777, 2649 and 2778, 2649 and 2779, 2649 and 2780, 2649 and 2781, 2649 and 2782, 2649 and 2783, 2649 and 2784, 2649 and 2785, 2649 and 2786, 2649 and 2787, 2649 and 2788, 2649 and 2789, 2649 and 2790, 2649 and 2791, 2649 and 2792, 2649 and 2793, 2649 and 2794 and/or 2649 and 2795 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1. More particularly, the target region is located between nucleobase positions 2727 and 2752 of the Syngr-3 mRNA transcript set forth in SEQ ID No. 1, more particularly between nucleobase positions 2728 and 2751, 2729 and 2750, 2730 and 2749, or 2731 and 2748, even more particularly between nucleobase positions 2732 and 2747 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1. In a more particular embodiment, the target region is defined by SEQ ID No. 181. In an even more particular embodiment, the target region is defined by (or comprises of consists of) SEQ ID No.180. In a most particular embodiment, the oligonucleotide (e.g., ASO, siRNA, shRNA) comprises or consists of SEQ ID No.421. PaVer/SyngrASO2/799 In another particular embodiment, the target region is a subsequence located between nucleobase positions 2962 and 3086 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1, or is comprised within the nucleotide subsequence defined by nucleobase 2962 and 3086 of the Syngr-3 mRNA transcript set forth in SEQ ID No. 1. Particularly, the target region is a subsequence located between nucleobase positions 2963 and 3086, 2964 and 3086, 2965 and 3086, 2966 and 3086, 2967 and 3086, 2968 and 3086, 2969 and 3086, 2970 and 3086, 2971 and 3086, 2972 and 3086, 2973 and 3086, 2974 and 3086, 2975 and 3086, 2962 and 3066, 2962 and 3067, 2962 and 3068, 2962 and 3069, 2962 and 3070, 2962 and 3071, 2962 and 3072, 2962 and 3073, 2962 and 3074, 2962 and 3075, 2962 and 3076, 2962 and 3077, 2962 and 3078, 2962 and 3079, 2962 and 3080, 2962 and 3081, 2962 and 3082, 2962 and 3083, 2962 and 3084 and/or 2962 and 3085 of the Syngr-3 mRNA transcript set forth in SEQ ID No. 1. More particularly, the target region is located between nucleobase positions 2975 and 3066 of the Syngr-3 mRNA transcript set forth in SEQ ID No. 1, more particularly between nucleobase positions 2976 and 3065, 2977 and 3064, 2978 and 3063, or 2979 and 3062, even more particularly between nucleobase positions 2980 and 3061 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1. In a more particular embodiment, the target region is defined by SEQ ID No.194. In another particular embodiment, the target region is a subsequence located between nucleobase positions 2962 and 3010 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1, or is comprised within the nucleotide subsequence defined by nucleobase 2962 and 3010 of the Syngr-3 mRNA transcript set forth in SEQ ID No. 1. Particularly, the target region is a subsequence located between nucleobase positions 2963 and 3010, 2964 and 3010, 2965 and 3010, 2966 and 3010, 2967 and 3010, 2968 and 3010, 2969 and 3010, 2970 and 3010, 2971 and 3010, 2972 and 3010, 2973 and 3010, 2974 and 3010, 2975 and 3010, 2962 and 3003, 2962 and 3004, 2962 and 3005, 2962 and 3006, 2962 and 3007, 2962 and 3008 or 2962 and 3009 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1. More particularly, the target region is located between nucleobase positions 2975 and 3003 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1, more particularly between nucleobase positions 2976 and 3002, 2977 and 3001, 2978 and 3000, or 2979 and 2999, even more particularly between nucleobase positions 2980 and 2998 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1. In a more particular embodiment, the target region is defined by SEQ ID No. 184. In an even more particular embodiment, the target region is defined by (or comprises of consists of) SEQ ID No. 182 and/or 183. In a most particular embodiment, the oligonucleotide (e.g., ASO, siRNA, shRNA) comprises or consists of SEQ ID No.422 and/or 423. PaVer/SyngrASO2/799 In another particular embodiment, the target region is a subsequence located between nucleobase positions 3000 and 3045 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1, or is comprised within the nucleotide subsequence defined by nucleobase 3000 and 3045 of the Syngr-3 mRNA transcript set forth in SEQ ID No. 1. Particularly, the target region is a subsequence located between nucleobase positions 3001 and 3045, 3002 and 3045, 3003 and 3045, 3004 and 3045, 3005 and 3045, 3006 and 3045, 3000 and 3037, 3000 and 3038, 3000 and 3039, 3000 and 3040, 3000 and 3041, 3000 and 3042, 3000 and 3043 or 3000 and 3044 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1. More particularly, the target region is located between nucleobase positions 3006 and 3037 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1, more particularly between nucleobase positions 3007 and 3036, 3008 and 3035, 3009 and 3034, or 3010 and 3033, even more particularly between nucleobase positions 3011 and 3032 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1. In a more particular embodiment, the target region is defined by SEQ ID No. 188. In an even more particular embodiment, the target region is defined by (or comprises of consists of) SEQ ID No.185, 186 and/or 187. In a most particular embodiment, the oligonucleotide (e.g., ASO, siRNA, shRNA) comprises or consists of SEQ ID No.424, 425 and/or 426. In another particular embodiment, the target region is a subsequence located between nucleobase positions 3020 and 3086 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1, or is comprised within the nucleotide subsequence defined by nucleobase 3020 and 3086 of the Syngr-3 mRNA transcript set forth in SEQ ID No. 1. Particularly, the target region is a subsequence located between nucleobase positions 3021 and 3086, 3022 and 3086, 3023 and 3086, 3024 and 3086, 3025 and 3086, 3026 and 3086, 3027 and 3086, 3028 and 3086, 3029 and 3086, 3020 and 3066, 3020 and 3067, 3020 and 3068, 3020 and 3069, 3020 and 3070, 3020 and 3071, 3020 and 3072, 3020 and 3073, 3020 and 3074, 3020 and 3075, 3020 and 3076, 3020 and 3077, 3020 and 3078, 3020 and 3079, 3020 and 3080, 3020 and 3081, 3020 and 3082, 3020 and 3083, 3020 and 3084 and/or 3020 and 3085 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1. More particularly, the target region is located between nucleobase positions 3029 and 3066 of the Syngr-3 mRNA transcript set forth in SEQ ID No. 1, more particularly between nucleobase positions 3030 and 3065, 3031 and 3064, 3032 and 3063, or 3033 and 3062, even more particularly between nucleobase positions 3034 and 3061 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1. In a more particular embodiment, the target region is defined by SEQ ID No. 193. In an even more particular embodiment, the target region is defined by (or comprises of consists of) SEQ ID No.189, 190, 191 and/or 192. In a most particular embodiment, the oligonucleotide (e.g., ASO, siRNA, shRNA) comprises or consists of SEQ ID No.427, 428, 429 and/or 430. PaVer/SyngrASO2/799 In another particular embodiment, the target region is a subsequence located between nucleobase positions 3153 and 3460 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1, or is comprised within the nucleotide subsequence defined by nucleobase 3153 and 3460 of the Syngr-3 mRNA transcript set forth in SEQ ID No. 1. Particularly, the target region is a subsequence located between nucleobase positions 3154 and 3460, 3155 and 3460, 3156 and 3460, 3157 and 3460, 3158 and 3460, 3159 and 3460, 3160 and 3460, 3161 and 3460, 3162 and 3460, 3164 and 3460, 3165 and 3460, 3166 and 3460, 3167 and 3460, 3168 and 3460, 3169 and 3460, 3170 and 3460, 3172 and 3460, 3173 and 3460, 3174 and 3460, 3175 and 3460, 3176 and 3460, 3177 and 3460, 3178 and 3460, 3179 and 3460, 3180 and 3460, 3181 and 3460, 3182 and 3460, 3183 and 3460, 3153 and 3417, 3153 and 3418, 3153 and 3419, 3153 and 3420, 3153 and 3421, 3153 and 3422, 3153 and 3423, 3153 and 3424, 3153 and 3425, 3153 and 3426, 3153 and 3427, 3153 and 3428, 3153 and 3429, 3153 and 3430, 3153 and 3431, 3153 and 3432, 3153 and 3433, 3153 and 3434, 3153 and 3435, 3153 and 3436, 3153 and 3437, 3153 and 3438, 3153 and 3439, 3153 and 3440, 3153 and 3441, 3153 and 3442, 3153 and 3443, 3153 and 3444, 3153 and 3445, 3153 and 3446, 3153 and 3447, 3153 and 3448, 3153 and 3449, 3153 and 3450, 3153 and 3451, 3153 and 3452, 3153 and 3453, 3153 and 3454, 3153 and 3455, 3153 and 3456, 3153 and 3457, 3153 and 3458 or 3153 and 3459 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1. More particularly, the target region is located between nucleobase positions 3183 and 3417 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1, more particularly between nucleobase positions 3184 and 3416, 3185 and 3415, 3186 and 3414, or 3187 and 3413, even more particularly between nucleobase positions 3188 and 3412 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1. In a more particular embodiment, the target region is defined by SEQ ID No.221. In another particular embodiment, the target region is a subsequence located between nucleobase positions 3153 and 3270 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1, or is comprised within the nucleotide subsequence defined by nucleobase 3153 and 3270 of the Syngr-3 mRNA transcript set forth in SEQ ID No. 1. Particularly, the target region is a subsequence located between nucleobase positions 3154 and 3270, 3155 and 3270, 3156 and 3270, 3157 and 3270, 3158 and 3270, 3159 and 3270, 3160 and 3270, 3161 and 3270, 3162 and 3270, 3164 and 3270, 3165 and 3270, 3166 and 3270, 3167 and 3270, 3168 and 3270, 3169 and 3270, 3170 and 3270, 3172 and 3270, 3173 and 3270, 3174 and 3270, 3175 and 3270, 3176 and 3270, 3177 and 3270, 3178 and 3270, 3179 and 3270, 3180 and 3270, 3181 and 3270, 3182 and 3270, 3183 and 3270, 3153 and 3260, 3153 and 3261, 3153 and 3262, 3153 and 3263, 3153 and 3264, 3153 and 3265, 3153 and 3266, 3153 and 3267, 3153 and 3268 or 3153 and 3269 of the Syngr-3 mRNA transcript set forth in ID No. 1. More particularly, the target region is PaVer/SyngrASO2/799 located between nucleobase positions 3183 and 3260 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1, more particularly between nucleobase positions 3184 and 3259, 3185 and 3258, 3186 and 3257, or 3187 and 3256, even more particularly between nucleobase positions 3188 and 3255 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1. In a more particular embodiment, the target region is defined by SEQ ID No. 210. In an even more particular embodiment, the target region is defined by (or comprises of consists of) SEQ ID No.195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208 and/or 209. In a most particular embodiment, the oligonucleotide (e.g., ASO, siRNA, shRNA) comprises or consists of SEQ ID No. 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444 and/or 445. In another particular embodiment, the target region is a subsequence located between nucleobase positions 3250 and 3360 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1, or is comprised within the nucleotide subsequence defined by nucleobase 3250 and 3360 of the Syngr-3 mRNA transcript set forth in SEQ ID No. 1. Particularly, the target region is a subsequence located between nucleobase positions 3251 and 3360, 3252 and 3360, 3253 and 3360, 3254 and 3360, 3255 and 3360, 3256 and 3360, 3257 and 3360, 3258 and 3360, 3259 and 3360, 3260 and 3360, 3261 and 3360, 3262 and 3360, 3263 and 3360, 3264 and 3360, 3265 and 3360, 3266 and 3360, 3267 and 3360, 3268 and 3360, 3269 and 3360, 3270 and 3360, 3271 and 3360, 3250 and 3342, 3250 and 3343, 3250 and 3344, 3250 and 3345, 3250 and 3346, 3250 and 3347, 3250 and 3348, 3250 and 3349, 3250 and 3350, 3250 and 3351, 3250 and 3352, 3250 and 3353, 3250 and 3354, 3250 and 3355, 3250 and 3356, 3250 and 3357, 3250 and 3358 or 3250 and 3359 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1. More particularly, the target region is located between nucleobase positions 3271 and 3342 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1, more particularly between nucleobase positions 3272 and 3341, 3273 and 3340, 3274 and 3339, or 3275 and 3338, even more particularly between nucleobase positions 3276 and 3337 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1. In a more particular embodiment, the target region is defined by SEQ ID No. 216. In an even more particular embodiment, the target region is defined by (or comprises of consists of) SEQ ID No.211, 212, 213, 214 and/or 215. In a most particular embodiment, the oligonucleotide (e.g., ASO, siRNA, shRNA) comprises or consists of SEQ ID No.446, 447, 448, 449 and/or 450. In another particular embodiment, the target region is a subsequence located between nucleobase positions 3370 and 3460 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1, or is comprised within the nucleotide subsequence defined by nucleobase 3370 and 3460 of the Syngr-3 mRNA transcript set forth in SEQ ID No. 1. Particularly, the target is a subsequence located between nucleobase PaVer/SyngrASO2/799 positions 3371 and 3460, 3372 and 3460, 3373 and 3460, 3374 and 3460, 3375 and 3460, 3376 and 3460, 3377 and 3460, 3378 and 3460, 3379 and 3460, 3380 and 3460, 3381 and 3460, 3382 and 3460, 3383 and 3460, 3384 and 3460, 3385 and 3460, 3386 and 3460, 3387 and 3460, 3388 and 3460, 3389 and 3460, 3390 and 3460, 3370 and 3417, 3370 and 3418, 3370 and 3419, 3370 and 3420, 3370 and 3421, 3370 and 3422, 3370 and 3423, 3370 and 3424, 3370 and 3425, 3370 and 3426, 3370 and 3427, 3370 and 3428, 3370 and 3429, 3370 and 3430, 3370 and 3431, 3370 and 3432, 3370 and 3433, 3370 and 3434, 3370 and 3435, 3370 and 3436, 3370 and 3437, 3370 and 3438, 3370 and 3439, 3370 and 3440, 3370 and 3441, 3370 and 3442, 3370 and 3443, 3370 and 3444, 3370 and 3445, 3370 and 3446, 3370 and 3447, 3370 and 3448, 3370 and 3449, 3370 and 3450, 3370 and 3451, 3370 and 3452, 3370 and 3453, 3370 and 3454, 3370 and 3455, 3370 and 3456, 3370 and 3457, 3370 and 3458 or 3370 and 3459 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1. More particularly, the target region is located between nucleobase positions 3390 and 3417 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1, more particularly between nucleobase positions 3391 and 3416, 3392 and 3415, 3393 and 3414, or 3394 and 3413, even more particularly between nucleobase positions 3395 and 3412 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1. In a more particular embodiment, the target region is defined by SEQ ID No. 220. In an even more particular embodiment, the target region is defined by (or comprises of consists of) SEQ ID No.217, 218 and/or 219. In a most particular embodiment, the oligonucleotide (e.g., ASO, siRNA, shRNA) comprises or consists of SEQ ID No.451, 452 and/or 453. In another particular embodiment, the target region is a subsequence located between nucleobase positions 3450 and 3530 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1, or is comprised within the nucleotide subsequence defined by nucleobase 3450 and 3530 of the Syngr-3 mRNA transcript set forth in SEQ ID No. 1. Particularly, the target region is a subsequence located between nucleobase positions 3451 and 3530, 3452 and 3530, 3453 and 3530, 3454 and 3530, 3455 and 3530, 3456 and 3530, 3457 and 3530, 3458 and 3530, 3459 and 3530, 3460 and 3530, 3461 and 3530, 3462 and 3530, 3463 and 3530, 3464 and 3530, 3465 and 3530, 3466 and 3530, 3467 and 3530, 3468 and 3530, 3469 and 3530, 3470 and 3530, 3471 and 3530, 3472 and 3530, 3473 and 3530, 3474 and 3530, 3475 and 3530, 3476 and 3530, 3477 and 3530, 3478 and 3530, 3479 and 3530, 3480 and 3530, 3481 and 3530, 3482 and 3530, 3483 and 3530, 3484 and 3530, 3485 and 3530, 3486 and 3530, 3487 and 3530, 3488 and 3530, 3489 and 3530, 3490 and 3530, 3450 and 3518, 3450 and 3519, 3450 and 3520, 3450 and 3521, 3450 and 3522, 3450 and 3523, 3450 and 3524, 3450 and 3525, 3450 and 3526, 3450 and 3527, 3450 and 3528 or 3450 and 3529 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1. More particularly, the target region is located between nucleobase 3490 and 3518 of the Syngr-3 mRNA transcript PaVer/SyngrASO2/799 set forth in SEQ ID No.1, more particularly between nucleobase positions 3491 and 3517, 3492 and 3516, 3493 and 3515, or 3494 and 3514, even more particularly between nucleobase positions 3495 and 3513 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1. In a more particular embodiment, the target region is defined by SEQ ID No. 224. In an even more particular embodiment, the target region is defined by (or comprises of consists of) SEQ ID No. 222 and/or 223. In a most particular embodiment, the oligonucleotide (e.g., ASO, siRNA, shRNA) comprises or consists of SEQ ID No.454 and/or 455. In another particular embodiment, the target region is a subsequence located between nucleobase positions 3508 and 3551 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1, or is comprised within the nucleotide subsequence defined by nucleobase 3508 and 3551 of the Syngr-3 mRNA transcript set forth in SEQ ID No. 1. Particularly, the target region is a subsequence located between nucleobase positions 3509 and 3551, 3510 and 3551, 3511 and 3551, 3512 and 3551, 3513 and 3551, 3514 and 3551, 3515 and 3551, 3516 and 3551, 3517 and 3551, 3518 and 3551, 3519 and 3551, 3520 and 3551, 3508 and 3549 or 3508 and 3550 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1. More particularly, the target region is located between nucleobase positions 3520 and 3549 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1, more particularly between nucleobase positions 3521 and 3548, 3522 and 3547, 3523 and 3546, or 3524 and 3545, even more particularly between nucleobase positions 3525 and 3544 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1. In a more particular embodiment, the target region is defined by SEQ ID No. 227. In an even more particular embodiment, the target region is defined by (or comprises of consists of) SEQ ID No. 225 and/or 226. In a most particular embodiment, the oligonucleotide (e.g., ASO, siRNA, shRNA) comprises or consists of SEQ ID No.456 and/or 457. In another particular embodiment, the target region is a subsequence located between nucleobase positions 3538 and 3636 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1, or is comprised within the nucleotide subsequence defined by nucleobase 3538 and 3636 of the Syngr-3 mRNA transcript set forth in SEQ ID No. 1. Particularly, the target region is a subsequence located between nucleobase positions 3539 and 3636, 3540 and 3636, 3541 and 3636, 3542 and 3636, 3543 and 3636, 3544 and 3636, 3538 and 3569, 3538 and 3570, 3538 and 3571, 3538 and 3572, 3538 and 3573, 3538 and 3574, 3538 and 3575, 3538 and 3576, 3538 and 3577, 3538 and 3578, 3538 and 3579, 3538 and 3580, 3538 and 3581, 3538 and 3582, 3538 and 3583, 3538 and 3584, 3538 and 3585, 3538 and 3586, 3538 and 3587, 3538 and 3588, 3538 and 3589, 3538 and 3590, 3538 and 3591, 3538 and 3592, 3538 and 3593, 3538 and 3594, 3538 and 3595, 3538 and 3596, 3538 and 3597, 3538 and 3598, 3538 and 3599, 3538 and PaVer/SyngrASO2/799 3600, 3538 and 3601, 3538 and 3602, 3538 and 3603, 3538 and 3604, 3538 and 3605, 3538 and 3606, 3538 and 3607, 3538 and 3608, 3538 and 3609, 3538 and 3610, 3538 and 3611, 3538 and 3612, 3538 and 3613, 3538 and 3614, 3538 and 3615, 3538 and 3616, 3538 and 3617, 3538 and 3618, 3538 and 3619, 3538 and 3620, 3538 and 3621, 3538 and 3622, 3538 and 3623, 3538 and 3624, 3538 and 3625, 3538 and 3626, 3538 and 3627, 3538 and 3628, 3538 and 3629, 3538 and 3630, 3538 and 3631, 3538 and 3632, 3538 and 3633, 3538 and 3634 or 3538 and 3635 of the Syngr-3 mRNA transcript set forth in SEQ ID No. 1. More particularly, the target region is located between nucleobase positions 3544 and 3569 of the Syngr-3 mRNA transcript set forth in SEQ ID No. 1, more particularly between nucleobase positions 3545 and 3568, 3546 and 3567, 3547 and 3566, or 3548 and 3565, even more particularly between nucleobase positions 3549 and 3564 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1. In a more particular embodiment, the target region is defined by SEQ ID No. 229. In an even more particular embodiment, the target region is defined by (or comprises of consists of) SEQ ID No.228. In a most particular embodiment, the oligonucleotide (e.g., ASO, siRNA, shRNA) comprises or consists of SEQ ID No.458. In another particular embodiment, the target region is a subsequence located between nucleobase positions 3626 and 4599 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1, or is comprised within the nucleotide subsequence defined by nucleobase 3626 and 4599 of the Syngr-3 mRNA transcript set forth in SEQ ID No. 1. Particularly, the target region is a subsequence located between nucleobase positions 3627 and 4599, 3628 and 4599, 3629 and 4599, 3630 and 4599, 3631 and 4599, 3632 and 4599, 3633 and 4599, 3634 and 4599, 3635 and 4599, 3636 and 4599, 3637 and 4599, 3638 and 4599, 3639 and 4599, 3640 and 4599, 3626 and 4567, 3626 and 4568, 3626 and 4569, 3626 and 4570, 3626 and 4571, 3626 and 4572, 3626 and 4573, 3626 and 4574, 3626 and 4575, 3626 and 4576, 3626 and 4577, 3626 and 4578, 3626 and 4579, 3626 and 4580, 3626 and 4581, 3626 and 4582, 3626 and 4583, 3626 and 4584, 3626 and 4585, 3626 and 4586, 3626 and 4587, 3626 and 4588, 3626 and 4589, 3626 and 4590, 3626 and 4591, 3626 and 4592, 3626 and 4593, 3626 and 4594, 3626 and 4595, 3626 and 4596, 3626 and 4597 or 3626 and 4598 of the Syngr-3 mRNA transcript set forth in SEQ ID No. 1. More particularly, the target region is located between nucleobase positions 3640 and 4567 of the Syngr-3 mRNA transcript set forth in SEQ ID No. 1, more particularly between nucleobase positions 3641 and 4566, 3642 and 4565, 3643 and 4564, or 3644 and 4563, even more particularly between nucleobase positions 3645 and 4562 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1. In a more particular embodiment, the target region is defined by SEQ ID No.269. PaVer/SyngrASO2/799 In another particular embodiment, the target region is a subsequence located between nucleobase positions 3626 and 3680 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1, or is comprised within the nucleotide subsequence defined by nucleobase 3626 and 3680 of the Syngr-3 mRNA transcript set forth in SEQ ID No. 1. Particularly, the target region is a subsequence located between nucleobase positions 3627 and 3680, 3628 and 3680, 3629 and 3680, 3630 and 3680, 3631 and 3680, 3632 and 3680, 3633 and 3680, 3634 and 3680, 3635 and 3680, 3636 and 3680, 3637 and 3680, 3638 and 3680, 3639 and 3680, 3640 and 3680, 3626 and 3665, 3626 and 3666, 3626 and 3667, 3626 and 3668, 3626 and 3669, 3626 and 3670, 3626 and 3671, 3626 and 3672, 3626 and 3673, 3626 and 3674, 3626 and 3675, 3626 and 3676, 3626 and 3677, 3626 and 3678 or 3626 and 3679 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1. More particularly, the target region is located between nucleobase positions 3640 and 3665 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1, more particularly between nucleobase positions 3641 and 3664, 3642 and 3663, 3643 and 3662, or 3644 and 3661, even more particularly between nucleobase positions 3645 and 3660 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1. In a more particular embodiment, the target region is defined by SEQ ID No. 231. In an even more particular embodiment, the target region is defined by (or comprises of consists of) SEQ ID No.230. In a most particular embodiment, the oligonucleotide (e.g., ASO, siRNA, shRNA) comprises or consists of SEQ ID No.459. In another particular embodiment, the target region is a subsequence located between nucleobase positions 3700 and 3800 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1, or is comprised within the nucleotide subsequence defined by nucleobase 3700 and 3800 of the Syngr-3 mRNA transcript set forth in SEQ ID No. 1. Particularly, the target region is a subsequence located between nucleobase positions 3701 and 3800, 3702 and 3800, 3703 and 3800, 3704 and 3800, 3705 and 3800, 3706 and 3800, 3707 and 3800, 3708 and 3800, 3709 and 3800, 3710 and 3800, 3711 and 3800, 3712 and 3800, 3713 and 3800, 3714 and 3800, 3715 and 3800, 3716 and 3800, 3717 and 3800, 3718 and 3800, 3719 and 3800, 3720 and 3800, 3721 and 3800, 3722 and 3800, 3723 and 3800, 3724 and 3800, 3725 and 3800, 3726 and 3800, 3727 and 3800, 3728 and 3800, 3729 and 3800, 3730 and 3800, 3700 and 3780, 3700 and 3781, 3700 and 3782, 3700 and 3783, 3700 and 3784, 3700 and 3785, 3700 and 3786, 3700 and 3787, 3700 and 3788, 3700 and 3789, 3700 and 3790, 3700 and 3791, 3700 and 3792, 3700 and 3793, 3700 and 3794, 3700 and 3795, 3700 and 3796, 3700 and 3797, 3700 and 3798 or 3700 and 3799 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1. More particularly, the target region is located between nucleobase positions 3730 and 3780 of the Syngr-3 mRNA transcript set forth in SEQ ID No. 1, more particularly between nucleobase positions 3731 and 3779, 3732 and 3778, 3733 and 3777, or 3734 and PaVer/SyngrASO2/799 3776, even more particularly between nucleobase positions 3735 and 3775 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1. In a more particular embodiment, the target region is defined by SEQ ID No. 235. In an even more particular embodiment, the target region is defined by (or comprises of consists of) SEQ ID No.232, 233 and/or 234. In a most particular embodiment, the oligonucleotide (e.g., ASO, siRNA, shRNA) comprises or consists of SEQ ID No.460, 461 and/or 462. In another particular embodiment, the target region is a subsequence located between nucleobase positions 3800 and 3910 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1, or is comprised within the nucleotide subsequence defined by nucleobase 3800 and 3910 of the Syngr-3 mRNA transcript set forth in SEQ ID No. 1. Particularly, the target region is a subsequence located between nucleobase positions 3801 and 3910, 3802 and 3910, 3803 and 3910, 3804 and 3910, 3805 and 3910, 3806 and 3910, 3807 and 3910, 3808 and 3910, 3809 and 3910, 3810 and 3910, 3811 and 3910, 3812 and 3910, 3813 and 3910, 3814 and 3910, 3815 and 3910, 3816 and 3910, 3817 and 3910, 3818 and 3910, 3819 and 3910, 3820 and 3910, 3821 and 3910, 3822 and 3910, 3823 and 3910, 3824 and 3910, 3825 and 3910, 3826 and 3910, 3827 and 3910, 3828 and 3910, 3829 and 3910, 3830 and 3910, 3831 and 3910, 3832 and 3910, 3833 and 3910, 3834 and 3910, 3835 and 3910, 3836 and 3910, 3837 and 3910, 3838 and 3910, 3839 and 3910, 3840 and 3910, 3841 and 3910, 3842 and 3910, 3843 and 3910, 3844 and 3910, 3845 and 3910, 3800 and 3898, 3800 and 3899, 3800 and 3900, 3800 and 3901, 3800 and 3902, 3800 and 3903, 3800 and 3904, 3800 and 3905, 3800 and 3906, 3800 and 3907, 3800 and 3908 or 3800 and 3909 of the Syngr-3 mRNA transcript set forth in SEQ ID No. 1. More particularly, the target region is located between nucleobase positions 3845 and 3898 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1, more particularly between nucleobase positions 3846 and 3897, 3847 and 3896, 3848 and 3895, or 3849 and 3894, even more particularly between nucleobase positions 3850 and 3893 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1. In a more particular embodiment, the target region is defined by SEQ ID No. 241. In an even more particular embodiment, the target region is defined by (or comprises of consists of) SEQ ID No.236, 237, 238, 239 and/or 240. In a most particular embodiment, the oligonucleotide (e.g., ASO, siRNA, shRNA) comprises or consists of SEQ ID No.463, 464, 465, 466 and/or 467. In another particular embodiment, the target region is a subsequence located between nucleobase positions 3900 and 4025 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1, or is comprised within the nucleotide subsequence defined by nucleobase 3900 and 4025 of the Syngr-3 mRNA transcript set forth in SEQ ID No. 1. Particularly, the target region is a subsequence located between nucleobase positions 3901 and 4025, 3902 and 4025, 3903 and 4025, 3904 and 4025, 3905 and 4025, 3906 and 4025, PaVer/SyngrASO2/799 3907 and 4025, 3908 and 4025, 3909 and 4025, 3910 and 4025, 3911 and 4025, 3912 and 4025, 3913 and 4025, 3914 and 4025, 3915 and 4025, 3900 and 4002, 3900 and 4003, 3900 and 4004, 3900 and 4005, 3900 and 4006, 3900 and 4007, 3900 and 4008, 3900 and 4009, 3900 and 4010, 3900 and 4011, 3900 and4012, 3900 and 4013, 3900 and 4014, 3900 and 4015, 3900 and 4016, 3900 and 4017, 3900 and 4018, 3900 and 4019, 3900 and 4020, 3900 and 4021, 3900 and 4022, 3900 and 4023 or 3900 and 4024 of the Syngr-3 mRNA transcript set forth in SEQ ID No. 1. More particularly, the target region is located between nucleobase positions 3915 and 4002 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1, more particularly between nucleobase positions 3916 and 4001, 3917 and 4000, 3918 and 3999, or 3919 and 3998, even more particularly between nucleobase positions 3920 and 3997 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1. In a more particular embodiment, the target region is defined by SEQ ID No. 246. In an even more particular embodiment, the target region is defined by (or comprises of consists of) SEQ ID No.242, 243, 244 and/or 245. In a most particular embodiment, the oligonucleotide (e.g., ASO, siRNA, shRNA) comprises or consists of SEQ ID No.468, 469, 470 and/or 471. In another particular embodiment, the target region is a subsequence located between nucleobase positions 4050 and 4150 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1, or is comprised within the nucleotide subsequence defined by nucleobase 4050 and 4150 of the Syngr-3 mRNA transcript set forth in SEQ ID No. 1. Particularly, the target region is a subsequence located between nucleobase positions 4051 and 4150, 4052 and 4150, 4053 and 4150, 4054 and 4150, 4055 and 4150, 4056 and 4150, 4057 and 4150, 4058 and 4150, 4059 and 4150, 4060 and 4150, 4061 and 4150, 4062 and 4150, 4063 and 4150, 4064 and 4150, 4065 and 4150, 4066 and 4150, 4067 and 4150, 4068 and 4150, 4069 and 4150, 4070 and 4150, 4071 and 4150, 4072 and 4150, 4073 and 4150, 4074 and 4150, 4075 and 4150, 4076 and 4150, 4077 and 4150, 4078 and 4150, 4079 and 4150, 4080 and 4150, 4081 and 4150, 4082 and 4150, 4083 and 4150, 4084 and 4150, 4085 and 4150, 4086 and 4150, 4087 and 4150, 4088 and 4150, 4089 and 4150, 4090 and 4150, 4091 and 4150, 4050 and 4116, 4050 and 4117, 4050 and 4118, 4050 and 4119, 4050 and 4120, 4050 and 4121, 4050 and 4122, 4050 and 4123, 4050 and 4124, 4050 and 4125, 4050 and 4126, 4050 and 4127, 4050 and 4128, 4050 and 4129, 4050 and 4130, 4050 and 4131, 4050 and 4132, 4050 and 4133, 4050 and 4134, 4050 and 4135, 4050 and 4136, 4050 and 4137, 4050 and 4138, 4050 and 4139, 4050 and 4140, 4050 and 4141, 4050 and 4142, 4050 and 4143, 4050 and 4144, 4050 and 4145, 4050 and 4146, 4050 and 4147, 4050 and 4148 or 4050 and 4149 of the Syngr- 3 mRNA transcript set forth in SEQ ID No. 1. More particularly, the target region is located between nucleobase positions 4091 and 4116 of the Syngr-3 mRNA transcript set forth in SEQ ID No. 1, more particularly between nucleobase positions 4092 and 4115, 4093 and 4114, 4094 and 4113, or 4095 and PaVer/SyngrASO2/799 4112, even more particularly between nucleobase positions 4096 and 4111 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1. In a more particular embodiment, the target region is defined by SEQ ID No. 248. In an even more particular embodiment, the target region is defined by (or comprises of consists of) SEQ ID No.247. In a most particular embodiment, the oligonucleotide (e.g., ASO, siRNA, shRNA) comprises or consists of SEQ ID No.472. In another particular embodiment, the target region is a subsequence located between nucleobase positions 4150 and 4250 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1, or is comprised within the nucleotide subsequence defined by nucleobase 4150 and 4250 of the Syngr-3 mRNA transcript set forth in SEQ ID No. 1. Particularly, the target region is a subsequence located between nucleobase positions 4151 and 4250, 4152 and 4250, 4153 and 4250, 4154 and 4250, 4155 and 4250, 4156 and 4250, 4157 and 4250, 4158 and 4250, 4159 and 4250, 4160 and 4250, 4161 and 4250, 4162 and 4250, 4163 and 4250, 4164 and 4250, 4165 and 4250, 4166 and 4250, 4167 and 4250, 4168 and 4250, 4169 and 4250, 4170 and 4250, 4171 and 4250, 4172 and 4250, 4173 and 4250, 4174 and 4250, 4175 and 4250, 4176 and 4250, 4177 and 4250, 4178 and 4250, 4179 and 4250, 4180 and 4250, 4181 and 4250, 4182 and 4250, 4183 and 4250, 4184 and 4250, 4185 and 4250, 4186 and 4250, 4187 and 4250, 4188 and 4250, 4189 and 4250, 4190 and 4250, 4191 and 4250, 4192 and 4250, 4150 and 4217, 4150 and 4218, 4150 and 4219, 4150 and 4220, 4150 and 4221, 4150 and 4222, 4150 and 4223, 4150 and 4224, 4150 and 4225, 4150 and 4226, 4150 and 4227, 4150 and 4228, 4150 and 4229, 4150 and 4230, 4150 and 4231, 4150 and 4232, 4150 and 4233, 4150 and 4234, 4150 and 4235, 4150 and 4236, 4150 and 4237, 4150 and 4238, 4150 and 4239, 4150 and 4240, 4150 and 4241, 4150 and 4242, 4150 and 4243, 4150 and 4244, 4150 and 4245, 4150 and 4246, 4150 and 4247, 4150 and 4248 or 4150 and 4249 of the Syngr- 3 mRNA transcript set forth in SEQ ID No. 1. More particularly, the target region is located between nucleobase positions 4192 and 4217 of the Syngr-3 mRNA transcript set forth in SEQ ID No. 1, more particularly between nucleobase positions 4193 and 4216, 4194 and 4215, 4195 and 4214, or 4196 and 4213, even more particularly between nucleobase positions 4197 and 4212 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1. In a more particular embodiment, the target region is defined by SEQ ID No. 250. In an even more particular embodiment, the target region is defined by (or comprises of consists of) SEQ ID No.249. In a most particular embodiment, the oligonucleotide (e.g., ASO, siRNA, shRNA) comprises or consists of SEQ ID No.473. PaVer/SyngrASO2/799 In another particular embodiment, the target region is a subsequence located between nucleobase positions 4250 and 4410 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1, or is comprised within the nucleotide subsequence defined by nucleobase 4250 and 4410 of the Syngr-3 mRNA transcript set forth in SEQ ID No. 1. Particularly, the target region is a subsequence located between nucleobase positions 4251 and 4410, 4252 and 4410, 4253 and 4410, 4254 and 4410, 4255 and 4410, 4256 and 4410, 4257 and 4410, 4258 and 4410, 4259 and 4410, 4260 and 4410, 4261 and 4410, 4262 and 4410, 4263 and 4410, 4264 and 4410, 4265 and 4410, 4266 and 4410, 4267 and 4410, 4268 and 4410, 4269 and 4410, 4270 and 4410, 4271 and 4410, 4272 and 4410, 4273 and 4410, 4274 and 4410, 4275 and 4410, 4276 and 4410, 4277 and 4410, 4278 and 4410, 4279 and 4410, 4280 and 4410, 4281 and 4410, 4282 and 4410, 4283 and 4410, 4284 and 4410, 4285 and 4410, 4286 and 4410, 4287 and 4410, 4288 and 4410, 4289 and 4410, 4250 and 4388, 4250 and 4389, 4250 and 4390, 4250 and 4391, 4250 and 4392, 4250 and 4393, 4250 and 4394, 4250 and 4395, 4250 and 4396, 4250 and 4397, 4250 and 4398, 4250 and 4399, 4250 and 4400, 4250 and 4401, 4250 and 4402, 4250 and 4403, 4250 and 4404, 4250 and 4405, 4250 and 4406, 4250 and 4407, 4250 and 4408 or 4250 and 4409 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1. More particularly, the target region is located between nucleobase positions 4289 and 4388 of the Syngr-3 mRNA transcript set forth in SEQ ID No. 1, more particularly between nucleobase positions 4290 and 4287, 4291 and 4386, 4292 and 4385, or 4293 and 4384, even more particularly between nucleobase positions 4294 and 4383 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1. In a more particular embodiment, the target region is defined by SEQ ID No. 259. In an even more particular embodiment, the target region is defined by (or comprises of consists of) SEQ ID No.251, 252, 253, 254, 255, 256, 257 and/or 258. In a most particular embodiment, the oligonucleotide (e.g., ASO, siRNA, shRNA) comprises or consists of SEQ ID No.474, 475, 476, 477, 478, 479, 480 and/or 481. In another particular embodiment, the target region is a subsequence located between nucleobase positions 4375 and 4599 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1, or is comprised within the nucleotide subsequence defined by nucleobase 4375 and 4599 of the Syngr-3 mRNA transcript set forth in SEQ ID No. 1. Particularly, the target region is a subsequence located between nucleobase positions 4376 and 4599, 4377 and 4599, 4378 and 4599, 4379 and 4599, 4380 and 4599, 4381 and 4599, 4382 and 4599, 4383 and 4599, 4384 and 4599, 4385 and 4599, 4386 and 4599, 4387 and 4599, 4388 and 4599, 4389 and 4599, 4390 and 4599, 4391 and 4599, 4392 and 4599, 4393 and 4599, 4394 and 4599, 4395 and 4599, 4396 and 4599, 4397 and 4599, 4398 and 4599, 4399 and 4599, 4400 and 4599, 4401 and 4599, 4402 and 4599, 4403 and 4599, 4404 and 4599, 4405 and 4599, 4406 and 4599, 4407 and 4599, 4408 and 4599, 4409 and 4599, 4410 and 4599, 4411 and 4599, 4375 and 4567, 4375 and PaVer/SyngrASO2/799 4568, 4375 and 4569, 4375 and 4570, 4375 and 4571, 4375 and 4572, 4375 and 4573, 4375 and 4574, 4375 and 4575, 4375 and 4576, 4375 and 4577, 4375 and 4578, 4375 and 4579, 4375 and 4580, 4375 and 4581, 4375 and 4582, 4375 and 4583, 4375 and 4584, 4375 and 4585, 4375 and 4586, 4375 and 4587, 4375 and 4588, 4375 and 4589, 4375 and 4590, 4375 and 4591, 4375 and 4592, 4375 and 4593, 4375 and 4594, 4375 and 4595, 4375 and 4596, 4375 and 4597 or 4375 and 4598 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1. More particularly, the target region is located between nucleobase positions 4411 and 4567 of the Syngr-3 mRNA transcript set forth in SEQ ID No. 1, more particularly between nucleobase positions 4412 and 4566, 4413 and 4565, 4414 and 4564, or 4415 and 4563, even more particularly between nucleobase positions 4416 and 4562 of the Syngr-3 mRNA transcript set forth in SEQ ID No.1. In a more particular embodiment, the target region is defined by SEQ ID No. 268. In an even more particular embodiment, the target region is defined by (or comprises of consists of) SEQ ID No.260, 261, 262, 263, 264, 265, 266 and/or 267. In a most particular embodiment, the oligonucleotide (e.g., ASO, siRNA, shRNA) comprises or consists of SEQ ID No.482, 483, 484, 485, 486, 487, 488 and/or 489. In a particular embodiment, the oligonucleotide of the present disclosure is complementary (full or partially complementary) to a target region of Synaptogyrin-3 selected from the group consisting of SEQ ID No. 66, 97, 126 and 138. In another particular embodiment, the oligonucleotide of the application comprises or consists of 14, 15, 16, 17, 18, 19, 20, 21, 22 or 23 nucleotides in length and comprises or consists of the sequence selected from the list consisting of SEQ ID No.321, 346, 373 and 384 or overlaps with one of said SEQ ID No.321, 346, 373, 384 for at least 12, 13, 14, 15 or 16 nucleotides. In a most particular embodiment, the oligonucleotide of the present disclosure is complementary (full or partially complementary) to a target region of Synaptogyrin-3 comprising or consisting of SEQ ID No. 66. In another most particular embodiment, the oligonucleotide of the application comprises or consists of SEQ ID No.321. In another most particular embodiment, the oligonucleotide of the present disclosure is complementary (full or partially complementary) to a target region of Synaptogyrin-3 comprising or consisting of SEQ ID No. 97. In another most particular embodiment, the oligonucleotide of the application comprises or consists of SEQ ID No.346. In another most particular embodiment, the oligonucleotide of the present disclosure is complementary (full or partially complementary) to a target region of Synaptogyrin-3 comprising or consisting of SEQ ID No. 126. In another most particular embodiment, the oligonucleotide of the application comprises or consists of SEQ ID No.373. PaVer/SyngrASO2/799 In a most particular embodiment, the oligonucleotide of the present disclosure is complementary (full or partially complementary) to a target region of Synaptogyrin-3 comprising or consisting of SEQ ID No. 138. In another most particular embodiment, the oligonucleotide of the application comprises or consists of SEQ ID No.384. In some aspects, the present disclosure provides a target region within the human Syngr-3 gene, particularly within the Synaptogyrin-3 mRNA transcript as depicted in SEQ ID No.1, that can be used for designing oligonucleotides or RNAi molecules (e.g. ASO, siRNA, shRNA) that are capable of reducing the expression level of Synaptogyrin-3 mRNA transcript in a cell, wherein the target region is any of the above described target regions. Also any of the target regions as described herein, for example a target region set forth in any of SEQ ID No.2-269, a subsequence thereof, a subsequence of synaptogyrin-3 mRNA transcript as set forth in SEQ ID No.1 comprising or overlapping with a target region set forth in any of SEQ ID No.2-269 is provided for designing antisense molecules or RNAi molecules, more particularly siRNA, di-siRNA or shRNA duplexes, that can statistically significantly reduce the expression level of the Synaptogyrin-3 mRNA transcript as depicted in SEQ ID No.1, the synaptogyrin-3 protein level, the synaptogyrin-3 activity level, or any combination thereof in a cell. Antisense Oligonucleotides (ASO): In some aspects, the oligonucleotide of the present disclosure is an ASO. Thus, in some aspects, an oligonucleotide of the present disclosure comprises an antisense oligonucleotide (ASO), e.g., an unconjugated or conjugated ASO. Antisense oligonucleotides or ASOs are small (generally, between about 16 nucleotides and about 30 nucleotides or shorter, e.g., between about 12 and about 20 nucleotides), synthetic, single-stranded nucleic acid polymers of diverse chemistries, which can be employed to modulate gene expression via various mechanisms. ASOs can be subdivided into two major categories: RNase H competent and steric block ASOs. In some aspects, the oligonucleotide of the present disclosure is RNase H competent. In some aspects, the oligonucleotide of the present disclosure is a steric block ASO. In some aspects, the oligonucleotide of the present disclosure is a gapmer. Gapmer designs are disclosed, e.g., in WO 2007/146511A2, which is herein incorporated by reference in its entirety. ASOs can also modulate gene expression by steric hindrance or occupancy and only mechanisms. Steric block oligonucleotides are designed to bind to target transcripts with high affinity but do not induce target transcript degradation as they lack RNase H competence. Such oligonucleotides therefore comprise either nucleotides that do not form RNase H substrates when paired with RNA or a mixture of PaVer/SyngrASO2/799 nucleotide chemistries such that runs of consecutive DNA-like bases are avoided. Steric block oligonucleotides can mask specific sequences within a target transcript and thereby interfere with transcript RNA-RNA and/or RNA-protein interactions. The most widely used application of steric block ASOs is in the modulation of alternative splicing in order to selectively exclude or retain a specific exon(s) in order to disrupt the translation of the target gene. ASOs can also be designed to interfere with maturation and stability of the RNA transcript or to block its interaction with the translation apparatus. In case the ASO can enter the nucleus, mRNA maturation can be modulated by inhibition of 5ʹ-cap formation, inhibition of mRNA splicing or activation of RNaseH (Chan et al 2006 Clin Exp Pharmacol Physiol 33:533-540; this reference also describes some of the software available for assisting in design of ASOs). In some aspects, the ASO comprises an antisense oligomer of 12 to 22 contiguous nucleotides in length, wherein the sequence of the antisense oligomer comprises a contiguous sequence 12 to 22 (e.g., 16) nucleotides in length which is 100% complementary to a sequence or to a subsequence of synaptogyrin- 3 target sequence selected from the group consisting of SEQ ID No.2-9, 11, 13-19, 21-24, 26-28, 32, 34- 49, 51-52, 54-57, 60-61, 63-68, 70-78, 80-83, 85-86, 88-90, 92-93, 95-109, 112-134, 136-139, 142-169, 171, 173-178, 180, 182-183, 185-187, 189-192, 195-209, 211-215, 217-219, 222-223, 225-226, 228, 230, 232-234, 236-240, 242-245, 247, 249, 251-258 and 260-267 or from the group consisting of SEQ ID No. 10, 12, 20, 25, 29-31, 33, 50, 53, 58-59, 62, 69, 79, 84, 87, 91, 94, 110-111, 135, 140-141, 170, 172, 179, 181, 184, 188, 193-194, 210, 216, 220-221, 224, 227, 229, 231, 235, 241, 246, 248, 250, 259, 268 and 269, wherein the antisense oligomer targets an RNA encoding synaptogyrin-3. In some aspects, the ASO comprises an antisense oligomer of 10 to 16 contiguous nucleotides in length, wherein the sequence of the antisense oligomer comprises a contiguous sequence of 10 to 25 nucleotides in length which is 100% complementary to a sequence or to a subsequence of synaptogyrin- 3 target sequence selected from the group consisting of SEQ ID No.2-9, 11, 13-19, 21-24, 26-28, 32, 34- 49, 51-52, 54-57, 60-61, 63-68, 70-78, 80-83, 85-86, 88-90, 92-93, 95-109, 112-134, 136-139, 142-169, 171, 173-178, 180, 182-183, 185-187, 189-192, 195-209, 211-215, 217-219, 222-223, 225-226, 228, 230, 232-234, 236-240, 242-245, 247, 249, 251-258 and 260-267, or from the group consisting of SEQ ID No. 10, 12, 20, 25, 29-31, 33, 50, 53, 58-59, 62, 69, 79, 84, 87, 91, 94, 110-111, 135, 140-141, 170, 172, 179, 181, 184, 188, 193-194, 210, 216, 220-221, 224, 227, 229, 231, 235, 241, 246, 248, 250, 259, 268 and 269, wherein the antisense oligomer targets an RNA encoding synaptogyrin-3. In some aspect, the ASO comprises an antisense oligomer of 10 to 16 contiguous nucleotides in length, wherein said antisense oligomer is at least 90%, at least 95% or 100% identical to a subsequence of any of SEQ ID No.270-489. In some aspects, the ASO is a gapmer. In some aspects, the ASO is conjugated to a targeting moiety, e.g., to a GalNAc moiety. PaVer/SyngrASO2/799 GAPMERs: In particular embodiments, the antisense oligonucleotide of the invention or the contiguous nucleotide sequence thereof is a gapmer. A gapmer or gapmer oligonucleotide comprises at least three distinct structural regions: a 5’-flank, a gap and a 3’-flank or F-G-F’ in the ‘5 -> 3’ orientation. The “gap” region (G) comprises a stretch of contiguous DNA nucleotides which enable the oligonucleotide to recruit RNase H. The gap region is flanked by a 5’ flanking region (F) comprising one or more sugar modified nucleosides, and by a 3’ flanking region (F’) comprising one or more sugar modified nucleosides. The one or more sugar modified nucleosides in region F and F’ enhance the affinity of the oligonucleotide for the target nucleic acid (i.e. are affinity enhancing sugar modified nucleosides). In some embodiments, the one or more sugar modified nucleosides in region F and F’ are 2’ sugar modified nucleosides, such as independently selected from LNA and 2’-MOE. In a gapmer design, the 5’ and 3’ most nucleosides of the gap region are DNA nucleosides, and are positioned adjacent to a sugar modified nucleoside of the 5’ (F) or 3’ (F’) region respectively. The flanks may further be defined by having at least one sugar modified nucleoside at the end most distant from the gap region, i.e. at the 5’ end of the 5’ flank and at the 3’ end of the 3’ flank. Regions F-G-F’ form a contiguous nucleotide sequence. Antisense oligonucleotides of the invention, or the contiguous nucleotide sequence thereof, may comprise a gapmer region of formula F-G-F’. Regions F and F’ independently comprise 1-8 contiguous nucleosides, of which 1-5 independently can be 2’ sugar modified and defines the 5’ and 3’ end of the F and F’ region. Region F is positioned immediately adjacent to the 5’ DNA nucleoside of region G. In one embodiment, the 3’ most nucleoside of region F is a sugar modified nucleoside, for example a 2’ substituted nucleoside, such as a MOE nucleoside, or an LNA nucleoside. Region F’ is positioned immediately adjacent to the 3’ DNA nucleoside of region G. In one embodiment, the 5’ most nucleoside of region F’ is a sugar modified nucleoside, for example a 2’ substituted nucleoside, such as a MOE nucleoside, or an LNA nucleoside. In one embodiment, region F is between 1 and 8 contiguous nucleotides in length, such as 2-6, such as 3-4 contiguous nucleotides in length. In particular embodiments, the 5’ most nucleoside of region F is a sugar modified nucleoside. In some embodiments the two 5’ most nucleoside of region F are sugar modified nucleoside. In some embodiments the 5’ most nucleoside of region F is an LNA nucleoside. In some embodiments the two 5’ most nucleoside of region F are LNA nucleosides. In some embodiments the two 5’ most nucleoside of region F are LNA nucleosides. In some embodiments the two 5’ most nucleoside of region F are 2’ substituted nucleoside nucleosides, such as two 3’ MOE nucleosides. In PaVer/SyngrASO2/799 some embodiments the 5’ most nucleoside of region F is a 2’ substituted nucleoside, such as a MOE nucleoside. In one embodiment, region F’ is between 2 and 8 contiguous nucleotides in length, such as 3-6, such as 4-5 contiguous nucleotides in length. Particularly embodiments provide that the 3’ most nucleoside of region F’ is a sugar modified nucleoside. In some embodiments the two 3’ most nucleoside of region F’ are sugar modified nucleoside. In some embodiments the two 3’ most nucleoside of region F’ are LNA nucleosides. In some embodiments the 3’ most nucleoside of region F’ is an LNA nucleoside. In some embodiments the two 3’ most nucleoside of region F’ are 2’ substituted nucleoside nucleosides, such as two 3’ MOE nucleosides. In some embodiments the 3’ most nucleoside of region F’ is a 2’ substituted nucleoside, such as a MOE nucleoside. It should be noted that when the length of region F or F’ is one, it is preferably an LNA nucleoside. In some embodiments, region F and F’ independently consists of or comprises a contiguous sequence of sugar modified nucleosides. In some embodiments, the sugar modified nucleosides of region F may be independently selected from 2’-O-alkyl-RNA units, 2’-O-methyl- RNA, 2’-amino-DNA units, 2’-fluoro-DNA units, 2’-alkoxy-RNA, MOE units, LNA units, arabino nucleic acid (ANA) units and 2’-fluoro-ANA units. In some embodiments, region F and F’ independently comprises both LNA and a 2’ substituted modified nucleosides. In some embodiments, region F and F’ consists of only one type of sugar modified nucleosides, such as only MOE or only beta-D-oxy LNA or only ScET. Such designs are also termed uniform flanks or uniform gapmer design. In some embodiments, all the nucleosides of region F or F’, or F and F’ are LNA nucleosides, such as independently selected from beta-D-oxy LNA, ENA or ScET nucleosides. In some embodiments region F consists of 1-5, such as 2-4, such as 3-4 such as 1, 2, 3, 4 or 5 contiguous LNA nucleosides. In some embodiments, all the nucleosides of region F and F’ are LNA nucleosides or beta-D-oxy LNA nucleosides. In some embodiments, all the nucleosides of region F or F’, or F and F’ are 2’ substituted nucleosides, such as OMe or MOE nucleosides. In some embodiments region F consists of 1, 2, 3, 4, 5, 6, 7, or 8 contiguous OMe or MOE nucleosides. In some embodiments only one of the flanking regions can consist of 2’ substituted nucleosides, such as OMe or MOE nucleosides. In some embodiments it is the 5’ (F) flanking region that consists 2’ substituted nucleosides, such as OMe or MOE nucleosides whereas the 3’ (F’) flanking region comprises at least one LNA nucleoside, such as beta-D-oxy LNA nucleosides or cET nucleosides. In some embodiments it is the 3’ (F’) flanking region that consists 2’ substituted nucleosides, such as OMe or MOE nucleosides whereas the 5’ (F) flanking region comprises at least one LNA nucleoside, such as beta-D-oxy LNA nucleosides or cET nucleosides. PaVer/SyngrASO2/799 In some embodiments the 5’ most and the 3’ most nucleosides of region F and F’ are LNA nucleosides, such as beta-D-oxy LNA nucleosides or ScET nucleosides. Region G comprises or consists of between 5 and 18 nucleosides which are capable of recruiting RNase H. Suitably gapmers may have a gap region of at least 5 or 6 contiguous DNA nucleosides, such as 5-16 contiguous DNA nucleosides, such as 6-15 contiguous DNA nucleosides, such as 7-14 contiguous DNA nucleosides, such as 8-12 contiguous DNA nucleotides, such as 8-12 contiguous DNA nucleotides in length. The gap region G may, in some embodiments consist of 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16 contiguous DNA nucleosides. One or more cytosine (C) DNA in the gap region may in some instances be methylated (e.g. when a DNA c is followed by a DNA g) such residues are either annotated as 5-methyl- cytosine (meC). In some embodiments the gap region G may consist of 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16 contiguous phosphorothioate linked DNA nucleosides. In some embodiments, all internucleoside linkages in the gap are phosphorothioate linkages The overall length of the gapmer design F-G-F’ may be, for example 12 to 32 nucleosides, such as 13 to 24, such as 14 to 22 nucleosides, such as from 14 to 17, such as 16 to18 nucleosides. In some embodiments, the internucleoside linkage between region F and region G is a phosphorothioate internucleoside linkage. In some embodiments, the internucleoside linkage between region F’ and region G is a phosphorothioate internucleoside linkage. In some embodiments, the internucleoside linkages between the nucleosides of region F or F’, F and F’ are phosphorothioate internucleoside linkages. In some embodiments, the gapmer of the invention is a LNA Gapmer. An LNA gapmer is a gapmer wherein either one or both of region F and F’ comprises or consists of LNA nucleosides. A beta-D-oxy gapmer is a gapmer wherein either one or both of region F and F’ comprises or consists of beta-D-oxy LNA nucleosides. In other embodiments, the gapmer of the invention is a MOE Gapmer. A MOE gapmers is a gapmer wherein regions F and F’ consist of MOE nucleosides. In some embodiments the MOE gapmer is of design [MOE]1-8-[Region G]-[MOE] 1-8, such as [MOE]2-7- [Region G]5-16-[MOE] 2-7, such as [MOE]3-6- [Region G]-[MOE] 3-6, wherein region G is as defined in the Gapmer definition. MOE gapmers with a 5- 10-5 design (MOE-DNA-MOE) have been widely used in the art. In particular embodiments, the gapmer of the invention can also comprise a region D’ and/or D’’. Said regions refer to additional 5’ and/or 3’ nucleosides which may or may not be fully complementary to the target nucleic acid. The addition of region D’ or D” be used for the purpose of joining the contiguous PaVer/SyngrASO2/799 nucleotide sequence, such as the gapmer, to a conjugate moiety or another functional group. When used for joining the contiguous nucleotide sequence with a conjugate moiety is can serve as a biocleavable linker. Alternatively, it may be used to provide exonuclease protection or for ease of synthesis or manufacture. Region D’ and D” can be attached to the 5’ end of region F or the 3’ end of region F’, respectively to generate designs of the following formulas D’-F-G-F’, F-G-F’-D” or D’-F-G-F’-D”. In this instance the F-G-F’ is the gapmer portion of the oligonucleotide and region D’ or D” constitute a separate part of the oligonucleotide. Region D’ or D” may independently comprise or consist of 1, 2, 3, 4 or 5 additional nucleotides, which may be complementary or non-complementary to the target nucleic acid. The nucleotide adjacent to the F or F’ region is not a sugar-modified nucleotide, such as a DNA or RNA or base modified versions of these. The D’ or D’ region may serve as a nuclease susceptible biocleavable linker (see definition of linkers). In some embodiments the additional 5’ and/or 3’ end nucleotides are linked with phosphodiester linkages, and are DNA or RNA. RNAi using duplex silencers: In some aspects, the oligonucleotide of the present disclosure is an RNAi molecule, particularly an RNAi duplex or a double stranded RNAi oligonucleotide, more particularly the antisense portion or the antisense strand of an RNAi duplex (double stranded RNA). In some aspects, the oligonucleotide of the present disclosure comprises an RNAi molecule, more particularly a siRNA, e.g., an unconjugated or conjugated siRNA. RNA interference (RNAi) is a mechanism by which double- stranded RNA triggers the loss of a homologous RNA molecule. Short interfering RNA (siRNA) molecules are the effector molecules of RNAi and classically consist of an RNA duplex (or alternatively phrased a duplex of RNA molecules) with a length of 21 nucleotides, i.e.19 complementary bases and 2 terminal 3ʹ overhangs. One of the strands of the siRNA (the guide or antisense strand) is complementary to a target transcript, whereas the other strand is designated the passenger or sense strand. siRNAs act to guide the Argonaute2 protein (AGO2), as part of the RNA-induced silencing complex (RISC), to complementary target transcripts. Complete complementarity between the siRNA and the target transcript results in cleavage of the target opposite position of the guide strand, catalysed by AGO2, leading to gene silencing. In a siRNA, the sense strand meets the formal definition of a drug delivery device: it is non-covalently bound, enhances the stability of the antisense strand and must be removed by the Ago2 loading complex before the pharmacophore, the antisense strand, is active. Numerous variations of the archetypal siRNA design have been developed in terms of reduced passenger strand activity and/or improved potency. These include Dicer substrate siRNAs, small internally PaVer/SyngrASO2/799 segmented siRNAs, self-delivering siRNAs (asymmetric and hydrophobic), single-stranded siRNAs and divalent siRNAs. In some aspects, the oligonucleotide of the present disclosure is the antisense portion of a shRNA. Short hairpin RNAs (shRNAs) are artificial RNA molecules that are transcribed as a single stranded RNA but because of internal complementarity form a loop or hairpin-like structure. The hairpin is subsequently processed to an siRNA and also leads to the degradation of mRNAs in a sequence-specific manner dependent upon complementary binding of the target mRNA. shRNAs are slightly larger than siRNA molecules and, unlike siRNAs, are produced inside the cell in the nucleus. Other non-limiting examples of RNAi-mediated duplex silencers are miRNAs and di-siRNAs. microRNAs (miRNAs) are endogenous non-coding RNA molecules that trigger RNAi and that have been implicated in a multitude of physiological and pathophysiological processes. miRNA hairpins embedded within long primary miRNA transcripts are sequentially processed by two RNase III family enzymes, DICER1 (Dicer) and DROSHA, which liberate the hairpin and then cleave the loop sequence, respectively. The resulting duplex RNA is analogous to an siRNA and is then loaded into an Argonaute protein (for example, AGO2) while one strand is discarded to generate the mature, single-stranded miRNA species. As with siRNAs, miRNAs guide RISC to target sequences where they initiate gene silencing. In contrast with siRNAs, miRNAs typically bind with partial complementarity and induce silencing via slicer-independent mechanisms. In some aspects, the oligonucleotide of the present disclosure is a di-siRNA. Divalent siRNAs (di-siRNAs) are recently developed RNA silencing agent alternatives and have been shown to support a potent, sustained gene silencing in the central nervous system of mice and non-human primates following a single injection into the cerebrospinal fluid (Alterman et al 2019 Nature Biotech 37, 884-894). Di-siRNAs are composed of two fully chemically modified, phosphorothioate-containing siRNAs connected by a linker. In some aspects, the siRNA of the present disclosure comprises an antisense strand 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 contiguous nucleotides in length, wherein the sequence of the antisense strand comprises a contiguous sequence of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 nucleotides in length which is 100% complementary to a sequence or to a subsequence of synaptogyrin-3 target sequence selected from the group consisting of SEQ ID No.2-9, 11, 13-19, 21-24, 26-28, 32, 34-49, 51-52, 54-57, 60-61, 63-68, 70-78, 80-83, 85-86, 88-90, 92-93, 95-109, 112-134, 136-139, 142-169, 171, 173-178, 180, 182-183, 185-187, 189-192, 195- 209, 211-215, 217-219, 222-223, 225-226, 228, 230, 232-234, 236-240, 242-245, 247, 249, 251-258 and 260-267 or from the group consisting of SEQ ID No.10, 12, 20, 25, 29-31, 33, 50, 53, 58-59, 62, 69, 79, 84, 87, 91, 94, 110-111, 135, 140-141, 170, 172, 179, 181, 184, 188, 193-194, 210, 216, 220-221, 224, PaVer/SyngrASO2/799 227, 229, 231, 235, 241, 246, 248, 250, 259, 268 and 269, wherein the siRNA targets an RNA encoding synaptogyrin-3. In some aspects, the siRNA of the present disclosure is conjugated to a targeting moiety, e.g., to a GalNAc moiety. CRISPR gRNA: Another recent genome editing technology is the CRISPR/Cas system, which can be used to achieve RNA-guided genome engineering. CRISPR interference is a genetic technique which allows for sequence-specific control of gene expression in prokaryotic and eukaryotic cells. It is based on the bacterial immune system-derived CRISPR (clustered regularly interspaced palindromic repeats) pathway. Recently, it was demonstrated that the CRISPR-Cas editing system can also be used to target RNA. It has been shown that the Class 2 type VI-A CRISPR-Cas effector C2c2 can be programmed to cleave single- stranded RNA targets carrying complementary protospacers (Abudayyeh et al 2016 Science 353/science.aaf5573). C2c2 is a single-effector endoRNase mediating ssRNA cleavage once it has been guided by a single crRNA guide toward the target RNA. Hence, the invention disclosed herein can also be applied to develop gRNAs specifically reducing the expression of Synaptogyrin-3 using the CRISPR/Cas system. Therefore, the application also provides that any of the oligonucleotides herein provided can be used as a gRNA or CRISPR gRNA, more particularly a gRNA or CRISPR gRNA is provided with at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or about 100% complementary to an equal length of a target region of Synaptogyrin-3 as depicted in SEQ ID No.1, wherein the target region is selected from any of target regions of the application or subsequences thereof. In some aspects, a gRNA or CRISPR gRNA provided herein has at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% complementary to an equal length of a target region of synaptogyrin-3 as depicted in SEQ ID No. 1, wherein the target region is located between nucleobase position 449 and 531, 549 and 653, 640 and 733, 720 and 875, 915 and 1108, 1197 and 1271, 1258 and 1344, 1332 and 1450, 1450 and 1527, 1515 and1600, 1580 and 1700, 1680 and 1837, 1824 and 1885, 1850 and 2100, 2100 and 2250, 2308 and 2428, 2416 and 2441, 2428 and 2625, 2649 and 2796, 2962 and 3086, 3153 and 3460, 3450 and 3530, 3508 and 3551, 3538 and 3636 or 3626 and 4599 of SEQ ID No.1 and wherein the endpoints are included or a subsequence thereof. In some aspects, a gRNA or CRISPR gRNA provided herein has at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% complementary to an equal length of a target region of synaptogyrin-3 as depicted in SEQ ID No. 1, wherein the target region is selected from any of SEQ ID No.10, 12, 20, 25, 29-31, 33, 50, 53, 58-59, 62, 69, 79, 84, 87, 91, 94, 110-111, 135, 140-141, 170, 172, 179, 181, 184, 188, 193-194, 210, 216, 220-221, 224, 227, 229, 231, 235, 241, 246, 248, 250, 259, 268 or 269,more particularly the target region is PaVer/SyngrASO2/799 selected from any of SEQ ID No.2-9, 11, 13-19, 21-24, 26-28, 32, 34-49, 51-52, 54-57, 60-61, 63-68, 70- 78, 80-83, 85-86, 88-90, 92-93, 95-109, 112-134, 136-139, 142-169, 171, 173-178, 180, 182-183, 185- 187, 189-192, 195-209, 211-215, 217-219, 222-223, 225-226, 228, 230, 232-234, 236-240, 242-245, 247, 249, 251-258 or 260-267. In some aspects, the gRNA comprises or consists of a sequence selected from the group consisting of SEQ ID No.2-9, 11, 13-19, 21-24, 26-28, 32, 34-49, 51-52, 54-57, 60-61, 63-68, 70-78, 80-83, 85-86, 88- 90, 92-93, 95-109, 112-134, 136-139, 142-169, 171, 173-178, 180, 182-183, 185-187, 189-192, 195-209, 211-215, 217-219, 222-223, 225-226, 228, 230, 232-234, 236-240, 242-245, 247, 249, 251-258 or 260- 267. In some aspects, the gRNA comprises or consists of a sequence comprising a subsequence selected from the target regions set forth in SEQ ID No.10, 12, 20, 25, 29-31, 33, 50, 53, 58-59, 62, 69, 79, 84, 87, 91, 94, 110-111, 135, 140-141, 170, 172, 179, 181, 184, 188, 193-194, 210, 216, 220-221, 224, 227, 229, 231, 235, 241, 246, 248, 250, 259, 268 or 269. In a particular embodiment, said gRNA is 10 to 50 or 10 to 40 or 10 to 30 nucleotides in length. For example, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 nucleotides in length. In another particular embodiment, the gRNA comprises a contiguous nucleotide sequence of at least 10 contiguous nucleotides in length comprising a sequence selected from the group consisting of SEQ ID No.270-489. In yet another particular embodiment, the gRNA of the present disclosure comprises a sequence that overlaps with a 9, 10, 11, 12, 13, 14, 15, or 16 nucleobase subsequence from a sequence selected from the group consisting of SEQ ID No.270-489. Chemical modifications In some aspects, the oligonucleotides of the present disclosure comprise non-naturally occurring nucleotide analogues, e.g., nucleotides which have modified sugar moieties, such as bicyclic nucleotides or 2' modified nucleotides, such as 2' substituted nucleotides. An essential step in the evolution of the antisense technology was the creation, innovation and evaluation of the medicinal chemistry of oligonucleotides. The goals were to enhance the affinity for the target sequence (thereby increasing potency), assure effective distribution to peripheral tissues, enhance the duration of action by increasing resistance to degradation by nucleases, improve pharmacokinetic characteristics, reduce the class generic (chemically based) toxicities of the chemical classes widely used for therapeutics, and create designs that support multiple post-binding mechanisms, thereby broadening the utility of the technology. PaVer/SyngrASO2/799 Within the antisense field a broad effort was initiated to modify essentially every position in a dinucleotide except those required for Watson-Crick base pairing. Thousands of analogues have been synthesized and evaluated so far, and novel analogues continue to be investigated. Three major classes of modifications can be distinguished: modifications of the internucleotide linkage, alterations of the ribose sugar and bioconjugations with for example GalNAc. Phosphorothioates In some aspects, the oligonucleotides of the present disclosure comprise one or more non-cleavable internucleotide linkages, e.g., phosphorothioate linkages. The phosphodiester backbone of unmodified DNA and RNA oligonucleotides is highly susceptible to degradation by nucleases in vivo. So, to develop oligonucleotides for therapeutic applications, it was necessary to identify backbone modifications that reduce their susceptibility to nuclease degradation while not compromising other key characteristics such as RNase H1 activation and RNA binding too much. In phosphorothioate (PS) linkages, a non-bridging oxygen in the phosphate group is substituted by sulfur. The PS moiety provides significant protection against nucleases. Importantly, because of the impact of the greater size of sulfur compared with oxygen, the negative charge of the PS moiety at physiological pH is more widely distributed than in a phosphodiester (PO) moiety. This increases the lipophilicity of oligonucleotides that contain PS moieties, facilitating binding to proteins and thereby preventing rapid excretion of the oligonucleotides by the kidney and facilitating uptake of oligonucleotides into cells and tissues. The PS moiety is the most widely used backbone modification in ASOs and RNAi molecules such as siRNAs. Ribose sugar modifications In some aspects, the oligonucleotides of the present disclosure comprise non-naturally occurring nucleotide analogues, e.g., nucleotides which have modified sugar moieties, such as bicyclic nucleotides or 2' modified nucleotides, such as 2' substituted nucleotides. Oligonucleotides are frequently modified at the ribose sugar, primarily with the aim of improving properties such as affinity and/or nuclease resistance. Such modifications include those where the ribose ring structure is modified (e.g. locked nucleic acids or LNAs), where the sugar moiety is replaced by a non-sugar moiety (e.g. peptide nucleic acids or PNAs) or where the substituent groups on the ribose ring are altered to groups other than the hydrogen or 2’ and OH group naturally found in DNA and RNA nucleosides. Non-limiting examples of ring structure modifications are HNAs (hexitol nucleic acids) where the ribose ring is replaced with a hexose ring, an UNA (unlocked nucleic acid) where an unlinked ribose ring lacks a bond between the C2 and C3 carbons or a Locked Nucleic Acid (LNA) where the C2’ and C4’ of the ribose PaVer/SyngrASO2/799 sugar ring are linked by a methylene bridge (also referred to as a“2’-4’ bridge”), which restricts or locks the conformation of the ribose ring. The locking of the conformation of the ribose (also referred to as Bridged Nucleic Acids or BNAs) is associated with an enhanced affinity of hybridization (duplex stabilization) when the LNA is incorporated into an oligonucleotide for a complementary RNA or DNA molecule. Non-limiting examples of LNA nucleosides are beta-D-oxy-LNA, 6’-methyl-beta-D-oxy LNA such as (S)-6’-methyl-beta-D-oxy-LNA (ScET) and 2ʹ-O,4ʹ-C-ethylene-bridged nucleic acid (ENA) or those disclosed in WO 1999/014226, WO 2000/66604, WO 1998/039352, WO 2004/046160, WO 2000/047599, WO 2007/134181 , WO 2010/077578, WO 2010/036698, WO 2007/090071 , WO 2009/006478, WO 2011/156202, WO 2008/154401 , WO 2009/067647, and WO 2008/150729, all of which are herein incorporated by reference in their entireties. Since BNA modifications enhance both nuclease stability and the affinity of the oligonucleotide for target RNA, they have been incorporated into the flanking regions of gapmers to improve target binding. As such, cEt-flanking 3-10-3 gapmers are more efficacious than the MOE 5-10-5 equivalents. Importantly, BNAs are excluded from the DNA gap region because they are not compatible with RNase H-mediated cleavage. LNA modifications have also been utilized in steric block ASOs, such as miRNA inhibitors. Non-limiting examples of 2’ substituted modified nucleosides are 2’-O-alkyl-RNA, 2’-O-methyl-RNA (2’- OMe), 2’-alkoxy-RNA, 2’-O-methoxyethyl-RNA (MOE), 2’-amino-DNA, 2’-Fluoro-RNA (2’-F), and 2’-F-ANA nucleoside. These modifications increase oligonucleotide nuclease resistance by replacing the nucleophilic 2ʹ-hydroxyl group of unmodified RNA, leading to improved stability in plasma, increased tissue half-lives and consequently prolonged drug effects. These modifications also enhance the binding affinity of the oligonucleotide for complementary RNA and some 2ʹ modifica^ons reduce pro- inflammatory effects. The 2ʹ-ribose modifications are not compatible with RNase H activity, meaning they are typically used for steric block oligonucleotides, or for the flanking sequences in gapmer ASOs. Although most effort was done in modifying the 2’ position, substituents can be introduced at the 3’, 4’ or 5’ positions as well. The present disclosure provides oligonucleotides comprising or consisting of a simple sequence of natural occurring nucleotides – preferably 2'-deoxynucleotides (referred here generally as “DNA”), but also possibly ribonucleotides (referred here generally as “RNA”), or a combination of such naturally occurring nucleotides and one or more non-naturally occurring nucleotides, i.e., “nucleotide analogues”, such as nucleotides having the ribose sugar modifications disclosed above. In some aspects, the oligonucleotide of the present disclosure (e.g., an ASO, a siRNA, or a shRNA) comprises at least two nucleotide analogues. In some aspects, the oligonucleotide of the present disclosure comprises from 3, 4, 5, 6, 7, or 8 nucleotide analogues, e.g. 6 or 7 nucleotide analogues. In some aspects, all the nucleotide analogues are the same. In some aspects, some nucleotide analogs are PaVer/SyngrASO2/799 different. In some aspects, all the nucleotides in the oligonucleotide of the present disclosure are nucleotide analogues, i.e., the oligonucleotide of the present disclosure (e.g., an ASO, siRNA, or shRNA) is fully modified. In some aspects, when all the nucleotides in the oligonucleotide of the present disclosure are nucleotide analogues, all the nucleotide analogues are the same. In some aspects, when all the nucleotides in the oligonucleotide of the present disclosure are nucleotide analogues, some of the nucleotide analogues are different. In some aspects, all nucleotides in an oligonucleotide of the present disclosure (e.g., an ASO, siRNA, or shRNA) are 2’ modified. In some aspects, all nucleotides in an oligonucleotide of the present disclosure (e.g., an ASO, siRNA, or shRNA) are 2’-Fluoride and 2’-O-Methyl nucleotides. In some aspects, all nucleotides in an oligonucleotide of the present disclosure (e.g., an ASO, siRNA, or shRNA) are 2’-Fluoride and 2’-O-methyl nucleotides in an alternating pattern. In some aspects, all nucleotides in a duplex of the present disclosure (e.g., siRNA, or shRNA) are 2’-Fluoride and 2’-O- Methyl nucleotides in an alternating pattern, wherein all or substantially all of the 2’-Fluoride modified nucleotides in the sense strand are complementary to all or substantially all of the 2’-O-methyl modified nucleotides in the antisense strand. In some aspects, a duplex oligonucleotide of the present disclosure (e.g., siRNA, or shRNA) comprises a nucleotide overhang. In some aspects, the nucleotide overhang is a dinucleotide overhang. In some aspects, the dinucleotide overhang is in the antisense strand. In some aspects, the dinucleotide overhang is at the 3’ end of the antisense strand. In some aspects, the overhang sequence follows the modification pattern (e.g., alternating pattern) of the rest of the strand. In some aspects, the overhang is complementary to the synaptogyrin-3 mRNA target sequence. In some aspects, the oligonucleotide of the present disclosure has a structure as shown in Figure 1 or comprises a modification motif set forth in Figure 2A or 2B. In some aspects, a nucleic acid or oligonucleotide of the present disclosure (e.g., an ASO, siRNA, or shRNA) comprises a modification motif (e.g., the pattern of distribution of nucleotide analogs along the sense and antisense sequences, internucleoside linkages, conjugate moieties, etc.) disclosed in U.S. Pat. Nos. 8,110,674; 8,420,799; 8,809,516; 9,222,091; 9,708,615; 10,273,477; 9,290,760; 10,233,448; or 9,796,974; U.S. Appl. Publ. No.2018 and 0258427A1; or Int’l Publ. WO2018098328A1, all of which are herein incorporated by reference in their entireties. In some aspects, a nucleic acid or oligonucleotide of the present disclosure (e.g., an ASO, siRNA, or shRNA) comprises at least one chiral internucleoside linkage. In some aspects, all internucleoside linkages are chiral internucleoside linkages. In some aspects, a nucleic acid or oligonucleotide of the present disclosure (e.g., an ASO, siRNA, or shRNA) comprises at least one 8-oxo-deoxyadenosine. In some aspects, a nucleic acid or oligonucleotide of the present disclosure (e.g., an ASO, siRNA, or shRNA) comprises at least one phosphoryl DMI amidate diester internucleoside linkage (PN). In some aspects, a nucleic acid or oligonucleotide of the present disclosure (e.g., an ASO, siRNA, or shRNA) comprises at PaVer/SyngrASO2/799 least one 8-oxo-deoxyadenosine. In some aspects, a nucleic acid or oligonucleotide of the present disclosure (e.g., an ASO, siRNA, or shRNA) comprises at least one phosphoramidite internucleoside linkage. In some aspects, a nucleic acid or oligonucleotide of the present disclosure (e.g., an ASO, siRNA, or shRNA) comprises at least one phosphoramidate internucleoside linkage. In some aspects, a nucleic acid or oligonucleotide of the present disclosure (e.g., an ASO, siRNA, or shRNA) comprises at least one pseudouridine. In some aspects, a nucleic acid or oligonucleotide of the present disclosure (e.g., an ASO, siRNA, or shRNA) comprises at least one isouridine. See, e.g., WO2022/099159 and WO2021/071858, which are herein incorporated by reference in their entireties. In some aspects, a nucleic acid or oligonucleotide of the present disclosure (e.g., an ASO, siRNA, or shRNA) comprises at least one glycol nucleic acid (GNA). In some aspects, a nucleic acid or oligonucleotide of the present disclosure (e.g., an ASO, siRNA, or shRNA) comprises a loop. In some aspects, a nucleic acid or oligonucleotide of the present disclosure (e.g., an ASO, siRNA, or shRNA) comprises a cleavable loop. Conjugation In some aspects, the oligonucleotide of the present disclosure is a conjugate, e.g., a GalNAc conjugate. The delivery potential of ASOs and RNAi molecules such as siRNAs can be enhanced through direct covalent conjugation of various moieties that promote intracellular uptake, target the drug to specific cells/tissues or reduce clearance from the circulation. Non-limiting examples are lipids, peptides, aptamers, antibodies and sugars. Bioconjugates constitute distinct, homogeneous, single-component molecular entities with precise stoichiometry, meaning that high-scale synthesis is relatively simple and their pharmacokinetic properties are well defined. Furthermore, bioconjugates are typically of small size meaning that they generally exhibit favourable biodistribution profiles. For example, conjugating ASOs or siRNAs to the sugar moiety GalNAc results in more productive delivery to hepatocytes without a meaningful shift in distribution to other tissues and results in 15-30 fold increases in potency for RNA targets in those cells. ASOs and RNAi molecules such as siRNAs can also be loaded to exosomes. Exosomes are heterogeneous, lipid bilayer-encapsulated vesicles approximately 100 nm in diameter that are generated as a result of the inward budding of the multivesicular bodies. Exosomes are thought to be released into the extracellular space by all cells, where they facilitate intercellular communication via the transfer of their complex macromolecular cargoes. Exosomes present numerous favourable properties in terms of oligonucleotide drug delivery of which crossing biological membranes, such as the blood-brain-barrier (BBB) is highly relevant for treatments of CNS disorders. Methods of the application PaVer/SyngrASO2/799 In one embodiment, the oligonucleotide(s) of the invention such as the RNAi molecule(s) of the invention is man-made and/or is chemically synthesized and/or is typically purified or isolated. Accordingly, the present disclosure provides a method of manufacturing the nucleic acid molecule(s) or the oligonucleotide(s) of the invention comprising chemically synthesizing the nucleic acid molecule(s) or the oligonucleotide(s) of the invention. In some aspects, the method comprises the conjugation of a delivery moiety, e.g., a GalNAc moiety. The present disclosure also provides a method for designing or manufacturing an oligonucleotide of the present disclosure (e.g., an ASO or a siRNA) capable of inhibiting a human synaptogyrin-3 (hSYNGR3) gene transcript and/or hSYNGR3 protein expression and/or activity in a cell, a tissue, or a subject, wherein the oligonucleotide of the present disclosure is complementary (partially or fully complementary) to any of the target regions of the application as described above. In some aspects, the complementary sequence of the oligonucleotide of the present disclosure comprises or consists of a subsequence of a nucleotide sequence set for in SEQ ID No.10, 12, 20, 25, 29-31, 33, 50, 53, 58-59, 62, 69, 79, 84, 87, 91, 94, 110-111, 135, 140-141, 170, 172, 179, 181, 184, 188, 193-194, 210, 216, 220-221, 224, 227, 229, 231, 235, 241, 246, 248, 250, 259, 268 or 269. In some aspects, the complementary sequence of the oligonucleotide of the present disclosure partially overlaps of a nucleotide sequence set for in SEQ ID No.270-489. In some aspects, the complementarity is at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% complementary. As used herein the term “manufacturing” refers to chemically synthesizing, e.g., using solid phase synthesis, an oligonucleotide of the present disclosure. In some aspects, manufacturing further comprises chemically attaching or conjugating a moiety such a delivery moiety (e.g., a GalNAc moiety), and/or a targeting moiety. The present disclosure also provides a method of manufacturing an oligonucleotide of the present disclosure, the method comprising chemically synthesizing the oligonucleotide of the present disclosure using sequential solid phase oligonucleotide synthesis. The present disclosure provides a method of manufacturing an oligonucleotide of the present disclosure comprising a conjugate moiety, wherein the method comprises covalently attaching the conjugate moiety (e.g., at least one non-nucleotide or non- polynucleotide moiety) covalently to the oligonucleotide disclosed herein. In some aspects, the conjugate moiety (e.g., a non-nucleotide or non-polynucleotide moiety, for example a carbohydrate PaVer/SyngrASO2/799 conjugate moiety such as a GalNAc moiety) is attached to an oligonucleotide disclosed herein directly or via a linker positioned between the oligonucleotide sequence and the conjugate moiety. In some aspects, the non-nucleotide or non-polynucleotide moiety is a liver targeting moiety that is attached to the 5’-end or to the 3’-end of an oligonucleotide disclosed herein. In some aspects, the liver targeting moiety is linked to the oligonucleotide via a linker. In some aspects, the liver targeting moiety comprises a carbohydrate conjugate moiety comprising a carbohydrate selected from the group consisting of galactose, lactose, N-acetylgalactosamine (GalNAc), mannose, mannose-6-phosphate, and combinations thereof. In some aspects, the carbohydrate conjugate moiety is not a linear carbohydrate polymer. In some aspects, the carbohydrate conjugate moiety is a carbohydrate group comprising 1, 2, 3, or 4 carbohydrate moieties. In some aspects, all the carbohydrate moieties are identical. In some aspects, at least one carbohydrate moiety is different (non-identical) with respect to the other carbohydrate moieties. In some aspects, the carbohydrate conjugate moiety comprises at least one asialoglycoprotein receptor targeting conjugate moiety. In some aspects, the asialoglycoprotein receptor targeting conjugate moiety comprises a monovalent, divalent, trivalent, or tetravalent GalNAc cluster. In some aspects, each GalNAc in the GalNAc cluster is attached to a branch point group via a spacer. In some aspects, the branch point group comprises di-lysine. In some aspects, the spacer comprises a PEG spacer. In some aspects, the linker comprises a C6 to C12 amino alkyl group or a biocleavable phosphate nucleotide linker comprising between 1 to 6 nucleotides. In some aspects, covalently attaching the conjugate moiety (e.g., a non-nucleotide or non-polynucleotide moiety, such as a GalNAc moiety) to the oligonucleotide comprises: (i) chemically synthesizing the oligonucleotide; and, (ii) adding by chemical synthesis or conjugation the conjugate moiety to the oligonucleotide to yield an oligonucleotide conjugate. In some aspects, adding by chemical synthesis or conjugation the conjugate moiety (e.g., a non-nucleotide or non-polynucleotide moiety, such as a GalNAc moiety) to the oligonucleotide to yield an oligonucleotide conjugate comprises: (i) incorporating by chemical synthesis or conjugation at least one conjugate moiety (e.g., a non-nucleotide or non- polynucleotide moiety, such as a GalNAc moiety) to the oligonucleotide; (ii) incorporating by chemical synthesis or conjugation at least one linker to the oligonucleotide or conjugate moiety (e.g., a non- nucleotide or non-polynucleotide moiety, such as a GalNAc moiety); (iii) incorporating by chemical synthesis or conjugation at least one branching point to the oligonucleotide or conjugate moiety (e.g., a non-nucleotide or non-polynucleotide moiety, such as a GalNAc moiety); (iv) incorporating by chemical synthesis or conjugation at least one spacer to the oligonucleotide or conjugate moiety (e.g., a non- nucleotide or non-polynucleotide moiety, such as a GalNAc moiety); or, (v) a combination thereof. In some aspects, (i) at least one linker is interposed between the oligonucleotide and a branching point; (ii) PaVer/SyngrASO2/799 at least one branching point is interposed between a linker and a conjugate moiety (e.g., a non- nucleotide or non-polynucleotide moiety, such as a GalNAc moiety); (iii) at least one, two, or three conjugate moieties (e.g., a non-nucleotide or non-polynucleotide moiety, such as a GalNAc moiety) are attached to a branching point; (iv) at least one polymer spacer (e.g., a PEG spacer) is interposed between a conjugate moiety (e.g., a non-nucleotide or non-polynucleotide moiety, such as a GalNAc moiety) and a branching point; or, (v) any combination thereof. Pharmaceutical salt The nucleic acid molecules or oligonucleotides according to the present invention may exist in the form of their pharmaceutically acceptable salts. The term “pharmaceutically acceptable salt” refers to conventional acid-addition salts or base-addition salts that retain the biological effectiveness and properties of the nucleic acid molecules or oligonucleotides of the present invention and are formed from suitable non-toxic organic or inorganic acids or organic or inorganic bases. Acid-addition salts include for example those derived from inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, sulfamic acid, phosphoric acid and nitric acid, and those derived from organic acids such as p-toluene sulfonic acid, salicylic acid, methane sulfonic acid, oxalic acid, succinic acid, citric acid, malic acid, lactic acid, fumaric acid, and the like. Base-addition salts include those derived from ammonium, potassium, sodium and, quaternary ammonium hydroxides, such as for example, tetramethyl ammonium hydroxide. The chemical modification of a pharmaceutical compound into a salt is a technique well known to pharmaceutical chemists in order to obtain improved physical and chemical stability, hygroscopicity, flowability and solubility of compounds. It is for example described by Bastin (2000 Organic Process Research & Development 4:427-435) or in Ansel (1995 In: Pharmaceutical Dosage Forms and Drug Delivery Systems, 6th ed., pp.196 and 1456-1457). For example, the pharmaceutically acceptable salt of the nucleic acid molecules or oligonucleotides provided herein may be a sodium salt. Provided herein is a pharmaceutically acceptable salt of the nucleic acid molecules or oligonucleotides described herein. In one embodiment, the pharmaceutically acceptable salt is a sodium or a potassium salt. Pharmaceutical Composition In another aspect, the invention provides pharmaceutical compositions comprising any of the nucleic acid molecules or oligonucleotides described herein or salts thereof and a pharmaceutically acceptable diluent, carrier, salt and/or adjuvant. A pharmaceutically acceptable diluent includes phosphate- buffered saline (PBS) and pharmaceutically acceptable salts include, but are not limited to sodium and potassium salts. In some embodiments the acceptable diluent is sterile phosphate PaVer/SyngrASO2/799 buffered saline. In some embodiments the nucleic acid molecules or oligonucleotides of the application are used in the pharmaceutically acceptable diluent at a concentration of 50-300 mM solution. Suitable formulations for use in the present invention are found in Remington's Pharmaceutical Sciences, Mack Publishing Company, Philadelphia, Pa., 17th ed., 1985. For a brief review of methods for drug delivery, see e.g. Langer (1990 Science 249:1527-1533). Non-limiting examples of pharmaceutically acceptable diluents, carriers, adjuvants, suitable dosages, formulations, administration routes, compositions, dosage forms, combinations with other therapeutic agents, pro-drug formulations are provided in W02007/031091. The nucleic acid molecules or oligonucleotides of the application or salts thereof may be mixed with pharmaceutically acceptable active or inert substances for the preparation of pharmaceutical compositions or formulations. Compositions and methods for the formulation of pharmaceutical compositions are dependent upon a number of criteria, including but not limited to route of administration, extent of disease, or dose to be administered. Pharmaceutical compositions comprising any of the nucleic acid molecules or oligonucleotides of the application or salts thereof may be sterilized by conventional sterilization techniques or may be sterile filtered. The resulting aqueous solutions may be packaged for use as is or lyophilized, the lyophilized preparation being combined with a sterile aqueous carrier prior to administration. The pH of the preparations typically will be between 3 and 11, more particularly between 5 and 9 or between 6 and 8, most particularly between 7 and 8, such as 7 to 7.5. The resulting compositions in solid form may be packaged in multiple single dose units, each containing a fixed amount of the nucleic acid molecules or oligonucleotides of the application or salts thereof, such as in a sealed package of tablets or capsules. The composition in solid form can also be packaged in a container for a flexible quantity. Tauopathic disorders It was previously shown that SYNGR-3 interacts with pathological Tau at the presynapse and that reducing the level of SYNGR-3 rescued Tau-induced defects in vesicle mobility and neurotransmitter release. Inhibiting the expression of synaptogyrin-3 to reduce binding between synaptogyrin-3 and (the N-terminal sequence of) the tau protein is thus at the heart of the current invention. Therefore in a second aspect, any of the nucleic acid molecules or oligonucleotides described in current application is provided for use as a medicament. More particularly for use to treat tauopathies. Tauopathies are a diverse group of disorders all having in common their association with prominent accumulation of intracellular tau protein. The tau protein is abundantly expressed in the central nervous system. The group of tauopathies is growing as recently Huntington disease (Fernandez-Nogales et al 2014 Nat Med 20:881-885) and chronic traumatic encephalopathy (CTE; McKee et al 2009 J Neuropathol Exp Neurol 68,709-735) were added. PaVer/SyngrASO2/799 Different classifications of tauopathies exist. In one classification system, tauopathic disorders are divided in predominant Tau pathologies, tauopathies associated with amyloid deposition and tauopathies associated with another pathology (Williams et al 2006 Intern Med J 36:652-660). Predominant Tau pathologies include progressive supranuclear palsy (PSP), progressive supranuclear palsy-parkinsonism (PSP-P), Richardson’s syndrome, argyrophilic grain disease, corticobasal degeneration, Pick’s disease, frontotemporal dementia with parkinsonism associated with chromosome 17 (FTDP-17), post-encephalitic parkinsonism, Parkinson’s disease complex of Guam, and Guadeloupean parkinsonism. Tauopathic disorders associated with amyloid deposition include Alzheimer’s disease, Down’s syndrome, dementia pugilistica, familial British dementia and familial Danish dementia. Tauopathic disorders associated with another pathology include myotonic dystrophy, Hallevorden–Spatz disease, and Niemann Pick type C. Another classification is based on the isoform type found in the aggregates although overlaps may exist: 4R tauopathies include progressive supranuclear palsy (PSP), corticobasal degeneration, tangle predominant dementia, and argyrophilic grain disease.3R tauopathies include Pick disease, and 3R+4R tauopathies include Alzheimer’s disease (Dickson et al 2011 J Mol Neurosci 45:384-389; Murray et al 2014 Alzheimer’s Res Ther 6:1). The tau protein is discussed herein in more detail further below. Further tauopathies include tangle-only dementia, white matter tauopathy with globular glial inclusions, subacute sclerosing panencephalitis, SLC9A6-related mental retardation, non-Guamanian motor neuron disease with neurofibrillary tangles, neurodegeneration with brain iron accumulation, Gerstmann- Sträussler-Scheinker disease, frontotemporal lobar degeneration, diffuse neurofibrillary tangles with calcification, chronic traumatic encephalopathy, amyotrophic lateral sclerosis of Guam, amyotrophic lateral sclerosis and parkinsonism-dementia complex, prion protein cerebral amyloid angiopathy, and progressive subcortical gliosis (Murray et al 2014 Alzheimer’s Res Ther 6:1; Spillantini & Goedert 2013 Lancet Neurol 12:609-622). Symptoms of tauopathic disorders include clinical or pathological symptoms such as mild cognitive impairment, dementia, cognitive decline (e.g. apathy, impairment in abstract thought), decline of motor function (causing e.g. postural instability, tremor or dystonia), oculomotor and bulbar dysfunction. Criteria for diagnosing dementia are outlined in e.g. the Diagnostic and Statistical Manual of Mental Disorders (DSM) or in the International Classification of Disease (ICD) and are subject to regular updates. The type of clinical symptoms depends on which region of the brain is affected by the tauopathy and explains why Alzheimer’s disease is mainly a dementing disease and why Parkinson’s disease is mainly affecting movement. Stereotypical temporospatial propagation of tau inclusions creates a consistent pattern of brain lesions in at least Alzheimer’s disease and argyrophilic grain disease. The spreading may PaVer/SyngrASO2/799 in part occur in a trans-synaptic manner (Spillantini & Goedert 2013 Lancet Neurol 12:609-622; Liu et al 2012 PloS One 7:e31802). Molecular symptoms of tauopathic disorders include synaptic dysfunction (in particular pre-synaptic dysfunction), neurotoxicity, neuronal degeneration, neuronal dysfunction, synapse loss and amyloid deposition. Given that the nucleic acid molecules or oligonucleotides herein described are able to target synaptogyrin-3 and reduce its expression, any of said nucleic acid molecules or oligonucleotides is thus applicable for use as a medicament. In one embodiment thereto, any of the nucleic acid molecules or oligonucleotides herein described is provided for use in (a method for) treating or inhibiting progression of a tauopathic disorder or for use in (a method for) treating or inhibiting a symptom of a tauopathic disorder. In particular, the nucleic acid molecules or oligonucleotides of the invention are inhibitors of human synaptogyrin-3 expression. The expression or function of synaptogyrin-3 is (partially) inhibited such as to restore pathological Tau-induced presynaptic dysfunction. In the methods for treating or inhibiting progression of a tauopathic disorder or a symptom of a tauopathic disorder, any of the nucleic acid molecules or oligonucleotides herein described is administered to a subject in need thereof (a subject suffering of or displaying a tauopathy or symptom thereof) in an effective amount, i.e. in an amount sufficient to treat or to inhibit progression of a tauopathic disorder or a symptom of a tauopathic disorder. For the purpose of treating, preventing or inhibiting (progression of) an intended disease or disorder, and in method for treating, preventing or inhibiting (progression of) an intended disease or disorder, an effective amount of the therapeutic compound is administered to a subject in need thereof. An “effective amount” of an active substance in a composition is the amount of said substance required and sufficient to elicit an adequate response in treating, preventing, inhibiting (progression of) the intended or targeted medical indication. It will be clear to the skilled artisan that such response may require successive (in time) administrations with the composition as part of an administration scheme. The effective amount may vary depending on the nature of the compound, the route of administration of the compound (crossing of the blood-brain barrier and the cell membrane are potential barriers to be taken by oligonucleotides as described herein), the health and physical condition of the individual to be treated, the age of the individual to be treated (e.g. dosing for infants may be lower than for adults) the taxonomic group of the individual to be treated (e.g. human, non-human primate, primate, etc.), the capacity of the individual's system to respond effectively, the degree of the desired response, the formulation of the active substance, the treating doctor's assessment and other relevant factors. The effective amount further may vary depending on whether it is used in monotherapy or in combination therapy. Determination of an effective amount of a usually follows from pre-clinical testing PaVer/SyngrASO2/799 in a representative animal or in vitro model (if available) and/or from dose-finding studies in early clinical trials. Any of the nucleic acid molecules or oligonucleotides described herein is provided for use in (a method for) treating or inhibition progression of a tauopathic disorder wherein the tauopathic disorder is selected from the group consisting of Alzheimer’s disease, progressive supranuclear palsy (PSP), progressive supranuclear palsy-parkinsonism (PSP-P), Richardson’s syndrome, argyrophilic grain disease, corticobasal degeneration Pick’s disease, frontotemporal dementia with parkinsonism associated with chromosome 17 (FTDP-17), post-encephalitic parkinsonism, Parkinson’s disease complex of Guam, Guadeloupean parkinsonism, Huntington disease, Down’s syndrome, dementia pugilistica, familial British dementia, familial Danish dementia, myotonic dystrophy, Hallevorden-Spatz disease, Niemann Pick type C, chronic traumatic encephalopathy, tangle-only dementia, white matter tauopathy with globular glial inclusions, subacute sclerosing panencephalitis, SLC9A6-related mental retardation, non- Guamanian motor neuron disease with neurofibrillary tangles, neurodegeneration with brain iron accumulation, Gerstmann-Sträussler-Scheinker disease, frontotemporal lobar degeneration, diffuse neurofibrillary tangles with calcification, chronic traumatic encephalopathy, amyotrophic lateral sclerosis of Guam, amyotrophic lateral sclerosis and parkinsonism-dementia complex, prion protein cerebral amyloid angiopathy, and progressive subcortical gliosis. Any of the nucleic acid molecules or oligonucleotides described herein is thus likewise applicable for use in (a method for) treating or inhibition progression of a symptom of tauopathic disorder selected from the group of mild cognitive impairment, dementia, cognitive decline, decline of motor function, oculomotor and bulbar dysfunction, synaptic dysfunction, neurotoxicity, neuronal degeneration, neuronal dysfunction, synapse loss, and amyloid deposition. In particular, in relation to synaptic dysfunction it concerns pre-synaptic dysfunction. “Treatment” refers to any rate of reduction or retardation of the progress of the disease or disorder compared to the progress or expected progress of the disease or disorder when left untreated. More desirable, the treatment results in no/zero progress of the disease or disorder (i.e. “inhibition” or “inhibition of progression”) or even in any rate of regression of the already developed disease or disorder. Tauopathies are in general progressive disorders, and progression may imply propagation of pathological tau protein (Asai et al 2015 Nat Neurosci 18:1584-1593; deCalignon et al 2012 Neuron 73:685-697). PaVer/SyngrASO2/799 “Reduction” or “reducing” as used herein refers to a statistically significant reduction. More particularly, a statistically significant reduction upon administering the inhibitor of the invention compared to a control situation wherein the inhibitor is not administered. In a particular embodiment, said statistically significant reduction is an at least 25%, 30%, 35%, 40%, 45% or 50% reduction compared to the control situation. The application also provides methods of treating or inhibiting progression of a symptom of a tauopathic disorder, the method comprises the step of administering any of the nucleic acid molecules or oligonucleotides herein described to a subject in need thereof. In one embodiment, a method of reducing the expression level of synaptogyrin-3 in a subject is provided, comprising the step of administering any of the nucleic acid molecules or oligonucleotides herein described to the subject. Diagnosis of tauopathic disorders The nucleic acid molecules or oligonucleotides of the present disclosure can also be used for diagnostic purposes. Magnetic resonance imaging (MRI) in itself allows for radiologic determination of brain atrophy. Midbrain atrophic signs such as the Hummingbird or Penguin silhouette are for instance indicators of progressive supranuclear palsy (PSP). Determination of tau protein content in the cerebrospinal fluid (CSF) may also serve as an indicator of tauopathies. The ratio between the 33 kDa/55 kDa tau-forms in CSF was e.g. found to be reduced in a patients with PSP (Borroni et al 2008 Neurology 71:1796-1803). Recently, in vivo imaging techniques of neurodegeneration have become available. Such techniques can clearly support the clinical diagnosis of neurodegenerative diseases in general and of tauopathies in particular. In vivo diagnosis of tauopathies benefits from the existence of Tau imaging ligands detectable by positron emission tomography (PET), and include the radiotracers 2-(1-(6-((2-[¹⁸F]fluoroethyl) (methyl) amino)-2-naphthyl)ethylidene) malononitrile ([¹⁸F]FDDNP), 2-(4-aminophenyl)-6-(2- ([¹⁸F]fluoroethoxy))quinolone ([¹⁸F]THK523), and [¹⁸F]T807 and [¹⁸F]T808 (Murray et al 2014 Alzheimer’s Res Ther 6:1). In addition, MRI can be used to detect tauopathies, and PET imaging with fluorodeoxyglucose (FDG, ¹⁸F agent) is indicative of synaptic activity (Murray et al 2014 Alzheimer’s Res Ther 6:1). Beta-amyloid, that can be detected in vivo, e.g. by using florbetapir (or other amyloid markers) in combination with PET, proved to be an accurate biomarker for at least Alzheimer’s disease (Clark et al 2011 J Am Med Assoc 305:275-283) and the florbetapir-PET technique received FDA approval in 2012. The availability of in vivo tauopathy detection techniques is further supportive for selecting subjects that can benefit from synaptogyrin-3 inhibitory as described herein. PaVer/SyngrASO2/799 Accordingly, the present disclosure provides nucleic acid molecules or oligonucleotides of the present disclosure which are conjugated to a detectable moiety, for example, a radiotracer, a fluorescent moiety (e.g., a fluorescent protein), or any detectable moiety known in the art. Also provided are methods for the diagnosis or prognosis of tauopathic disorders, methods to monitor the efficacy of a treatment, methods to select a patient for treatment, or methods to select a subject for a clinical trial or to exclude a subject from a clinical trial comprising administering a nucleic acid molecule or oligonucleotides of the present disclosure. Inhibition of synaptogyrin-3 By using the oligonucleotides of the disclosure, inhibition of synaptogyrin-3 is obtained at the expression level. In other words, the administration of an oligonucleotide of the present disclosure can reduce the level of mRNA encoding synaptogyrin-3, which in turn would result in a lower protein expression level of synaptogyrin-3. In some aspects, such reduction of expression levels of synaptogyrin-3 can result in a reduction in synaptogyrin-3 activity. As demonstrated previously (see WO2019/016123 and US20220403021A1, which are herein incorporated by reference in their entireties), partial inhibition of synaptogyrin-3 is sufficient to restore pathological Tau-induced presynaptic dysfunction. As such, inhibition of synaptogyrin-3 expression and/or activity implies several possible levels of inhibition. In some aspects, the administration an oligonucleotide of the disclosure can result in a reduction in synaptogyrin-3 mRNA level of at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least 95%, or even about 100% with respect to control conditions (e.g., prior to the administration of the oligonucleotide of the present disclosure). In some aspects, the administration an oligonucleotide of the disclosure can result in a reduction in synaptogyrin-3 protein level of at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least 95%, or about 100% with respect to control conditions (e.g., prior to the administration of the oligonucleotide of the present disclosure). In some aspects, the administration an oligonucleotide of the disclosure can result in a reduction in synaptogyrin-3 activity level of at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least PaVer/SyngrASO2/799 95%, or about 100% with respect to control conditions (e.g., prior to the administration of the oligonucleotide of the present disclosure). The skilled person is familiar with multiple ways of determining the level of synaptogyrin-3 in a cell and hence to determine a reduction of the Syngr-3 transcript level compared to a control. A non-limiting example is quantitative reverse transcriptase (RT)-PCR. In current application the Syngr-3 levels have been determined using a TaqMan assay. Administrating the nucleic acid molecules of the invention The nucleic acid molecules or the oligonucleotides of the present invention may be administered via intravenous, subcutaneous, intramuscular, intracerebral, intracerebroventricular, intraventricular, intraocular, or intrathecal administration. In some embodiments, the administration is via intrathecal administration. SYNGR-3 gene inactivation, i.e. inhibition of expression of the target gene, can be also achieved through the creation of transgenic organisms expressing one of the oligonucleotides of the invention (e.g. siRNA), or by administering said inhibitor to the subject (see Examples). The nature of the inhibitor (siRNA, shRNA, gapmer, …) and whether the effect is achieved by incorporating the oligonucleotide into the subject’s genome or by administering the oligonucleotide is not vital to the invention, as long as said oligonucleotide reduces the level of SYNGR-3 transcripts. An oligonucleotide construct can be delivered, for example as an expression plasmid, which when transcribed in the cell, produces the oligonucleotide that is complementary to at least a unique portion of the cellular SYNGR-3 RNA. Alternatively, oligonucleotide inhibitors such as siRNA can also be expressed from recombinant circular or linear DNA plasmids using any suitable promoter. Suitable promoters for expressing these inhibitors targeted against SYNGR-3 from a plasmid include, for example the U6 or H1 RNA polymerase III promoter sequences and the cytomegalovirus promoter. Selection of other suitable promoters is within the skill in the art. Non-limiting examples are neuronal-specific promoters, glial cell specific promoters, the human synapsin 1 gene promoter, the Hb9 promotor or the promoters disclosed in US7341847B2. The recombinant plasmids comprising any of the nucleic acid molecules or oligonucleotides of the invention can also comprise inducible or regulatable promoters for expression of the nucleic acid molecule or oligonucleotide in a particular tissue or in a particular intracellular environment. The nucleic acid molecule or oligonucleotide expressed from recombinant plasmids can either be isolated from cultured cell expression systems by standard techniques, or can be expressed intracellularly, e.g. in brain tissue or in neurons. Nucleic acid molecules or oligonucleotides can also be expressed intracellularly from recombinant viral vectors. The recombinant viral vectors comprise sequences encoding the nucleic acid molecules or oligonucleotides of the invention and any suitable promoter for expressing them. The PaVer/SyngrASO2/799 nucleic acid molecules or oligonucleotides will be administered in an “effective amount” which is an amount sufficient to cause a statistically significant reduction of the SYNGR-3 transcript. Generally, an effective amount of a nucleic acid molecule or oligonucleotide targeting SYNGR-3 transcripts comprises an intracellular concentration of from about 1 nanomolar (nM) to about 100 nM, preferably from about 2 nM to about 50 nM, more preferably from about 2.5 nM to about 10 nM. It is contemplated that greater or lesser amounts of inhibitor can be administered. shRNAs for example can be introduced into the nuclei of target cells using a vector (e.g. bacterial or viral) that optionally can stably integrate into the genome. shRNAs are usually transcribed from vectors, e.g. driven by the Pol III U6 promoter or H1promoter. Vectors allow for inducible shRNA expression, e.g. relying on the Tet-on and Tet-off inducible systems commercially available, or on a modified U6 promoter that is induced by the insect hormone ecdysone. A Cre-Lox recombination system has been used to achieve controlled expression in mice. Synthetic shRNAs can be chemically modified to affect their activity and stability. Plasmid DNA or dsRNA can be delivered to a cell by means of transfection (lipid transfection, cationic polymer-based nanoparticles, lipid or cell-penetrating peptide conjugation) or electroporation. Viral vectors include lentiviral, retroviral, adenoviral and adeno-associated viral vectors. Drug administration across blood-brain barrier The blood-brain barrier (BBB) is a protective layer of tightly joined cells that lines the blood vessels of the brain which prevents entry of harmful substances (e.g. toxins, infectious agents) and restricts entry of (non-lipid) soluble molecules that are not recognized by specific transport carriers into the brain. This poses a challenge in the delivery of drugs, such as the synaptogyrin-3 inhibitors described herein, to the central nervous system/brain in that drugs transported by the blood not necessarily will pass the blood- brain barrier. Although the BBB often is to some degree affected or broken down in case of a tauopathic disorder, it may be needed to rely on a means to enhance permeation of the BBB for a candidate drug for treating a tauopathic disorder to be able to enter the affected brain cells. Several options are nowadays available for delivery of drugs across the BBB (Peschillo et al 2016 J Neurointervent Surg 8:1078-1082; Miller & O’Callaghan 2017 Metabolism 69:S3-S7; Drapeau & Fortin 2015 Current Cancer Drug Targets 15:752-768). Drugs can be directly injected into the brain (invasive strategy) or can be directed into the brain after BBB disruption with a pharmacological agent (pharmacologic strategy). Invasive means of BBB disruption are associated with the risk of hemorrhage, infection or damage to diseased and normal brain tissue from the needle or catheter. Direct drug be improved by the technique of convection- PaVer/SyngrASO2/799 enhanced delivery. Longer term delivery of a therapeutic protein (e.g. a neurotrophic factor or nerve growth factor, or a proteinaceous synaptogyrin-3 inhibitor as describe herein) can be achieved by implantation of genetically modified stem cells, by recombinant viral vectors, by means of osmotic pumps, or by means of incorporating the therapeutic drug in a polymer (slow release; can be implanted locally). Pharmacologic BBB disruption has the drawback of being non-selective and can be associated with unwanted effects on blood pressure and the body's fluid balance. This is circumvented by targeted or selective administration of the pharmacologic BBB disrupting agent. As an example, intra-arterial cerebral infusion of an antibody (bevacizumab) in a brain tumor was demonstrated after osmotic disruption of the BBB with mannitol (Boockvar et al. 2011, J Neurosurg 114:624-632); other agents capable of disrupting the BBB pharmacologically include bradykinin and leukotriene C4 (e.g. via intracarotid infusion; Nakano et al.1996, Cancer Res 56:4027–4031). BBB transcytosis and efflux inhibition are other strategies to increase brain uptake of drugs supplied via the blood. Using transferrin or transferrin-receptor antibodies as carrier of a drug is one example of exploiting a natural BBB transcytosis process (Friden et al.1996, J Pharmacol Exp Ther 278:1491-1498). Exploiting BBB transcytosis for drug delivery is also known as the molecular Trojan horse strategy. Another mechanism underlying BBB, efflux pumps or ATP-binding cassette (ABC) transporters (such as breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (Pgp/MDR1/ABCB1)), can be blocked in order to increase uptake of compounds (e.g. Carcaboso et al.2010, Cancer Res 70:4499-4508). Kumar et al (2007 Nature 448:39-43) demonstrated uptake of siRNAs in the brain after coupling to a 29- amino acid peptide derived from rabies virus glycoprotein (RVG) which is specifically binding the acetylcholine receptor. Therapeutic drugs can alternatively be loaded in liposomes to enhance their crossing of the BBB, an approach also known as liposomal Trojan horse strategy. Especially in the field of treating cognitive and neurodegenerative disorders there has been quite some interest in intranasal delivery of drugs (e.g. Muhs et al.2007, Proc Natl Acad Sci USA 104:9810-9815; Kao et al.2000, Pharm Res 17:978-984; Hanson & Frey 2008, BMC Neurosci 9 (Suppl3): 55). This strategy is based on the trigeminal and olfactory nerves that innervate the nasal epithelium, representing direct connections between the external environment and the brain. PaVer/SyngrASO2/799 A more recent and promising avenue for delivering therapeutic drugs to the brain consists of (transient) BBB disruption by means of ultrasound, more particularly focused ultrasound (FUS; Miller et al. 2017, Metabolism 69:S3-S7). Besides being non-invasive, this technique has, often in combination with real- time imaging, the advantage of precise targeting to a diseased area of the brain. Therapeutic drugs can be delivered in e.g. microbubbles e.g. stabilized by an albumin or other protein, a lipid, or a polymer. Therapeutic drugs can alternatively, or in conjunction with microbubbles, be delivered by any other method, and subsequently FUS can enhance local uptake of any compound present in the blood (e.g. Nance et al.2014, J Control Release 189:123-132). Just one example is that of FUS-assisted delivery of antibodies directed against toxic amyloid-beta peptide with demonstration of reduced pathology in mice (Jordao et al.2010, PloS One 5:e10549). Microbubbles with a therapeutic drug load can also be induced to burst (hyperthermic effect) in the vicinity of the target cells by means of FUS, and when driven by e.g. a heat shock protein gene promoter, localized temporary expression of a therapeutic protein can be induced by ultrasound hyperthermia (e.g. Lee Titsworth et al. 2014, Anticancer Res 34:565-574). Alternatives for ultrasound to induce the hyperthermia effect are microwaves, laser-induced interstitial thermotherapy, and magnetic nanoparticles (e.g. Lee Titsworth et al.2014, Anticancer Res 34:565-574). Intracellular drug administration Besides the need to cross the BBB, drugs targeting disorders of the central nervous system, such as the synaptogyrin-3 inhibitors described herein, may also need to cross the cellular barrier. Although most antisense oligonucleotides are readily taken up by neurons and glia after reaching the nervous system, it can be advantageous to use facilitators of intracellular drug uptake. One solution is the use of cell-penetrating proteins or peptides (CPPs). Such peptides enable translocation of the drug of interest coupled to them across the plasma membrane. CPPs are alternatively termed Protein Transduction Domains (TPDs), usually comprise 30 or less (e.g.5 to 30, or 5 to 20) amino acids, and usually are rich in basic residues, and are derived from naturally occurring CPPs (usually longer than 20 amino acids), or are the result of modelling or design. A non-limiting selection of CPPs includes the TAT peptide (derived from HIV-1 Tat protein), penetratin (derived from Drosophila Antennapedia – Antp), pVEC (derived from murine vascular endothelial cadherin), signal-sequence based peptides or membrane translocating sequences, model amphipathic peptide (MAP), transportan, MPG, polyarginines; more information on these peptides can be found in Torchilin 2008 (Adv Drug Deliv Rev 60:548-558) and references cited therein. The commonly used CPP is the transduction domain of TAT termed TATp. The TAT peptide was e.g. used to shuffle a tau-fragment into neuronal cells (Zhou et al. 2017). PaVer/SyngrASO2/799 CPPs can be coupled to carriers such as nanoparticles, liposomes, micelles, or generally any hydrophobic particle. Coupling can be by absorption or chemical bonding, such as via a spacer between the CPP and the carrier. To increase target specificity an antibody binding to a target-specific antigen can further be coupled to the carrier (Torchilin 2008, Adv Drug Deliv Rev 60:548-558) CPPs have already been used to deliver payloads as diverse as plasmid DNA, oligonucleotides, siRNA, peptide nucleic acids (PNA), proteins and peptides, small molecules and nanoparticles inside the cell (Stalmans et al.2013, PloS One 8:e71752). Kits and products of manufacture Also provided herein are kits and products of manufacture comprising one or more compositions (e.g., an oligonucleotide of the present disclosure or pharmaceutical compositions comprising an oligonucleotide of the present disclosure) described herein. In some aspects, provided herein is a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions described herein. In some aspects, the kit or product of manufacture comprises, e.g., a first container comprising a first pharmaceutical composition comprising an oligonucleotide of the present disclosure, a second container containing a solvent, and optionally an instruction for use. In some aspects, the kit or product of manufacture comprises a container comprising an oligonucleotide of the present disclosure and optionally an instruction for use. In some aspects, the kit contains a pharmaceutical composition described herein and any prophylactic or therapeutic agent, such as those described herein. In some aspects, the kit further comprises instructions to administer a composition of the present disclosure according to any method disclosed herein. In some aspects, the kit is for use in the treatment of a medical indication disclosed herein. In some aspects, the kit is a diagnostic kit. All of the references cited above, as well as all references cited herein, are incorporated herein by reference in their entireties. The sequences of biomolecules (e.g., proteins, genes) disclosed herein and identified by either database accession number or gene name are incorporated by reference. The database accession numbers disclosed herein (e.g, Genbak accession numbers) refer to the database version that in effect on February 1, 2023. The nucleic acid sequences of genes identified by name as well as their official names and alternative names correspond to those in the version of the Genbank database active on February 1, 2023, and are herein incorporated by reference. The amino acid sequences of proteins identified by name or translation products of genes identified by name as well as their official and alternative names PaVer/SyngrASO2/799 correspond to those in the version of the UniProt database active on February 1, 2023, and are herein incorporated by reference. Although the invention has been described and illustrated in the foregoing illustrative embodiments, it is understood that the present disclosure has been made only by way of example, and the numerous changes in the details of implementation of the invention can be made without departing from the spirit and scope of the invention, which is only limited by the claims that follow. Features of the disclosed embodiments can be combined and rearranged in various ways. The various embodiments can be combined with one or more other embodiments to form new embodiments. The following examples are offered by way of illustration and not by way of limitation. Protein expression Protein Expression was measure by western blot after 8 days of ASOs incubation using a Polyclonal Rabbit SYNGR3 (Novus Biologicals). Gapdh (glyceraldehyde-3-phosphate dehydrogenase) or Actin were used as loading controls. EXAMPLES Example 1. Design and synthesis of antisense oligonucleotides specifically directed against human SYNGR3 transcripts A bioinformatic analysis was performed to identify an ASO screening set designed to mediate RNaseH dependent cleavage of human Syngr3 (pre-)mRNA (NCBI Gene ID: 9143, ENSG 00000127561). We derived all possible ASO sequences, from the human target mRNA, in a 16 mer 3-10-3 LNA gapmer design based on relevant spliced and unspliced transcripts (reference transcript SYNGR 3-201; ENST 00000248121.7). The following parameters were taken into consideration for the in-silico analysis: (a) Species cross reactivity for human, cynomolgus monkey, rhesus monkey and mouse ASOs were first selected based on the Syngr 3-201 transcript. Additionally, ASOs specifically directed against the remaining human SYNGR3 transcripts were identified as well (isoform specific ASOs). (b) Specificity Target specificity in human, rhesus monkey, cynomolgus monkey and mouse was performed to identify ASOs with a low number of predicted off-targets to avoid unintended downregulation of non-target transcripts by full or partial complementarity to a ASO sequence. For each ASO sequence, the specificity was predicted based on the identification of predicted off-targets with up to 3 mismatches both in unspliced and primary transcript (nuclear and cytoplasmic targets) of the following species: human, cynomolgus monkey, rhesus monkey and mouse. up the calculation and focus only on relevant PaVer/SyngrASO2/799 ASOs, the candidate set was gradually reduced based on the predicted specificity. For this purpose, preliminary analyses were carried out that only consider off targets with few mismatches. This allowed an early exclusion of ASOs for which very many off targets are predicted. (c) Analysis of sequences that contain hepatoxic, immune-stimulatory motifs Motifs that can lead to toxicity were identified based on the published literature. Motifs such as TCC+TGC, CG+CT+TG+GC, and GT, are predicted to induce hepatoxicity, and motifs such as GC are known to induce the immune system. The number of occurrences of such motifs were counted and used to rank the ASO sequences. (d) Sequence motifs known to influence activity (as described in literature) Motifs predicted to decrease ASOs activity were identified and used for sequence ranking. Motifs such as GGGG+ACTG+AAA+TAA are known to reduce ASOs activity. Similarly, the identification of sequence motifs expected to increase activity, were also counted and taken into account for sequence ranking (CCAC+TCCC+ACTC+GCCA+ CTCT). (e) Single nucleotide polymorphism (SNP) SNPs located in ASO target sites were identified and mapped to human transcripts NC_000016.10 (1989970…1994275) and NM_004209.6. Targeting regions with high number of SNP occurrences were avoided. (f) Exclusion of ASOs with runs of 4 or more consecutive Gs or ASOs showing G tetraplex motifs Example 2. Dual-dose screening We seeded SH-SY5Y cells at a density of 20.000 cells/well on collagen-coated 96-well tissue culture plates, followed by transfection of cells using Dharmafect-4 (0.5 µl/well). The two final ASOs concentrations tested were 30 nM and 3 nM. Cells were incubated for 24h at 37°C/5% CO2 in a humidified incubator, followed by cell lysis and branched DNA (bDNA) analysis to monitor on-target mRNA expression levels relative to hsGAPDH mRNA levels. The bDNA assay provides a unique and powerful tool for reliable quantification of nucleic acid molecules. The bDNA assay directly measures nucleic acid molecules at physiological levels by boosting the reporter signal, rather than replicating target sequences as the means of detection, and hence avoids the errors inherent in the extraction and amplification of target sequences. More detailed, after a 24-hour incubation with ASOs, media was removed and SH-SY5Y cells (sourced from ATCC, CRL-2266) were lysed by addition of 150 µl lysis mixture (1 volume lysis mixture, 2 volumes nuclease-free water) per 96-well and incubated for at least 60 minutes. Upon release of the PaVer/SyngrASO2/799 target RNA, several oligonucleotide probes were incubated to allow binding to Syngr3 (and GAPDH as a control). Probes for Syngr3 were custom and made by ThermoFisher Scientific, Assay ID: DRAAACA). During this incubation, the probes cooperatively hybridize to the Syngr3. 50µl working probe set hsSYNGR3 (gene target, Synaptogyrin 3 from Homo sapiens) and 90µl working probe set hsGAPDH (endogenous control, Glyceraldehyde-3-phosphate dehydrogenase from Homo sapiens), and 50µl (for hsSYNGR3) and 10µl (for hsGAPDH) of cell lysate were then added to the capture plates provided by the manufacturer. Capture plates were incubated at 53°C for approximately 16-20 hours. The next day, the capture plates were washed 3 times with at least 300µl of 1x Wash Buffer (nuclease-free water, wash buffer component 1 and wash buffer component 2).100µl of pre-amplifier working reagent was added to both hsSYNGR3 and hsGAPDH capture plates, which were sealed with clear adhesive foil and incubated for 1 hour at 53°C. Following incubation, the wash step was repeated, then 100µl amplifier working reagent was added to both hsSYNGR3 and hsGAPDH capture plates. After 1 hour incubation at 53°C, the wash and dry steps were repeated, and 100µl label probe was added per 96-well to all capture plates. Capture plates were incubated for 53°C for 1 hour. The plates were then washed with 1x wash buffer and dried, and then 100µl substrate was added to the capture plates sealed by adhesive aluminum foil. Following 30 minutes of incubation in the dark, luminescence was read using 1420 Luminescence Counter (WALLAC VICTOR Light, Perkin Elmer, Rodgau-Jügesheim, Germany). For each ASOs, four wells with SH-SY5Y cells were transfected in parallel, and individual data points were collected from each well separately. For each well, the hsSYNGR3 mRNA level was normalized to the hsGAPDH mRNA level. The activity of a given hsSYNGR3 targeting ASO was expressed as percent hsSYNGR3 mRNA concentration (normalized to hsGAPDH mRNA) in treated cells, relative to the hsSYNGR3 mRNA concentration (normalized to hsGAPDH mRNA) averaged across control wells. All data were generated in quadruplicates. Results of the dual-dose screen are shown in Table 1. As can be observed from Table 1, when we selected for a reduced synaptogyrin-3 expression level of at least 45% in the 3 nM or 30 nM concentration, several regions within the synaptogyrin-3 emerged as target regions for designing antisense and/or RNAi molecules capable of reducing the expression of Syngr-3 in a cell, tissue or subject. We further selected 48 ASO molecules to be tested in a dose-response curve. Selection was based on activity, target sequence binding, and cross-reactivity. Example 3. Dose-response curve We seeded SH-SY5Y cells at a density of 20.000 cells/well on collagen-coated 96-well tissue culture plates, followed by transfection of cells using Dharmafect-4 (0.5 µl/well). For the transfection the highest final ASOs concentration tested was 60nM, 2-fold steps, 10 data points. Cells were incubated for PaVer/SyngrASO2/799 48h at 37°C/5% CO₂ in a humidified incubator, followed by cell lysis and bDNA analysis to monitor on- target mRNA expression levels relative to hsGAPDH mRNA levels. All data were generated in quadruplicates. Results of the Dose-response curve are shown in Table 2. Example 4. Human iPSC-derived neurons To further confirm the silencing effect of the selected hits, we tested several ASOs in human iPSC-derived neurons (obtained from healthy donors). iPSCs are adult pluripotent stem cells generated from somatic cells by the introduction of reprogramming factors. Like other pluripotent stem cells, iPSCs can be differentiated into neurons and glial cells by exposure to a combination of growth factors and cell culture conditions. Human iPSCs (hiPSCs) thus make it possible to study to perform screening and functional assay in a more physiological environment. In particular, we have used Ncyte Cortical Neuron Cells or KOLF2.1J (Jax laboratory) cell line. Ncyte cortical neurons are produced through a well-defined in vitro differentiation process from hiPSC. The iPSC line is generated by introducing specific transcription factors, described by Yamanaka in a human skin fibroblast, using a non-viral system. Ncyte Cortical Neuron Cells are primarily composed of glutamatergic neurons expressing typical markers of the human cerebral cortex neurons, such as Beta III Tubulin, NeuN, MAP2, FOXG1, TBR1 and Ctip2. They exhibit spontaneous activity, presenting firing properties as early as day 4 after thawing and evolve into more complex structured patterns of activity. KOLF2.1J parental cell line was used to generate neurons accordingly to published protocol (Pantazanis, Cell Stem Cell, 2022) . Briefly, hiPSC were maintained on matrigel-coated plates with StemFlex medium (Gibco) and medium changes were performed every two days. At day 21 of differentiation, neural progenitors were plated on coverslips coated with poly-D-lysine and mouse laminin in terminal differentiation medium (Neurobasal-A medium (Gibco), supplemented with 1x B27 devoid of vitamin A; 1x GlutaMax, 1x PenSrep; 10ng/ml GDNF; 10ng/ml BDNF; 0.5mM dbcAMP; 10µM DAPT; 0.2mM Ascorbic Acid; 100nM SR11237). The levels of Syngr3 mRNA during neuronal differentiation were investigated. It was confirmed that after 3 weeks in culture, Syngr3 mRNA expression peaks, and is stable for another two weeks. Ncyte neuron cells or KOLF2.1J derived neurons were seeded 30k density/well, in a 96-well plate. Culture medium was changed 2-3 times a week during subsequent culture using specific medium at room temperature. After 21 days in culture, the different ASOs were directly added to the culture medium. After 4 days in culture, cells were processed for the different readout. To quantify the amount of mRNA, RNA extraction using ‘Cells-to-CT technology’ was performed. Amount of SYNGR3 mRNA quantified after ASO treatment PaVer/SyngrASO2/799 was quantified by qPCR, using specific and validated Taqman probes. For normalization, the amounts of GAPDH and HPRT1 were used as reference. Vehicle-treated samples were set to 1 and results are shown in Table 2. Table 2 shows that some areas of SYNGR3 transcript are accessible and amenable to downregulation by antisense molecules, while others are not. Example 5. Toxicity assay 5.1. Off-target toxicity (acute toxicity) - Calcium-oscillation assay: Oligonucleotides can produce acute, nonhybridization dependent, neurobehavioral side effects after intracerebroventricular (ICV) dosing in mice. To identify potential toxic molecules, an in vitro toxicity assay in hiPSc was performed. The in vitro assay measures spontaneous calcium oscillations after acute treatment with ASOs. Alterations in spontaneous calcium oscillations have been shown to predict the behavioral side effects after ICV injection in mice. Commonly, in vivo ASOs activity is tested by direct injection into the brain of mice. However, some of the ASOs are not well tolerated due to safety concerns. By filtering out molecules based on their in vitro toxicity profile, we can reduce the number of acutely toxic molecules synthesized and tested in mice. Ncyte CNS Cells were thawed and cultured accordingly to manufacturer instructions. Cells were seeded 40k density/well, in a 384-well plate. Culture medium was changed 3 times a week during subsequent culture using Cortical Neuronal Culture medium at room temperature. ASOs toxicity was measure via calcium imaging assay after 23 days in culture. Baseline signal of intracellular calcium levels was read for 5 min (1 reading/s) before the addition of ASO. Molecules were added in assay buffer to 2 µM and 20 µM final concentration. Fluorescence signal was read for additional 15 minutes. Data analysis was calculated for the spike amplitude and frequency of the fluorescent signal. Signal obtained from non- treated wells was used as control. A scoring system was adapted from a previous publication, such as that a score of 1 was given for each 1s read where signal increase was 50% of the control amplitude value. When the signal was <50% of the average control, a score of 0 was given. For each condition, the scores were summed and converted to a % of nontreated wells. Results are shown in Table 3 (calcium assay 20 μM) for fourteen ASOs, concerning the period between 5-10min after compound addition. 5.2. On-target toxicity - Cell viability of long-term exposure to ASOs: KOLF2.1J derived neurons were plate in 96-well in terminal medium. Medium was changed every 2-3 days. At day 21, ASOs were added at the final concentration of 10 µM and cellular viability (ATP metabolism) was measured after 8 days of incubation. The timepoint of 8 days was chosen based on the low levels of protein expression after addition of the ASOs molecules. The results of the experiment are shown in Table 3. PaVer/SyngrASO2/799 Table 3. Potency, target engagement and toxicity characterization of ASO sequences. Syngr3 mRNA Syngr3 Off-target toxicity protein On-Target Seq ID expression 3 IC50 (nM) (% of vehicle) expressio toxicity (% of µM n at 3 µM vehicle) 280 0,57 >3000 62,1 - - 318 0,23 526 70,8 - - 321 0,13 150 59,9 32,8 75 324 0,27 919 74,7 - - 325 0,19 485,7 83,4 - - 345 0,19 356,5 60,5 - - 346 0,06 63,3 63,2 35,7 106 370 0,29 1217 40,5 - - 373 0,10 86,2 40,5 34,7 122 384 0,11 77,1 46,4 39,9 107 433 0,16 336,4 26,8 - - 482 0,52 2739 60,4 - - 484 0,17 169,4 80,4 - - 470 0,22 214 78,5 - - Example 6. ASOs off-target prediction in silico. An off-target prediction for human, cynomolgus monkey, and rhesus monkey was conducted with the NCBI RefSeq and the Ensembl database using the latest database version available. For this analysis we have included 14 ASOs sequences. Based on these analyses a detailed listing of all predicted off- target transcripts matched by the candidate ASOs with up to 2 mismatches was generated. The off-target analysis was conducted using 1) the mature transcriptome (defines cytoplasmic off-targets) and the primary transcriptome (defines nuclear and mitochondrial off-target). Potential off targets were defined as essential (Wang, T. et al., 2015; Blomen, V. A. et al., 2015; Hart, T. et al., 2015) or housekeeping genes (Hounkpeet al., 2021; Eisenberg et al., 2013). The levels of gene expression was obtained from expression Atlas EMBL-EBI. Additionally, binding affinity of the ASO with on and off target sites was calculated with a dedicated software. Free energy of duplex destabilization was calculated by subtraction of the free energy of the match (on target site) from that of the mismatch (off target site). The closer free energy values are to zero, the more stable the potential binding to the off-target site. Therefore, we have considered off- target genes with a free energy level up to 2 to experimentally validate the in-silico predictions. In addition we considered the classification into housekeeping/essential gene, the expression in the CNS and the availability of TaqMan probes. The off- analysis of 4 selected ASOs is shown in Table 4 PaVer/SyngrASO2/799 below. Shortly, the potential genes that may be affected by each of the ASOs molecules are listed, including the position and free energy of the predicted mismatch. For three of the ASOs molecules, the top ranked off-target genes were experimentally tested. The fold-difference represents the ratio of the off-target gene potency/Syngr3 potency. Table 4. Off-target analysis of four ASOs sequences. In-silico prediction Experimental validation Express Position within Free Essential in CNS (T Neuronal Genes oligo energy of and/or PM); Potency Fold- from 5’. Mismatch household Low<10; Me (mRNA) IC50 difference gene d: 10- *G:U bp 30; nM High>30 Syngr3 - - - - 312,8 - E_HD3 ^15* _-0,8 ^{No High - -} TTC7A 15*, 16 -0,4 No Med - - 1 SUN1 3*, 16 -0,4 No High - - 2 3 D _GET4 3*, 16 -0,4 Yes Low - - Iqe FAHD1 3*, 16 -0,4 Yes Med - - S ZNF536 4*, 15* -0,3 No Med - - G_SE1 ^{3*, 16} _1,4 ^{No Low - -} SAMD4B 14* 1,2 Yes High - - H_K2 3*, 15 _1,4 No Low - - S_yngr3 - - ^{- - 259,2 -} E_HD3 15* -0,8 No High >3000 NA T_TC7A 15*, 16 _-0,4 No Med >3000 NA 4 3*, 16 -0,4 No High unstable 8 _SUN1 NA 3 D _GET4 3*, 16 _-0,4 Yes Low unstable NA Iq _FAHD1 3*, 16 -0,4 Yes Med unstable NA e S _ZNF536 ^{4*, 15*} _-0,3 ^{No Med - -} G_SE1 3*, 16 1,4 No Low - - S_AMD4B ^14* _1,2 ^{Yes High 1353 5,2} H_K2 3*, 15 1,4 No Low - Syngr3 - - - - 117,1 - PTPRJ 16 -0,1 No Low 1260,8 10,8 6 4*, 11* 1,4 No High unstable NA 4 _CTNNA2 3 D STS 4* 1,9 No Med >3000 NA Iqe CDC40 4 3,7 Yes Med - - S _XKR4 ³ _4,1 ^{No Med - -} PACSIN2 3 4,3 Yes High - - NAALAD2 3 4,5 No Low - - PaVer/SyngrASO2/799 In-silico prediction Experimental validation Express Position n Free Essential in CNS withi Neuronal Genes oligo energy of and/or (TPM); Low< Potency Fold- from 5’. Mismatch household 10; Med: (mRNA) IC50 difference U bp gen 10- *G: e 30; nM High>30 P_OR 13 5,8 No Med - - S_yngr3 - - ^{- - 207,15} RAD51B 1 0,4 No Low 653,1 3,23 EXOC4 1, 5* 0,4 Yes Med >3000 NA7 ³ D _OR2A7 ^{2, 3*} _1,5 ^{No Low - - I}qe _SNRNP200 ^{5 3,7 Yes High - -} S _GPM6B ⁴ _3,9 ^{No High - -} P_HKB 15 4,6 Yes Med - - N_ECTIN3 ¹⁴ _5,6 ^{No Low - -}

Claims

PaVer/SyngrASO2/799 CLAIMS 1. An oligonucleotide of 10 to 50 nucleotides in length, comprising a contiguous nucleotide sequence of at least 10 contiguous nucleotides in length, the contiguous nucleotide sequence being at least 90% complementary to an equal length portion of a target region within the Synaptogyrin-3 nucleotide sequence as depicted in SEQ ID No.1, wherein the target region is comprised between nucleobase positions 449 and 531, 549 and 653, 640 and 733, 720 and 875, 915 and 1108, 1197 and 1271, 1258 and 1344, 1332 and 1450, 1450 and 1527, 1515 and1600, 1580 and 1700, 1680 and 1837, 1824 and 1885, 1850 and 2100, 2100 and 2250, 2308 and 2428, 2416 and 2441, 2428 and 2625, 2649 and 2796, 2962 and 3086, 3153 and 3460, 3450 and 3530, 3508 and 3551, 3538 and 3636 or between 3626 and 4599 of SEQ ID No.1 and wherein the endpoints are included. 2. The oligonucleotide according to claim 1, wherein the oligonucleotide can bind to the Synaptogyrin- 3 transcript as depicted in SEQ ID No.1. 3. The oligonucleotide according to any one of the previous claims, wherein the oligonucleotide is capable of statistically significantly reducing the level of Synaptogrin-3 transcript in a cell compared to a control condition in the absence of the oligonucleotide. 4. The oligonucleotide according to any one of claims 1-3, wherein the oligonucleotide is a single stranded nucleic acid molecule. 5. The oligonucleotide according to claim 4, wherein the single stranded oligonucleotide is an antisense oligonucleotide (ASO) or the antisense portion of an RNAi molecule. 6. The oligonucleotide according to any one of the previous claims, wherein the contiguous nucleotide sequence is at least 16 nucleotides in length. 7. The oligonucleotide according to any one of the previous claims, wherein said target region is selected from SEQ ID No.10, 12, 20, 25, 29-31, 33, 50, 53, 58-59, 62, 69, 79, 84, 87, 91, 94, 110-111, 135, 140-141, 170, 172, 179, 181, 184, 188, 193-194, 210, 216, 220-221, 224, 227, 229, 231, 235, 241, 246, 248, 250, 259, 268 or 269. 8. The oligonucleotide according to any one of the previous claims, wherein said target region is selected from SEQ ID No.2-9, 11, 13-19, 21-24, 26-28, 32, 34-49, 51-52, 54-57, 60-61, 63-68, 70-78, 80-83, 85-86, 88-90, 92-93, 95-109, 112-134, 136-139, 142-169, 171, 173-178, 180, 182-183, 185- 187, 189-192, 195-209, 211-215, 217-219, 222-223, 225-226, 228, 230, 232-234, 236-240, 242-245, 247, 249, 251-258 or 260-267. 9. The oligonucleotide according to any one of the previous claims wherein the contiguous nucleotide sequence of at least 10 contiguous nucleotides in length shows at least 90% sequence identity to any of SEQ ID No.270-489. PaVer/SyngrASO2/799 10. The oligonucleotide according to any one of the previous claims, wherein the contiguous nucleotide sequence of at least 10 contiguous nucleotides in length shows at least 90% sequence identity to the sequence selected from the group consisting of SEQ ID No.321, SEQ ID No.346, SEQ ID No.373, SEQ ID No.384. 11. The oligonucleotide according to any one of the previous claims, wherein the contiguous nucleotide sequence is 100% complementary to one of the target regions. 12. The oligonucleotide according to any one of the previous claims, wherein the oligonucleotide comprises one or more internucleoside linkage and/or one or more 2’ sugar modified nucleosides. 13. The oligonucleotide according to claim 12 wherein the internucleoside linkage is a phosphorothioate internucleoside linkage and/or the 2’ sugar modified nucleoside is selected from the group consisting of 2ʹ-O-methyl-, 2ʹ-O-methoxyethyl-, 2’-O-alkyl-, 2’-alkoxy, 2’-amino-, 2ʹ-fluoro- and LNA nucleosides. 14. The oligonucleotide according to any one of previous claims, wherein the oligonucleotide comprises a gapmer of formula 5’-F-G-F’-3’, where region F and F’ independently comprise between 1 and 8 nucleosides, of which 1 to 5 independently are 2’ sugar modified nucleosides and define the 5’ and 3’ end of the F and F’ region, and G is a region between 5 and 18 nucleosides for recruiting RNaseH. 15. The oligonucleotide according to claim 14, wherein the internucleoside linkages between one or more nucleosides of region F and/or F’ and/or between F and G and/or between F’ and G are phosphorothioate internucleoside linkages. 16. A pharmaceutical composition comprising the oligonucleotide according to any one of the preceding claims. 17. The oligonucleotide according to any of claims 1-14 or the pharmaceutical composition according to claim 15 for use as a medicament. 18. The oligonucleotide according to any of claims 1-15 or the pharmaceutical composition according to claim 16 for use in treating or inhibiting progression of a tauopathic disorder or for use in treating or inhibiting a symptom of a tauopathic disorder. 19. The oligonucleotide according to any of claims 1-15 or the pharmaceutical composition according to claim 16 for use according to claim 18 wherein the tauopathic disorder is selected from the group consisting of Alzheimer’s disease, progressive supranuclear palsy (PSP), progressive supranuclear palsy-parkinsonism (PSP-P), Richardson’s syndrome, argyrophilic grain disease, corticobasal degeneration Pick’s disease, frontotemporal dementia with parkinsonism associated with chromosome 17 (FTDP-17), post-encephalitic parkinsonism, Parkinson’s disease complex of Guam, Guadeloupean parkinsonism, Huntington disease, Down’s syndrome, dementia pugilistica, familial British dementia, familial Danish dementia, myotonic dystrophy, Hallevorden-Spatz disease, PaVer/SyngrASO2/799 Niemann Pick type C, chronic traumatic encephalopathy, tangle-only dementia, white matter tauopathy with globular glial inclusions, subacute sclerosing panencephalitis, SLC9A6-related mental retardation, non-Guamanian motor neuron disease with neurofibrillary tangles, neurodegeneration with brain iron accumulation, Gerstmann-Sträussler-Scheinker disease, frontotemporal lobar degeneration, diffuse neurofibrillary tangles with calcification, chronic traumatic encephalopathy, amyotrophic lateral sclerosis of Guam, amyotrophic lateral sclerosis and parkinsonism-dementia complex, prion protein cerebral amyloid angiopathy, and progressive subcortical gliosis. 20. The oligonucleotide according to any of claims 1-15 or the pharmaceutical composition according to claim 16 for use according to claim 18 wherein the symptom of the tauopathic disorder is selected from the group of mild cognitive impairment, dementia, cognitive decline, decline of motor function, oculomotor and bulbar dysfunction, synaptic dysfunction, neurotoxicity, neuronal degeneration, neuronal dysfunction, synapse loss, and amyloid deposition. 21. The oligonucleotide according to any of claims 1-15 or the pharmaceutical composition according to claim 16 for use according to claim 20 wherein the synaptic dysfunction is pre-synaptic dysfunction. 22. A nucleic acid sequence selected from SEQ ID No.10, 12, 20, 25, 29-31, 33, 50, 53, 58-59, 62, 69, 79, 84, 87, 91, 94, 110-111, 135, 140-141, 170, 172, 179, 181, 184, 188, 193-194, 210, 216, 220-221, 224, 227, 229, 231, 235, 241, 246, 248, 250, 259, 268 or 269 for designing an antisense or RNAi molecule capable of reducing the level of Synaptogyrin-3 transcript in a cell with at least 45% compared to a control situation in the absence of said antisense or RNAi molecule. 23. A method of treating or inhibiting progression of a tauopathic disorder or treating or inhibiting a symptom of a tauopathic disorder comprising administering an effective dose of an oligonucleotide according to any of claims 1 and 15 or the pharmaceutical composition according to claim 16 to a subject in need thereof. 24. The method of claim 23, wherein the tauopathic disorder is selected from the group consisting of Alzheimer’s disease, progressive supranuclear palsy (PSP), progressive supranuclear palsy- parkinsonism (PSP-P), Richardson’s syndrome, argyrophilic grain disease, corticobasal degeneration Pick’s disease, frontotemporal dementia with parkinsonism associated with chromosome 17 (FTDP- 17), post-encephalitic parkinsonism, Parkinson’s disease complex of Guam, Guadeloupean parkinsonism, Huntington disease, Down’s syndrome, dementia pugilistica, familial British dementia, familial Danish dementia, myotonic dystrophy, Hallevorden-Spatz disease, Niemann Pick type C, chronic traumatic encephalopathy, tangle-only dementia, white matter tauopathy with globular glial inclusions, subacute sclerosing panencephalitis, SLC9A6-related mental retardation, non-Guamanian motor neuron disease with neurofibrillary tangles, neurodegeneration with brain iron accumulation, Gerstmann-Sträussler-Scheinker disease, frontotemporal lobar degeneration, diffuse neurofibrillary PaVer/SyngrASO2/799 tangles with calcification, chronic traumatic encephalopathy, amyotrophic lateral sclerosis of Guam, amyotrophic lateral sclerosis and parkinsonism-dementia complex, prion protein cerebral amyloid angiopathy, and progressive subcortical gliosis. 25. The method of claim 24, wherein the symptom of the tauopathic disorder is selected from the group of mild cognitive impairment, dementia, cognitive decline, decline of motor function, oculomotor and bulbar dysfunction, synaptic dysfunction, neurotoxicity, neuronal degeneration, neuronal dysfunction, synapse loss, and amyloid deposition. 26. The method of claim 25, wherein the synaptic dysfunction is pre-synaptic dysfunction. 27. An antisense oligonucleotide or RNAi molecule capable of reducing the level of synaptogyrin-3 mRNA, synaptopgyrin-3 protein, synaptogyrin-3 activity, or a combination thereof in a cell by least 45% compared to a control situation in the absence of said antisense or RNAi molecule, wherein the antisense oligonucleotide or RNAi molecule nucleic acid sequence targets a subsequence of an mRNA encoding synaptogyrin-3 selected from the group consisting of SEQ ID No.10, 12, 20, 25, 29- 31, 33, 50, 53, 58-59, 62, 69, 79, 84, 87, 91, 94, 110-111, 135, 140-141, 170, 172, 179, 181, 184, 188, 193-194, 210, 216, 220-221, 224, 227, 229, 231, 235, 241, 246, 248, 250, 259, 268 or 269.